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1 Abstract 
Depression and anxiety disorders affect a great number of people in the world. Although 
remarkable efforts have been devoted to understanding the clinical and biological basis of 
these disorders, progress has been relatively slow. Furthermore, no laboratory test 
currently is available for diagnosis of anxiety and depression. These disorders are mainly 
diagnosed empirically on the basis of a doctor’s personal observations and experiences. 
Hence, discovery of biomarkers for these psychiatric disorders deserves much scientific 
attention.  
The animal models investigated in the present study represent high, low, and normal 
anxiety-like phenotypes (HAB, LAB, NAB) and were established by selective inbreeding. To 
compare the protein expression levels between different animal lines, living animals were 
metabolically labeled with the 15N stable isotope and then investigated by quantitative 
mass spectrometry. In addition, metabolomic studies were performed to shed light on 
pathways affected in the trait anxiety mouse model. A number of proteins and metabolites 
were found to be significantly altered in their expression levels between the three mouse 
lines. Both protein and metabolite information was used for in silico network analysis to 
find pathways pertinent to the pathobiology of anxiety disorders.  
Another focus of this thesis was the development of new methodologies for the metabolic 
labeling approach. This includes improved identification of labeled proteins and the 
analysis of protein turnover. The latter represents another important aspect in the field of 
proteomics and adds a dynamic dimension to the field. The method allows the detection 
of protein expression alterations at a much earlier stage. The newly developed ProTurnyer 
(Protein Turnover Analyzer) algorithm is able to calculate in a high throughput manner 
turnover for individual proteins. 
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2 Introduction 
2.1 Anxiety and depression 
2.1.1 Anxiety and depressive disorders 
Up to 20% of the world’s population suffers from depression or anxiety disorders (Kessler 
et al., 1994). According to data published by the World Health Organization (WHO), 
currently depressive disorders are the fourth leading cause of disability in the world and 
are likely to rise to the second position by 2020. The symptoms of depression and anxiety, 
such as sadness, hopelessness, feeling of being worthless, diminished interest, anxiety, 
worry, fear etc., exist in almost everyone’s daily life, but in people without mental illness 
these feelings usually appear to be reasonable and disappear within a couple of hours or 
days. However, these symptoms are much more persistent and excessive in a person with 
depression or anxiety or both. Thus, these disorders can interfere severely with patients’ 
lives, the lives of their families, and society in general.  
Although remarkable efforts have been devoted to understanding the clinical and 
biological basis of depression and anxiety, progress has been relatively slow. Epidemiologic 
studies have demonstrated that heredity factors can contribute roughly 40%-50% to the 
risk for depression (Fava and Kendler, 2000). In twin studies, 15%-20% heritability was 
observed for anxiety disorders (Hettema et al., 2001). One promising hypothesis of 
depression is based on dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and 
the relevant components, such as corticotrophin-releasing factor (CRF), 
adrenocorticotropin (ACTH) and glucocorticoid. Hyperactivity of the HPA axis is observed 
in approximately half of depressed individuals. A number of factors have been studied and 
found to be highly relevant for anxiety. For instance, inactivation of the gamma-amino 
butyric acid (GABA) synthesis enzyme or its receptors resulted in increased anxiety-like 
behavior (Kash et al., 1999; Low et al., 2000). Similarly, inactivation of the 5-HT1A receptor 
also increased anxiety-like behavior in mice (Heisler et al., 1998; Parks et al., 1998; Ramboz 
et al., 1998). In addition, monoamine oxidase A (MAO-A) (Cases et al., 1995), and CRF and 
its receptors (Bale et al., 2002; Smith et al., 1998a) have been found to regulate anxiety. 
Comorbidity is a quite common occurrence in psychiatric disorders. Data have shown that 
during one year, almost 50% of psychiatric patients have two or more syndromes (Kessler 
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et al., 2005). Therefore, it is not surprising that depression and anxiety frequently co-occur 
(Devane et al., 2005; Moffitt et al., 2007; Regier et al., 1998), although they represent 
distinct phenotypes. The comorbidity between anxiety and depression disorders is as high 
as 50%-60% (Kaufman and Charney, 2000; Landgraf, 2001). The genetic correlation 
between major depression and generalized anxiety has been investigated in twin studies 
(Kendler et al., 2007): correlation scores of 1 and 0.74 were observed in women and men, 
respectively. 
Currently, no laboratory test is available for diagnosis of anxiety and depression. These 
disorders are mainly diagnosed empirically on the basis of a doctor’s personal 
observations and experiences. The patients’ reported symptoms, behavior, way of 
speaking, and family medical history can all help make the correct diagnosis. The 
diagnostic criteria also are summarized in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR), a commonly used classification system. Despite our limited 
knowledge of anxiety and depression, medication, electroconvulsive seizures (ECS), and 
psychotherapy are normally effective treatments. Eighty percent of patients with 
depression benefit from clinical treatment (Holsboer, 2001; Nestler et al., 2002). 
2.1.2 Anxiety mouse model 
Emotions, cognitions, environmental experience, and individual genetic background vary 
enormously in human psychiatric disorders, such as anxiety (Blanchard et al., 2001; 
Gordon and Hen, 2004). To facilitate the study of anxiety, animal models have been 
introduced to model particular aspects of anxiety-like behavior. There are several 
advantages to using animals instead of human patients. First, the anxiety-like behavior of 
the animal models can be very stable. Second, both the genetic and environmental 
background of the animals can be well controlled via an inbreeding approach and 
conditioned feeding. Moreover, there is no theoretical limitation to the type and number 
of specimens, since the animals can be easily bred. In contrast, clinical specimens from 
patients are always heterogeneous, more difficult to obtain, and limited to body fluids. 
Despite the above attractive features, the animal phenotype will never be expected fully 
to mirror the corresponding human phenotype, since it is impossible to know the real 
emotional status of an animal. 
Animal models mainly are established by genetic means or selective breeding. Transgenic 
mouse models—which may have a gene and its product overexpressed, underexpressed, 
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lost or wrongly synthesized by adding, deleting, silencing, or mutating a gene—have been 
created for many neurotransmitters, receptors, messengers, and transporters (Gross et al., 
2002; Heisler et al., 1998; Kash et al., 1999). Selective breeding is the process of breeding 
animals to obtain particular behavioral and genetic traits. Animals with a homogeneous 
appearance, behavior, and other characteristics are mated and inbred to obtain offspring 
with a stable phenotype. The characteristic behavior can be maintained steadily after 
selective breeding for several generations. The behavioral phenotype is the outcome of 
the integration of all the factors ongoing in both internal and external environments. A 
single gene change normally does not result in disease occurrence. In this regard, an 
animal model established on the basis of behavioral selection can be more applicable to 
simulating the same phenotype in humans. 
Behavioral tests normally are used to evaluate the phenotype. The anxiety-like behavioral 
tests for mice include the elevated plus maze (EPM) (Cook et al., 2001; Handley and 
Mithani, 1984; Lister, 1987; Pellow et al., 1985) (Figure 1), light-dark transitions test 
(Crawley and Goodwin, 1980), marble burying (Broekkamp et al., 1986; Jacobson et al., 
2007), and shock-probe burying (Gasparotto et al., 2007; Sluyter et al., 1996). The tail 
suspension test (TST) and forced swim test (FST) (Crowley et al., 2005; Cryan et al., 2005; 
Porsolt et al., 1978; Steru et al., 1985) are the two main tests used to assess 
depression-like behavior. The EPM test is essential in our animal model development and 
will be the main focus of the discussion below. EPM has been established on the basis of 
the fact that anxiety patients avoid exposing themselves to threatening situations and 
places. In the EPM, the mouse has the opportunity to choose freely between highly 
elevated, unguarded open arms and unchallenged enclosed arms; the high anxiety level 
mouse will avoid entering an open arm (Figure 1).  
Proteomics 
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Figure 1. Elevated plus maze set up. Unlike non-anxious LAB-M mice, which explore the 
aversive open arms of the EPM, the anxious HAB-M mice spend most of the test time in 
the dimly lit closed arms. 
On the basis of EPM behavior, both rats and mice were bred selectively to obtain different 
animal models with high/low/normal anxiety-related behavior (HAB/LAB/NAB) (Kessler et 
al., 2007; Kromer et al., 2005; Landgraf et al., 2007; Landgraf and Wigger, 2002; Liebsch et 
al., 1998a; Liebsch et al., 1998b)(Figure 1). HAB mice commonly spend ~10% of time or 
even less on an open arm; by contrast, LAB mice spend more than 50% of time on an open 
arm. NAB mice spend ~30% of time on an open arm, which is close to the mean value of 
outbred mice. These mouse lines have maintained their featured behavior for more than 
50 generations. Besides EPM, these animal models were verified by some other 
anxiety-related and depression-related tests, including the dark-light avoidance test, 
open-arm exposure test, ultrasound vocalization test, TST and FST (Kromer et al., 2005). 
The HAB mice also showed a higher passive level of activity in desperate situations during 
TST and FST.  
2.2 Proteomics 
Genomics has been used to elucidate the complete sequence of genomes for a number of 
species (Lander et al., 2001; Venter et al., 2001). Although the whole human 
genome—with less than 20,325 annotated protein-coding genes—has been fully identified, 
the function of probably 100,000 of human proteins (Gstaiger and Aebersold, 2009) 
encoded by those genes remains elusive. Genomic studies are inadequate mainly because: 
1) the level of transcription of a gene does not always reflect its level of protein expression; 
2) protein post-translational modifications (PTM) play an important role in protein 
function and activity, but this aspect is undetectable in genomics; 3) a given transcription 
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can affect more than one protein by altering splicing or PTM or both; and 4) many proteins 
have bioactivity only when they co-exist with other proteins or RNA molecules.  
The study of proteins can complement genomic research because proteins are the 
bio-functional molecular parts in living organisms, i.e. the actual main components that 
take part in the physiological mechanisms of biological processes. Moreover, proteins can 
interact with any other molecular compounds. The word proteome initially came from 
merging "protein" and "genome" and was created by Wilkins in 1994 (Wilkins et al., 1996). 
The proteome can be defined as the entire set of proteins expressed by a genome in any 
organism. The organism can be a cell, tissue, or even whole living body. The term 
“proteomics” was coined soon after “proteome”, in 1997 (James, 1997), in analogy with 
genomics. Therefore, proteomics can be described as a post-genomic science. Proteomics 
characterizes the identification and quantification of proteome(s), including protein 
expression, protein subcellular distribution, protein interaction, protein post-translational 
modifications, and protein turnover. 
2.2.1 Mass spectrometry 
2.2.1.1 What is mass spectrometry? 
Mass spectrometry (MS) is an analytical approach that measures the mass-to-charge (m/z) 
ratios of charged compounds. The determined m/z of charged ions or their fragments can 
be used to interpret the elemental composition of molecules, even the chemical structures. 
John B Fenn, who received the Nobel Laureate in Chemistry for inventing electrospray 
ionization, described mass spectrometry as follows: “Mass spectrometry is the art of 
measuring atoms and molecules to determine their molecular weight. Such mass or weight 
information is sometimes sufficient, frequently necessary, and always useful in determining 
the identity of a species. To practice this art one puts charge on the molecules of interest, 
i.e., the analyte, then measures how the trajectories of the resulting ions respond in 
vacuum to various combinations of electric and magnetic fields.” (Siuzdak, 2006) 
A typical mass spectrometer consists of three modules: an ionization source, a mass 
analyzer, and a detector (Figure 2). The ionization source is the mechanical device that 
allows ionization to occur. This can be achieved by either addition or loss of electrons, 
protons, cations, anions, and even charged molecules. A mass analyzer measures the ion 
behaviors in an electric or magnetic field. The ions are separated based on their m/z. The 
Proteomics 
8 
detector records the electric signal of either the charge induced or the current produced 
when an ion passes by or hits a surface. The value reflects the abundances of each ion 
present.  
Before the development of Matrix-assisted laser desorption/ionization (MALDI) and 
electrospray ionization (ESI), MS was incapable of measuring large biomolecules whose 
molecular weights exceeded the limitation of the electron ionization (EI) source. The 
concept of electrospray was initially described by Dole et al. at the end of the 1960s (Dole 
et al., 1968). Twenty years later, the well-known breakthrough of ESI occurred when John 
Fenn of Yale University claimed to have identified polypeptides and proteins with a 
molecular weight of 130,000 kDa (Fenn et al., 1989). The ESI disperses the liquid 
containing the analytes of interest into a fine aerosol, which is transferrable to and 
measureable in a normal MS set-up. The first innovation for application of the laser 
desorption method to large biomolecules, in which the proteins with m/z up to 100,000 
Figure 2. Schematic representation of a mass spectrometer and its constituents. 
The mass spectrometer has three main modules: an ionization source, a mass 
analyzer, and a detector. (reproduced with permission from (Bayes and Grant, 2009)) 
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were successfully ionized and detected by mass spectrometry, was reported by Koichi 
Tanaka in 1988 (Tanaka et al., 1988). MALDI is triggered by a laser beam. The matrix, which 
consists of crystallized molecules, is used to protect the analytes from being destroyed by 
the direct laser beam and to facilitate vaporization and ionization. 
2.2.1.2 Orbitrap mass analyzer 
The ion trap is a robust mass analyzer because of its fast scan rates, MSn ability, easy 
maintenance, reasonable resolution, sensitivity, and mass accuracy. However, the 
sensitivity and mass accuracy of the traditional ion trap are relatively low, making it 
difficult to identify and quantify peptides accurately (Mann and Kelleher, 2008). The 
Orbitrap mass analyzer initially was developed by Makarov (Makarov, 2000; Makarov et al., 
2006a) to overcome these drawbacks. The Orbitrap is a robust instrument with high 
resolution (150,000 full width at the half height [FWHH]), high mass accuracy (2–5 ppm), a 
dynamic range (greater than 103), an m/z range over 6,000, and high sensitivity (Hu et al., 
2005; Makarov et al., 2006b). It is innately capable of very high mass accuracy because the 
m/z of the ion is the only element affecting the ion axial motion along the central spindle, 
and there is no impairment by the initial injection condition.  
2.2.1.3 Nano HPLC and ESI 
High performance liquid chromatography (HPLC) and MS are two important analytical 
tools in proteomics. Proteomic analytes often are present in biological samples at very low 
concentrations. To separate and ionize these complex compounds effectively, nano HPLC 
and nano ESI—in which the HPLC column and ESI emitter are at the micro-/nano-meter 
level—are frequently employed (Emmett and Caprioli, 1994; Griffina et al., 1991). The 
internal diameter (ID) of an HPLC column is a critical parameter that influences the 
detection sensitivity and separation selectivity during chromatographic elution. A smaller 
ID of the HPLC column can result in a higher sensitivity. Theoretically, the column 
sensitivity is inversely proportional to the square of the ID of the HPLC column. This means 
that a change in column ID from a conventional 4.6 mm ID column to a 75 µm column 
would result in a theoretical sensitivity gain of more than 3,700 fold. Besides the 
extraordinary sensitivity, nano HPLC is chosen for proteomics studies because of the 
column loading capacity. The great complexity and extreme dynamic range of biological 
samples usually make it difficult to purify or enrich the target proteins. Therefore, the 
quantity of individual analytes is normally very small. The nano HPLC is able to work with 
minute sample sizes; moreover, nano HPLC—especially the splitless nano HPLC system—is 
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reasonably priced in terms of consumption of mobile phases. The nano ESI was introduced 
by Wilm and Mann in 1996 to couple nano HPLC with ESI MS (Wilm and Mann, 1996). The 
nano ESI emitter is made by pulling laser-heated fused silica into a very fine taper filament, 
whose orifice is only several microns across. A verified theoretical model predicts a 
proportionality between the two-thirds power of the flow rate and the size of droplets 
emitted from the tip of a stable Taylor cone (Wilm and Mann, 1994). A smaller droplet has 
a higher surface/volume ratio, which makes a larger proportion of analyte molecules 
available for desorption. 
2.2.2 Protein identification by mass spectrometry 
MS has become the central technology in proteomics today. To identify a peptide and 
protein, the mass spectrometer collects both MS and MSn for peptide/protein precursor 
ions and their fragments. There are three main approaches to identifying peptides through 
MS data: de novo sequencing, spectrum library search, and peptide database search. De 
novo sequencing is the only method that can identify previously unknown peptides or 
peptides that go against the parameter setting in the search engine. Spectrum library 
search (Frewen et al., 2006) was developed recently and is based on the establishment of 
an MS2 spectrum database. Previously identified MS2 data were collected into a reference 
spectrum library that is used to identify new spectra. With this approach, peptide 
identification seems to be reliable and faster.  
Peptide database search is the most widely used technique in protein identification. For a 
bottom-up proteomic strategy, the MS actually measures the enzymatic digests, but not 
intact proteins. Two types of mass spectra are typically obtained: MS spectra containing 
peptides digested from proteins and MS2 spectra that contain fragments of those peptide 
precursors. Application of the MS peptide mass fingerprinting (PMF) approach typically 
requires relatively pure proteins, such as those obtained from two-dimensional gel 
electrophoresis (2-DE). Thus, proteins can be identified by mapping the peaks in the MS to 
those of theoretical proteolytic peptides. MS2 is composed of the fragments of a 
particular precursor peptide, whose m/z is already determined in MS. Ideally, the 
fragmented ions form a ladder in which each successive fragment contains one additional 
residue, thus allowing the sequence to be interpreted from the mass shift between the 
peaks. MS2 can provide information on both the amino acid sequence and the mass of the 
precursor peptide, resulting in very high confidence identification. Therefore, MS2 is the 
most preferred technique for peptide identification in current proteomic studies. 
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Moreover, more than one approach can be employed simultaneously. For example, 
peptide sequence tag identification (Mann and Wilm, 1994; Mortz et al., 1996) combines 
de novo sequencing and peptide database search.  
Since MS2 peptide database search is the most commonly used method, and also the only 
one performed in the studies presented in this paper, the following description of 
identification algorithms will cover only this workflow. Several peptide database search 
engines have been developed to identify peptides in a high throughput manner, such as 
Mascot (Perkins et al., 1999), SEQUEST (Eng et al., 1994), and X!Tandem (Craig and Beavis, 
2004). The overall designs of the different identification algorithms are similar; they all 
attempt to match experimental spectra with theoretical spectra generated from the 
sequences in a protein database. Before submitting the data to the search engine, several 
parameters must be defined, including database, mass accuracy, modification, etc. The 
algorithm usually has a particular built-in approach to evaluate the match between 
experimental and theoretical spectra. Users normally can optimize the output on the basis 
of different filtering thresholds. False discovery rate (FDR) (Balgley et al., 2007; Cargile et 
al., 2004; Jones et al., 2009; Wang et al., 2009) is usually employed as the criterion for the 
success rate of the identification. However, the algorithmic difference behind these 
platforms will not be discussed here; more detailed information can be found in the 
following informative review articles on this topic (Balgley et al., 2007; Kapp and Schutz, 
2007; Martens and Apweiler, 2009; McHugh and Arthur, 2008; Nesvizhskii, 2007; 
Shadforth et al., 2005). 
2.2.3 2-DE based proteomics 
To investigate thousands or even more proteins from an organism comprehensively, it is 
critical to reduce the sample complexity. At the beginning of the proteomic era, 2-DE 
predominantly was exploited as a tool to separate complex protein mixtures. In a typical 
2-DE experiment, the protein mixture is usually loaded onto an immobilized pH gradient 
(IPG) gel. The proteins move along the gel until they reach their isoelectric points, where 
the overall charge on the protein is neutral. After the first isoelectric focusing (IEF) 
separation, the IPG gel saturated with proteins is transferred to a sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins with similar isoelectric points 
can then be further separated on the basis of their molecular weights. 2-DE based 
quantification is normally performed by comparing the staining densities or patterns of 
proteins. This provides researchers with a rough idea of the relative quantification. 
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However, 2-DE has some limitations. First of all, the 2-DE gel has a low resolution, which 
makes it difficult to resolve all or the majority of the proteome. The incompatibility with 
hydrophobic proteins means it cannot be used for membrane proteins. 2-DE can handle 
high abundant proteins but is incapable of analysing low abundant proteins existing in a 
high dynamic range sample such as plasma, whose dynamic range of protein expression 
can vary by up to 12 orders of magnitude (Corthals et al., 2000). 2-DE–based quantification 
detects only extreme differences and inaccurately estimates quantity changes. 
Furthermore, 2-DE is a low throughput strategy that allows only individual gel spots to be 
identified. 
2.2.4 Shotgun proteomics 
The shotgun proteomics approach (Link et al., 1999; Wolters et al., 2001; Yates, 2004), also 
known as MS-based proteomics (Aebersold and Mann, 2003; Ong et al., 2003; Ong and 
Mann, 2005), was introduced to obtain large-scale analyses of high-complexity samples 
(Figure 3). It is equivalent to shotgun genomic sequencing. In a typical shotgun proteomics, 
protein complex mixtures are digested into predictable peptides by a site-specific enzyme, 
such as trypsin. The peptide mixtures then are separated by an HPLC column and injected 
directly into a MS system. A number of separating techniques can be used in shotgun 
proteomics, including SDS gel, one or multiple-dimensional chromatography, IEF, or a 
combination thereof. Because the amino acid sequence of a peptide is rather unique, the 
protein can be identified by identifying its peptides. 
 
Figure 3. Shotgun proteomics. (reproduced with permission from (Gstaiger and Aebersold, 
2009)) 
2.2.5 Quantitative proteomics 
A protein expression map of a certain proteome can now be routinely generated in some 
depth by the shotgun methods described above (Baerenfaller et al., 2008; Brunner et al., 
2007; de Godoy et al., 2008; Schrimpf et al., 2009). The Mann group even demonstrated 
that MS-based proteomics can cover almost the whole proteome of yeast, with its more 
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than 4,000 proteins (de Godoy et al., 2008). In its inchoate stage, proteomics was largely 
aimed at qualitative analysis; however, the expression map normally does not address 
biological issues efficiently. The absolute or relative quantity change of proteins is 
probably an important reflection of the disease stage. Altered proteins are possible drug 
targets and also potential clinical biomarkers for disease diagnosis, even at an early clinical 
phase. Consequently, quantification has become the essential aspect (Ong and Mann, 
2005) by which scientists are attempting to study disease processes. The categorization of 
the current quantitative approaches is shown in Figure 4. As mentioned above, 
2-DE-based quantification has inherent weaknesses and is being replaced by MS-based 
methods. Therefore, the following discussion will cover only the MS-based quantitative 
strategy. MS-based quantitative data are obtained by either stable isotope labeling or 
label-free approaches. The isotope labeling approach can be furthermore classified as 
absolute and relative quantification. 
 
Figure 4. Categorization of current techniques for quantitative proteomics. 
The label-free strategy aims to quantify two or more experiments by either comparing the 
MS ion intensity of peptides (Bondarenko et al., 2002; Chelius and Bondarenko, 2002; 
Higgs et al., 2008; Wang et al., 2003; Wiener et al., 2004) or using the number of acquired 
spectra (Gilchrist et al., 2006; Liu et al., 2004; Washburn et al., 2001) matching a 
peptide/protein as an indicator for their respective amounts in a given sample. The ion 
intensity is obtained by extracting the chromatographic elution profile of all the 
Quantitative 
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isotoplogues of a given peptide (Ono et al., 2006) for highly resolved MS data. The 
spectrum-counting approach works because of the fact that more MS2 scans will be 
triggered when the peptide is present at a higher concentration. 
Label-free approaches probably are the least accurate of the MS-based quantification 
techniques, since both the ion intensity and MS2 count are affected by any systematic or 
non-systematic alteration. Therefore, variations in sample preparation and 
chromatographic and electrospraying behavior should be minimized. Despite its poor 
quantitative accuracy, the label-free method still is considered a powerful quantitative tool 
in proteomics for several reasons. First, it omits the need for introducing artificially 
enriched heavy isotope, which can dramatically reduce the complexity of experimental 
design, and avoids the high cost resulting from stable isotope reagents. Second, an 
unlimited number of experiments can be compared; in contrast, isotope labeling 
experiments are limited by the number of isotope reagent patterns. Third, label-free 
samples result in “pure” spectra, which contain only the peptide with natural isotope 
composition; these less complex spectra enable a better precursor selection during data 
acquisition and better peptide identification in the database search. 
Stable isotope labeling is the most accurate method in relative quantitative proteomics, 
and its development has been reviewed in a number of papers (Aebersold and Mann, 
2003; Bantscheff et al., 2007; Becker, 2008; Gstaiger and Aebersold, 2009; Guerrera and 
Kleiner, 2005; Ong et al., 2003; Ong and Mann, 2005; Tao and Aebersold, 2003). A typical 
stable isotope labeling approach compares two or more physiological states of a biological 
target. One is labeled with the natural isotope abundance (light/unlabeled) and the 
other(s) with a stable heavy isotope (heavy/labeled). The labeled and unlabeled samples 
are mixed and processed together, and the paired peptides behave identically during HPLC 
separation. The mass difference of the heavy and light peptides or their fragments can be 
distinguished by mass spectrometry, and the subsequent quantification is achieved by 
comparing their signal intensities. 
Several approaches have been taken to introducing stable isotope tags into 
proteins/peptides via chemical, enzymatic, or metabolic reactions (Figure 5). The first two 
forms are accomplished in vitro, whereas the metabolic labeling is executed in vivo. 
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Figure 5. Common quantitative mass spectrometry workflows. Blues and organge boxes 
represent two experimental conditions. Horizontal lines indicate when samples are 
combined. Dashed lines indicate points at which experimental variation and thus 
quantification errors can occur (reproduced with permission from Ref.(Bantscheff et al., 
2007)) 
Enzymatic labeling refers mainly to proteolytic 18O-labeling (Reynolds et al., 2002a; 
Reynolds et al., 2002b; Yao et al., 2001), which generates 16O/18O .isotope-labeled peptides 
by proteolytic digestion with H2
16O /H2
18O and protease. 18O-labeling is an easily adapted 
and cost-saving approach; however, the variable incorporation of 18O atoms into peptides 
(Johnson and Muddiman, 2004; Julka and Regnier, 2004; Ramos-Fernandez et al., 2007) 
complicates data analysis.  
Chemical labeling targets reactive groups on the side chains of amino acids or peptide 
termini. The first type of chemical labeling methods usually makes use of the reactions 
between cysteine and isotope-coded tag. The original successful application was the 
so-called ICAT (isotope-coded affinity tag) procedure (Gygi et al., 1999; Smolka et al., 2001), 
in which cysteine residues specifically were derivatized with a reagent containing either 
eight 1H or eight 2H atoms and a biotin group, and the peptide mixture is then subjected to 
avidin affinity chromatography to purify ICAT coded peptides. Thereafter, the isolated 
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peptides are analyzed by liquid chromatography-mass spectrometry (LC-MS). As cysteine is 
not an abundant amino acid, the ICAT technique can reduce significantly the complexity of 
the peptide mixture, which can be valuable for complex samples. On the other hand, ICAT 
obviously eliminates all non–cysteine-containing peptides and therefore is not suitable for 
comprehensive large-scale quantification. Furthermore, a deuterium tag results in a 
retention time shift between light and heavy peptides in reversed-phase chromatography, 
which complicates the subsequent data analysis. ICAT has been modified to give several 
techniques (Hansen et al., 2003; Li et al., 2003; Oda et al., 2003) that are more adaptable 
for practical applications. Another group of labeling reagents is aimed at the peptide 
N-terminus and lysine residues, such as isotope-coded protein label (ICPL) (Schmidt et al., 
2005), isotope tags for relative and absolute quantification (iTRAQ) (Ross et al., 2004), 
tandem mass tags (TMT) (Thompson et al., 2003), etc. Of these isotope-coded reagents, 
iTRAQ, which is compatible with up to eight isobaric mass tags, has become popular and 
commercially successful. The iTRAQ technique determines the tag ions that are detached 
from the peptide precursor by MS2 fragmentation. The intensities of these reporter ions 
enable a relative quantification of the peptides. The most important feature of the iTRAQ 
strategy is its capability to analyze eight separately labeled pools of protein in a single 
analysis, improving analytical time significantly. The iTRAQ reagents are undetectable in 
conventional ion trap instruments because these low-mass reporters are not stable during 
the activation step, owing to the principle known as the “low mass cut off 1/3 rule” (Louris 
et al., 1987). A recently developed, new activation method, pulsed q dissociation 
(PQD)(Cunningham et al., 2006), enables MS/MS reporter ions from isobaric peptide tags 
such as iTRAQ to be detected in an ion trap mass analyzer. A transformation of chemical 
isotope labeling is the creation of the labeled peptide/protein from two chemically 
different tags (Beardsley and Reilly, 2003; Cagney and Emili, 2002) rather than from variant 
isotope of the same chemical. Although this substitute is much more economical, the 
labeling reaction, HPLC, and MS behavior may not be identical, which obviously affects the 
accuracy of the quantification.  
Metabolic labeling employs an isotope-enriched medium or diet to culture or feed living 
systems. The isotopic tracer is incorporated into the whole proteome through protein 
synthesis during protein turnover and cell multiplication. The labeled peptide has a mass 
increase that can be detected by a mass spectrometer. When labeled and unlabeled 
samples are combined, the ratio of peak intensities in the mass spectrum reflects the 
relative protein abundance. Metabolic labeling is considered to have higher quantitative 
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accuracy than in vitro labeling, since it allows the control and case samples to be mixed 
prior to any sample preparation, avoiding potential artificial variance (Figure 5). However, 
in vitro isotope labeling can be applied universally for any type of sample, which is the 
major advantage over the in vivo metabolic labeling method. In the past, metabolic 
labeling has been used with radioactive isotopes mainly for metabolite monitoring. By 
contrast, stable isotope metabolic labeling first was introduced into proteomics by Langen 
et al. in 1998, who used an 15N- and 13C-labeling approach to compare protein quantities 
with 2-DE (Langen et al., 1998). Other research groups soon after reported the successful 
application of 15N metabolic labeling in both yeast (Oda et al., 1999) and a mammalian cell 
line (Conrads et al., 2001). Nitrogen commonly is chosen rather than carbon, mainly 
because the isotopic reagent of nitrogen is easier to synthesize. Moreover, there are on 
average four times as many carbon atoms in a protein than nitrogen atoms. As a result, the 
13C-labeled peptide usually results in a broad distribution of the peptide isotopic peak, 
making data analysis challenging. Up until now, the 15N-labeling technology has been 
applied successfully to cells in culture (Conrads et al., 2001; Ishihama et al., 2005), plants 
(Huttlin et al., 2007; Nelson et al., 2007; Palmblad et al., 2007; Schaff et al., 2008), 
Drosophila melanogaster (Krijgsveld et al., 2003), Caenorhabditis elegans (Dong et al., 
2007; Krijgsveld et al., 2003), and mammals (McClatchy et al., 2007a; Wu et al., 2004). The 
15N labeling of mammals also is called stable isotope labeling of amino acids in mammals 
(SILAM) (Liao et al., 2008; McClatchy et al., 2007b). Another metabolic labeling method, 
known as stable isotope labeling with amino acids in cell culture (SILAC), was introduced in 
2002 (Ong et al., 2002). In a typical SILAC experiment, cells are differentially labeled by 
growing them in light medium with normal arginine or lysine (e.g. Arg-0 or Lys-0) or 
labeled medium with heavy arginine or lysine (e.g. Arg-6 or Lys-6). The subsequent trypsin 
digest cleaves the proteins at arginine and lysine residues. Therefore, every tryptic peptide 
except for the C-terminal contains one labeled amino acid, which makes the mass increase 
of the labeled peptide predictable. Conventionally, SILAC is suitable only for cell culture. 
However, the SILAC approach also has been recently applied to mouse labeling (Kruger et 
al., 2008) by feeding the mice a 13C6-lysine–labeled diet for four generations. 
As the two main forms of metabolic labeling, SILAM and SILAC have both strengths and 
shortcomings (Table 1). SILAC and SILAM represent different isotope patterns for labeled 
peptides in mass spectra. Since only one labeled amino acid can be included for any given 
tryptic SILAC peptide, the mass difference between the unlabeled and labeled peptide can 
be predicted, which facilitates data analysis. By contrast, the mass increase of labeled 
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SILAM peptide depends on the peptide chemical composition as well as on the labeling 
incorporation rate. This variable mass gain usually makes data analysis more challenging. 
Moreover, the SILAM and SILAC relative isotope abundance (RIA) ordinarily does not reach 
100% because of residual unlabeled atoms in the nutritional source and metabolic amino 
acid recycling. The SILAM peptide usually contains a number of nitrogen atoms, and these 
nitrogen atoms are normally more than the labeled number of atoms in SILAC peptide. 
The incomplete RIA and relatively numerous potentially labeled nitrogen atoms result in a 
complex and broad isotopic pattern for labeled SILAM peptides. By contrast, SILAC 
peptides are much easier to handle, since the labeled peptide appears at a certain mass in 
the spectrum. 
Table 1. Comparison of SILAC and SILAM in quantitative proteomics 
 SILAC SILAM 
Mass shift for labeled 
peptide 
Predictable 
Dependent on both peptide 
sequence and 15N% 
Number of mixed 
samples 
Maximal 3 2 
Isotope effect unknown reported in a few cases 
Identification of labeled 
peptide 
Easy Challenging 
Incorporation 
requirement 
Must be high Can be relatively low 
Cost for mouse labeling ~7,000 EURO/mouse ~1,000 EURO/mouse 
 
SILAC peptides usually appear only in two forms in the MS: labeled and unlabeled. If a 
protein is only partially labeled, the MS of unlabeled peptide is a mixture composed of two 
parts: the original unlabeled peptide and the unlabeled peptide resulting from the partial 
labeling. To avoid this, the labeling incorporation rate of SILAC should be close to 100%. By 
contrast, as the incorporation rate increases, the labeled MS peaks of SILAM peptide 
gradually move toward the high mass range. A rather low labeling incorporation rate is 
sufficient to separate the labeled and unlabeled MS peak envelopes of SILAM peptides. 
Consequently, partial labeling is also applicable to the SILAM quantitative strategy, 
reducing the cost and time required for the experiment. Complete labeling usually is 
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achievable in cell-based experiments because the medium that contains the labeled amino 
acids can take the place of the whole nutritional source for protein synthesis after the 
replacement. Moreover, the metabolic rate of cultured cells normally is very high. 
Mammals such as mouse and rat, which are more relevant for biological research, are not 
easily labeled fully because of the relatively slow turnover of both proteins and the amino 
acid pool. Hence, SILAM works better than SILAC for mammal labeling because of its lower 
incorporation rate compatibility. 
In addition, 15N partial labeling can facilitate the determination of protein turnover in 
mammals. Protein turnover measurement usually tries to calculate the fraction of newly 
synthesized protein after the isotope tracer has been added. As mentioned above, part of 
the newly synthesized SILAC peptide will appear in the unlabeled pattern and co-exist with 
pre-existing peptide, and it is impossible for MS to distinguish between the two. Although 
the newly synthesized SILAM peptide may appear at a low incorporation rate shortly after 
the labeling, it is still possible to separate it from the pre-existing unlabeled peptide. The 
strategy involved will be discussed in depth in the following sections.  
The relative quantification methods described above currently dominate the quantitative 
proteomics field. However, conducting absolute quantification studies is yet another 
attractive dimension of proteomics. In principle, relative quantification can be 
incorporated into absolute quantification, since the relative ratios easily can be obtained if 
the absolute quantities of the proteins are known. 
Absolute quantitative proteomics, commonly known as AQUA (absolute quantification of 
proteins), employs a synthetic stable isotope-labeled peptide at a known concentration 
(Gerber et al., 2003) as a reference for calculating the concentration of the target peptide. 
The AQUA method relies on the relative comparison between internal isotope-labeled 
standard peptide and unlabeled sample digest, in which a chemically identical peptide also 
is expected. Analysis of the peptide mixture in selected reaction monitoring (SRM) or 
multiple reaction monitoring (MRM) (Kirkpatrick et al., 2005) modes enables the MS to 
monitor both the intact peptide mass and one or more specific fragment ions of that 
peptide over the course of an LC-MS experiment. In combination with the retention time, 
the AQUA platform can eliminate ambiguities in peptide assignments and extend the 
quantification range to 4–5 orders of magnitude (Wolf-Yadlin et al., 2007). Unlike the other 
relatively quantitative approaches, because of the low synthetic efficiency of 
isotope-labeled peptides AQUA does not measure the protein quantity in a high 
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throughput manner but determines one or a few specific peptides of interest. The 
selection of the optimal peptide standard and the amount of the standard to be added to 
the sample are very important criteria for the AQUA method. Therefore, preliminary 
experiments are required to determine optimal conditions. However, the degree to which 
the determined amount in fact reflects the absolute quantity, after the time-consuming 
sample preparation procedure and physical/chemical treatment of the sample, is still 
under debate. There is a good probability that it does not reflect the real protein level in 
vivo.  
2.3 Metabolomics 
Findings concerning DNA (genomics), RNA (transcriptomics), proteins (proteomics), and 
small molecules (metabolomics) have to be combined to obtain a complete profile of living 
organisms and to allow a systematic understanding of the occurrence of disease. 
Metabolite analysis usually is restricted to small molecules, which are the intermediates 
and products of metabolism. The term metabolome (Oliver et al., 1998) refers to the 
complete collection of small molecule metabolites, such as metabolic intermediates, 
hormones, and other signalling molecules, to be found within a biological sample. 
Metabolomics can be defined as “the quantitative measurement of the dynamic 
multiparametric response of a living system to pathophysiological stimuli or genetic 
modification” (Nicholson et al., 2002; Nicholson et al., 1999). The techniques involved 
should be able to detect, identify, and quantify the global profiling of the metabolome in a 
high throughput manner. Various platforms are suitable for metabolomic analysis, such as 
nuclear magnetic resonance (NMR), fourier transform infrared spectroscopy (FT-IR), gas 
chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry 
(LC-MS), ultra performance liquid chromatography-mass spectrometry (UPLC-MS), and 
capillary electrophoresis-MS (Lenz and Wilson, 2007; Want et al., 2007). This paper 
focuses on chromatography-MS–based methods. 
Two steps typically can be applied to identify metabolites. First, a limited number of 
possible chemical formulae can be derived from the accurate measurement of the 
chemical mass. Second, the structure can be deduced from the MS2 fragments of the 
precursor, which also can be performed by searching an MS/MS library. Moreover, a 
database can be established, which greatly facilitates identification of the metabolite. If 
the metabolite has been identified previously, the features of mass, MS/MS, and retention 
time on the chromatography can be used to identify it again. The signal intensities of MS 
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are used for the quantification. It should be noted that, like proteomics, metabolomics is 
still incapable of identifying the entire metabolome.   
2.4 Systems biology 
The popularity of molecular biology has led scientists toward detailed research at the 
molecular level, where a specific biomolecule or a few biomolecules are studied. Although 
millions of –omics data (e.g. from proteomics, metabolomics) have been generated, there 
is still a long way to go before either a particular molecule or –omics data can be 
interpreted and eventually applied in therapeutics or as a ‘‘cure’’ for diseases. Except for 
Mendelian diseases, most common human disorders originate from not only one genetic 
mutation but from the complex interplay between DNAs, proteins, metabolites, and 
external environmental influences. Therefore, there is a great demand for integrative 
analysis of data across a wide range of fields; however, this cannot normally be achieved 
with any independent traditional biological approach. Systems biology thus was 
introduced to help scientists unravel the organization and interactions of cellular networks 
between DNAs, RNAs, proteins, and metabolites (Barabasi and Oltvai, 2004; Kitano, 2002) 
(Figure 6). Several technical aims still have to be achieved before these intricate networks 
can be established on the basis of both validated and predicted interactions (Sauer et al., 
2007): 1) identification and quantification of all participants at the –omics level, such as 
proteomics and metabolomics; 2) experimental identification of physical component 
interactions; 3) computational deduction of data; and 4) rigorous integration of 
heterogeneous data.  
Obviously, to handle the enormous amount of data in systems biology, computational 
tools capable of analyzing -omics data from multiple platforms are crucial. A number of 
algorithmic packages are available, such as KEGG (Kanehisa et al., 2008), PathVisio (van 
Iersel et al., 2008), pSTIING (Ng et al., 2006), MetaCoret (Ekins et al., 2007), Cytoscape 
(Shannon et al., 2003), VANTED (Junker et al., 2006), Pathway-Express (Draghici et al., 
2007), Systems Biology Markup Language (SBML) (Hucka et al., 2003), and also the 
commercial tool PathwayStudio® (Sivachenko and Yuryev, 2007) (Ariadne Genomics, 
Rockville, MD, USA). PathwayStudio, for example, enables a high-throughput, 
cross-platform analysis of gene, protein, chemical, and disease data. The potential 
network of any form of interest can be visualized. Although all these tools seem to be 
highly advanced and powerful enough to uncover the true fundamental physiological 
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processes, they are still a long way from completely characterizing all the interactions 
involved in biological events.  
 
Figure 6. A systems roadmap. (reproduced with permission from (Sauer et al., 2007)) 
2.5 Biomarkers 
According to the North American National Institute of Health (NIH) 
(http://www.biomarkersconsortium.org/), “Biomarkers are characteristics that are 
objectively measured and evaluated as indicators of normal biological processes, 
pathogenic processes, or pharmacologic responses to therapeutic intervention. 
Biomarkers can be used in clinical practice to identify risk for or diagnose a disease, stratify 
patients, assess disease severity or progression, predict prognosis, or guide treatment. In 
drug development biomarkers may be used to help determine how a drug works in the 
body, to determine a biologically effective dose of a drug, to help assess whether a drug is 
safe or effective, and to help identify patients most likely to respond to a treatment, or at 
least likely to suffer an adverse event when treated with a drud. Biomarkers can 
sometimes be used as part of the approval process for a drug or treatment, to inform 
regulatory decision-making.” As discussed above, biomarkers can be any kind of physical or 
chemical change between health and disease. Of the potential biomarker targets, proteins 
are likely the most ubiquitously affected in any cellular process, and protein patterns are 
more directly related to the phenotype of an organism. In addition, the advances of 
MS-based proteomics enable the construction of a comprehensive biomarker discovery 
pipeline. Therefore, protein biomarker discovery is the main focus of this thesis. 
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The first step is to look for protein biomarker candidates using a quantitative proteomics 
approach. Afterwards, all or at least a subset of the biomarker candidates require 
verification. Verification can confirm the MS-based result and provide support for better 
quantification. A commonly used verification method is the Western blotting technique, 
which combines one-dimensional gel electrophoresis (1-DE) and antibody 
immunoreactions. Similarly, enzyme-linked immunosorbent assay (ELISA), which is based 
on the immune-affinity principle, can be used for verification. Although Western blot is 
used routinely in every proteomic lab, there are bottlenecks associated with this approach: 
the method is only semi-quantitative; moreover, the central reagents in Western blot, 
antibodies, often are of poor specificity, especially those against novel candidate proteins 
or post-translational modifications. 
Alternatively, proteomic data can be verified by SRM or MRM. As described above, 
together with a standard peptide, MRM enables both the structure and quantity of the 
analyte to be determined. The final step of the biomarker validation is the clinical 
evaluation. Despite many efforts and promising biomarker candidates generated from 
proteomic studies, it remains a formidable, undefined, and expensive task to demonstrate 
their final clinical usefulness and compliance with regulatory requirements. 
Thanks to the great research efforts in the past few decades, a few biomarkers have been 
validated for complex disorders like diabetes and heart disease; however, currently there 
are still no biomarkers for psychiatric disorders. Progress in studies of psychiatric disorders 
is relatively slow because of the limited knowledge of etiology and pathogenesis, the large 
clinical heterogeneity, uncertain phenotype boundaries, genetic overlap between 
disorders, and the large influence of non-genetic factors. Despite the existing challenges, 
MS-based proteomics facilitates the identification of potential biomarkers. 
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3 Proteomic and metabolomic brain and plasma profiling of 
a trait anxiety mouse model 
3.1 Introduction 
As mentioned above, up to 20% of the world’s population suffers from depression or 
anxiety disorders (Kessler et al., 1994), and the number of people is still growing. Although 
remarkable efforts have been devoted to understanding the clinical and biological basis of 
depression and anxiety, only relatively slow progress has been made. Currently, no 
laboratory test is available for diagnosing anxiety and depression. Diagnoses mainly are 
made empirically, on the basis of a doctor’s personal observations.  
Emotions, cognitions, environmental experience, and genetic background vary enormously 
in human psychiatric disorders, such as anxiety (Blanchard et al., 2001; Gordon and Hen, 
2004). To make the study of anxiety more realistic, animal models have been introduced to 
model particular aspects of anxiety-like behavior. The study of animal models has several 
advantages over the study of humans. First, the anxiety-like behavior of the animal models 
can be very stable. Second, both the genetic and environmental background of the animals 
can be well controlled via an inbreeding approach and conditioned feeding. Moreover, 
there is no theoretical limitation to the type and number of specimens, since the animals 
can be easily bred. In contrast, clinical samples from patients are always heterogeneous, 
more difficult to obtain, and limited to body fluids. 
On the basis of behaviour on the EPM, both rats and mice have been bred selectively to 
obtain different animal models with high, low, and normal anxiety-related behavior (HAB, 
LAB, NAB, respectively) (Kessler et al., 2007; Kromer et al., 2005; Landgraf et al., 2007; 
Landgraf and Wigger, 2002; Liebsch et al., 1998a; Liebsch et al., 1998b). HAB mice 
commonly spend ~10% of time or even less on an open arm of the EPM; by contrast, LAB 
mice spend more than 50% of time on an open arm. NAB mice spend ~30% of time on an 
open arm, which is close to the mean value of outbred mice. These mouse lines have 
maintained their featured behavior for more than 50 generations. Besides verfication with 
the EPM, these animal models were verified by using some other anxiety-related and 
depression-related tests, including the dark-light avoidance test, open-arm exposure test, 
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ultrasound vocalization test, TST and FST (Kromer et al., 2005). The HAB mice also showed 
a higher passive level of activity in desperate situations during the TST and FST.  
Stable isotope metabolic labeling of living animals followed by quantitative mass 
spectrometry is a powerful method for accurately comparing protein expression levels 
between two or more specimens. Metabolomic studies also can provide additional 
information and give deeper insights into disease pathobiology. For this purpose, in this 
study mice were metabolically labeled, starting in utero, by feeding a 15N-enriched diet for 
56 days. Metabolomic analyses were carried out using a GS-MS platform. 
3.2 Material and methods 
3.2.1 Materials 
The standard rodent diet was purchased from Harlan (Harlan Laboratories, Inc. 
Indianapolis, IA, USA), and the bacterial protein-based rodent diets were purchased from 
Silantes (Silantes GmbH, Munich, Germany). Two isotopic forms of bacterial diets were 
used: natural isotopic (denoted as 14N) and 15N enriched. All the other chemicals were 
from Sigma-Aldrich (St. Louis, MO, USA), Merck (Darmstadt, Germany), and BioRad 
(Hercules, CA, USA).  
3.2.2 Animal experiments 
All the animal experiments were conducted in accordance with the “Guide for the Care 
and Use of Laboratory Animals of the Government of Bavaria”. High (HAB), normal (NAB), 
and low (LAB) anxiety-related behavior mouse models were established from CD1 mice by 
using a selective inbreeding approach. The anxiety-related behavior mainly is assessed by 
the time that the animals spend on the open arm of an EPM device: HAB mice spend 
approximately 10% of the total time on an open arm, LAB mice > 50% of time, and NAB 
animals around 30% (Kromer et al., 2005). The animals were bred and housed in the 
animal facility of Max Planck Institute of Psychiatry. Dams were housed in type 3 
macrolone cages, mature animals in groups of four animals in type 2 macrolone cages with 
12 h light/dark cycle (lights on at 6 a.m.), room temperature 23±2°C, humidity 60%; tap 
water and food were available ad libitum. All the behavioral tests were performed 
between 8 a.m. and 1 p.m. 
3.2.2.1 Mouse feeding  
Proteomic and metabolomic brain and plasma profiling of a trait anxiety mouse model 
27 
The 15N/14N feeding started in utero. Four to eight female mice from each line were mated 
one-to-one with an adequate male (i.e. sibling) to increase the pregnancy probability. 
After 10 days, the pregnancy was detected visually and/or by palpation of the embryos 
along the backbone, and the males were removed from the cage. To allow them to adapt 
to the bacterial protein diet, the pregnant females were fed 14N or 15N bacterial diet with 
standard diet for 4 days. Subsequently, only bacterial diets were provided. All the female 
pups were sacrificed on postnatal day (PND) 5, 14, and 28. On PND 28, the remaining male 
pups were weaned and grouped into new cages (2–4 animals per cage) and fed with pure 
bacterial diets. On PND 56, all the mice were sacrificed for proteomic analysis (Figure 7). 
Blood was taken by cardiac puncture, and plasma was obtained by centrifuging the blood 
in an EDTA and protease inhibitor cocktail tablet (F. Hoffmann-La Roche Ltd. Basel, 
Switzerland) pre-added tube at 1,300 × g for 10 min. The pellets were saved as blood cells. 
The remaining body blood was removed by 0.9% saline perfusion. The brains were divided 
into four sections: cerebellum, cortex, hippocampus, and amygdale. All the other organs 
were isolated. The plasma and organs were snap-frozen in liquid nitrogen, and the samples 
stored at -80°C for further use. The animals did not show any discernible health effects 
compared with animals fed a standard diet.  
 
Figure 7. Protocol for feeding mice with the bacteria diet. After pregnancy detection, the 
animals were given a free choice of standard or bacteria diet for 4 days before being fed 
the bacteria diet only. Organs were harvested at PND 5, 14, 28 and 56 to determine the 
15N incorporation rate and line-specific protein expression pattern. 
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3.2.2.2 Behavior test 
3.2.2.2.1 Ultrasonic vocalization test (USV) 
On PND 5, pups were individually separated from their mothers and gently placed on a 
Petri dish (15 cm diameter) cleaned with 70% ethanol. The temperature was kept constant 
at 23°C by a water bath underneath the dish. Lines were drawn to divide the dish into 2×2 
cm squares. The number of line crossings (two forepaws across the line) was counted 
during the 5 min test. USV calls were detected and recorded for 5 min with a bat detector 
(Mini 3 bat-detector, Ultra Sound Advice, U.K.) at 70 kHz.  
3.2.2.2.2 Elevated plus maze test (EPM) 
The EPM tests were performed on PND 49. The EPM was built of black plastic and 
consisted of two open arms (30 × 5 cm; 100 lux) and two enclosed arms (30 × 5 × 15 cm; 
10 lux). The arms extended from a central platform (5 × 5 cm; 90 lux). The EPM was 
located 40 cm above the table surface. The whole device was surrounded by a black 
curtain (Pellow et al., 1985). The mice were put onto the central platform facing a closed 
arm, and then behavior was recorded for 5 min via a video camera fixed above the maze. 
The number of entries into the closed and open arms and the percentage of time spent on 
the open arms were monitored by a trained observer blind to treatment or tracking 
software. Mice were considered to have entered an open or closed arm when both 
forepaws and front shoulders were on the arm. 
3.2.2.2.3 Tail suspension test (TST) 
On PND 51, each mouse was suspended from a bar 35 cm above the floor by affixing the 
end of its tail to the bar with adhesive scotch tape (Steru et al., 1985). The animals' 
behavior was videotaped for 6 min and the duration of total immobility scored by a 
trained observer blind to the treatment. 
3.2.3 Quantitative proteomics 
3.2.3.1 Determination of 15N incorporation  
The development of 15N incorporation rates during the labeling was monitored with the 
software QuantiSpec to determine 15N in both brain and plasma collected on PND 5, 14, 28, 
and 56 (Haegler et al., 2009a). The 14N and 15N samples were combined at an approximate 
ratio of 1:1 for cerebella (w/w) and plasma (v/v). The brain and tissue mixtures were put 
Proteomic and metabolomic brain and plasma profiling of a trait anxiety mouse model 
29 
into an ice-cold 5× buffer of 250mM sucrose, 50mM Tris - HCl (pH 7.4), 5mM MgCl2, 1mM 
DTT, 25 µg/ml Spermine, 25 µg/ml Spermidine, and a protease inhibitor cocktail tablet (F. 
Hoffmann-La Roche Ltd. Basel, Switzerland), and then homogenized by using a Teflon-glass 
dounce homogenizer and an electric drill at 1,200 rpm for 3 min. The homogenates were 
centrifuged at 20,000 g for 30 min at 4°C and the supernatants collected. The protein 
mixture was resolved by SDS-PAGE and the gel stained with Coomassie blue. Several 
selected gel pieces were subjected to in-gel tryptic digestion. Gel pieces were de-stained 
twice with 100 µL 50mM NH4HCO3 /ACN (1:1, vol/vol) for 30 min, and disulfide bonds 
reduced with 10mM DTT in 50mM NH4HCO3 at 56°C for 30 min, and then alkylated with 
55mM iodoacetamide in 50mM NH4HCO3 in the dark for 30 min. Subsequently, 12.5 ng/µL 
trypsin in 25mM NH4HCO3 was added to saturate and cover gel slices. The enzymatic 
reaction was carried out overnight at 37°C. After digestion, the peptides were extracted 
from the gel pieces by adding 5% formic acid at 37°C for 30 min. The gel pieces were spun 
down and the liquid collected. The extraction was repeated twice. Finally, the extracted 
peptide mixture was lyophilized to dryness and dissolved in 10 µL 0.1% trifluoroacetic acid 
(TFA). The peptide mixtures were then desalted by OMIX tips (Varian, Palo Alto, CA, USA) 
according to the manufacturer’s recommended procedure. The eluted cleaned peptides 
were spotted with 4-hydroxy-α-cyano-cinnamic acid (HCCA) onto AnchorChip™ targets 
(Bruker Daltonics, Bremen, Germany) (Schuerenberg et al., 2000). Both peptide mass 
fingerprinting (PMF) and MS/MS data were acquired by using an Ultraflex mass 
spectrometer (Bruker Daltonics).  
3.2.3.2 QuantiSpec  
Both PMF and MS/MS data were subjected to a MASCOT database search. The PMF 
spectra were exported in DAT format by using the script that was part of the FlexAnalysis 
2.4 software (Bruker Daltonics). Furthermore, the Mascot results were exported in XML 
format via the Mascot server XML-export service. The DAT and XML files were processed 
by QuantiSpec, written in ActivePerl language. Briefly, on the basis of the theoretical 
isotopologue distribution of identified peptides with a known amino acid sequence, the 
15N incorporation rate was determined by comparing the experimental isotope patterns 
with a set of theoretical ones. Relative quantitation was accomplished by calculating the 
signal intensity ratios for each 14N/15N peptide pair. 
3.2.3.3 Sample preparation 
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The hippocampus and plasma of male mice from PND56 were used for quantitative 
proteomics. The 14N-HAB/15N-HAB comparison was processed by a direct strategy (Figure 
8), whereas the HAB/LAB comparison was processed by indirect comparison (Figure 9).  
The plasma samples were first diluted 1:50 with a dilution buffer (10 mM Tris-HCl, pH 7.4, 
150 mM NaCl) provided in an IgY-M7 Spin column kit (GenWay Biotech, Inc., CA). The 
protein concentrations were estimated by Bradford assay, and then the two samples being 
compared (14N-HAB vs. 15N-HAB, 14N-HAB vs. 15N-NAB, 14N-LAB vs. 15N-NAB) were mixed at 
a ratio of 1:1, based on their protein content. The protein mixtures were subjected to 
IgY-M7 Spin column to remove the 7 high abundant proteins (Mouse Serum Albumin, IgG, 
Fibrinogen, Transferrin, IgM, Haptoglobin, and alpha1-Antitrypsin), according to the 
manufacturer’s guidelines. Briefly, the mixed proteins were first incubated with IgY 
microbeads, which bound the 7 high abundant proteins with the immobilized specific IgY 
antibodies. The other unbound proteins were spun down and collected as the 
flow-through factions, which contained the low abundant proteins. The flow-through 
fractions were concentrated by ultrafiltration with a centrifugal YM-3, 3 kDa cut-off filter 
(Millipore, MA). The resulting proteins were ready for SDS-PAGE separation. The bound 
fractions were eluted out with stripping buffer (0.1M Glycine-HCl, pH 2.5), and the 
columns regenerated by adding neutralization buffer (0.1M Tris-HCl, pH 8.0).  
The blood pellets collected from the plasma preparation were used to extract red blood 
cell proteins. For red blood cell lysis, the pellets were thawed on ice, and cold water 
containing 1mM PMSF was added. After the removal of cellular debris, the concentrations 
of supernatants were measured and 14N-LAB and 15N-HAB samples were mixed at a ratio of 
1:1. 
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Figure 9. Proteomic indirect comparison between two mouse strains. 
Figure 8. Proteomic direct comparison between two mouse strains 
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The brain proteins were extracted by using methods slightly modified from earlier ones 
(Cox and Emili, 2006). The mouse hippocampus was put into an ice-cold 10× buffer of 
250mM sucrose, 50mM Tris - HCl (pH 7.4), 5mM MgCl2, 1mM DTT, 25 µg/ml
 Spermine, 25 
µg/ml Spermidine and a protease inhibitor cocktail tablet (F. Hoffmann-La Roche Ltd., 
Basel, Switzerland) and then homogenized with a Teflon-glass dounce homogenizer and an 
electric drill at 1,200 rpm for 3 min. The homogenates were then centrifuged at 6,000g for 
15 min at 4°C to pellet the nuclei and mitochondria. The supernatants were collected, and 
the protein concentrations were measured by Bradford assay. The two samples being 
compared (14N-HAB vs. 15N-HAB, 14N-HAB vs. 15N-NAB, 14N-LAB vs. 15N-NAB) were mixed at 
a ratio of 1:1, based on their protein content. The protein mixtures were then subjected to 
an ultracentrifuge for 1 h at 100,000g in a swing bucket at 4°C. The supernatants were 
collected as the cytosol proteins. The pellets were re-suspended with 0.5 ml of ME buffer 
(20mM Tris-HCl [pH 7.8], 0.4M NaCl, 15% glycerol, 1mM DTT, protease inhibitor cocktail 
tablet [F. Hoffmann-La Roche Ltd., Basel, Switzerland], and 1.5% Triton-X-100) and 
incubated for 1 h with gentle rocking. The supernatants were collected as microsome 
proteins after a centrifuge at 9,000g, 4°C for 30 min. The protein concentrations of the 
cytosol and microsome fractions were measured by Bradford assay.  
The brain, plasma and blood cell protein mixtures were resolved by Criterion XT Bis-Tris 
precast gels (Biorad), and the gel stained with Coomassie Brilliant Blue. The gel lane 
containing the separated proteins was cut into 2 mm wide pieces, and the resulting pieces 
subjected to in-gel tryptic digestion. Gel pieces were de-stained twice with 100 µL 50mM 
NH4HCO3 /ACN (1:1, vol/vol) for 30 min, and disulfide bonds reduced with 10mM DTT in 
50mM NH4HCO3 at 56°C for 30 min, and then alkylated with 55mM iodoacetamide in 
50mM NH4HCO3 in the dark for 30 min. Subsequently, 12.5 ng/µL trypsin in 25mM 
NH4HCO3 was added to saturate and cover gel slices. The enzymatic reaction was carried 
out overnight at 37°C. After digestion, the peptides were extracted from the gel pieces by 
adding 5% formic acid at 37°C for 30 min. The gel pieces were spun down and the liquid 
collected. The extraction was repeated twice. Finally, the extracted peptide mixture was 
lyophilized to dryness and dissolved in 10 µL 0.1% formic acid. 
3.2.3.4 HPLC and Mass Spectrometry  
The peptide mixtures were analyzed by nanoHPLC (Eksigent Technologies, Inc., Dublin, CA) 
coupled to an LTQ-Orbitrap (Thermo Fisher Scientific, Bremen, Germany) hybrid mass 
spectrometer. The C18 reverse-phase columns were made by packing PicoFrit emitters 
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(New Objective, Inc., Woburn, MA) with a methanol slurry of reverse-phase ReproSil-Pur 
C18-AQ 3µm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) under a constant 
pressure of 100 bar. The packed columns were cut to approximately 15 cm length. 
Peptides were separated at a 200 nl/min flowrate by using a gradient of 2%-98% solvent B 
(98% ACN in water, 0.1% FA) over 130 min. The eluates were on-line electrosprayed into 
the mass spectrometer via a nanoelectrospray ion source (Thermo Fisher Scientific, San 
Jose, CA). 
The LTQ-Orbitrap was running in positive ion, top 5 data-dependent acquisition mode. For 
full scans in the Orbitrap, the target ion value was 1,000,000, and the maximal injection 
time was 500 ms at a resolution of r=60,000 at m/z 400. The MS full scan range was 
380-1600 m/z. The 5 most intense peaks in the MS scan were fragmented in the LTQ by 
collision-induced dissociation with a target value of 10,000 ions and an injection time of 
250 ms. Former precursor ions selected for MS/MS were dynamically excluded for a period 
ranging from 30 to 60 s. 
The mass spectrometric conditions were: spray voltage, 2.1 kV; no sheath and auxiliary gas 
flow; ion transfer tube temperature, 200°C; normalized collision energy using wide-band 
activation mode, 35% for MS2. 
3.2.3.5 Data processing 
For SEQUEST database analysis, the ORBITRAP raw files were searched against a 
concatenated forward/reversed IPI-mouse database v 3.46. The 14N database search was 
performed by using the following parameters: 20 ppm mass tolerance for the MS scan, 1 
Da for the MS/MS scan, fixed carbamidomethylation for cysteine, and variable oxidation 
for methionine. The 15N database search was executed using 15N amino acid masses and an 
additional -1 Da variable modification for arginine and lysine residues (Zhang et al., 2009). 
Assembly and removal of redundant proteins based on their accession numbers were 
performed by using Perl scripts written in-house. The SEQUEST results were filtered by 
using peptide XCorr >1.9 for 1+ charged ions, >2.7 for 2+ charged ions, >3.5 for 3+ or 
above charged ions, and DeltaCN >0.08. The false discovery rate (FDR) was then 
determined by calculating the ratio of the number of peptides identified from decoy to the 
number identified from forward database searches. Relative quantification of the peptide 
pair signals was performed with the ProRata software (Pan et al., 2006) on the basis of the 
SEQUEST identification results. Briefly, the ion chromatograms were extracted for both 
labeled and unlabeled isotope envelopes according to the identified amino acid sequence. 
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The m/z window for the natural isotopologue was calculated from the natural isotopic 
envelope of the peptide. The m/z window for the heavy isotopologue was calculated by 
using pre-defined 15N% for all nitrogen atoms. The retention time window of the selected 
ion chromatograms was defined as from 2 min before the identified MS/MS scans to 2 min 
after the identified MS/MS scans. The ratios of areas of labeled and unlabeled 
chromatographic peaks were used for peptide quantification.  
3.2.4 Corticosterone assay 
Corticosterone is the principle glucocorticoid secreted by the adrenal cortices of mice 
(Shimizu et al., 1983). Glucocorticoid (cortisol in humans and corticosterone in most 
laboratory rodents) exerts potent actions in the brain, influencing brain function by either 
shutting off the response of the hypothalamic-pituitary-adrenal (HPA) axis to stress or 
modulating behavioral states such as mood and emotion and cognitive functions such as 
learning and memory (Yu et al., 2008). Corticosterone concentrations were measured by 
radio immunoassay (RIA; DGR Instruments GmbH, Germany). Briefly, 100 μL of unlabeled 
corticosterone standards at the concentrations 25, 50, 100, 250, 500, and 1000 ng/ml, or 
1:200 diluted plasma samples, were mixed with 200 μL 125I-labeled corticosterone. A 
limited amount of anti-corticosterone was added to react with both labeled and unlabeled 
corticosterone. As the amount of antigen added increases, the fraction of labeled antigen 
bound to the antibody decreases correspondingly. After precipitating all antibody-bound 
antigen, the radioactivity was counted in a gamma counter.  
3.2.5 GO and KEGG analysis 
Quantified proteins were sorted by log2 ratio in ascending order and divided into five bins 
with log2 ratios of -1.0, -0.5, 0.5, 1.0. The GO analysis (Ashburner et al., 2000) was 
processed with the methods described previously (Pan et al., 2009) by using R (Team, 2009) 
and the GOstats (Falcon and Gentleman, 2007) package. Briefly, for each bin the P values 
for each GO category were calculated with the conditional hypergeometric test by using 
the quantitative proteome as a background. After obtaining the P value for each category 
and bin, GO categories were filtered on the basis of their P values. Categories with no 
significant enrichment (P < 0.05) in any bin were filtered out. Those categories that after 
filtering did not have a P value for a bin were provided a conservative P value of 1. Finally, 
the P values were transformed with the equation x = -log10 P, and the z-scores were 
calculated by [x-mean(x)]/sd(x). For the KEGG analysis (Kanehisa et al., 2004), the mouse 
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proteins were mapped to the KEGG ortholog level. This allows an interspecies comparison 
for further investigations. Afterwards, the hypergeometric test was calculated by using R. 
The background of the test was set to all mouse proteins in KEGG with at least one 
pathway entry (3319). Similar to the GO analysis, the P values were transformed into 
z-scores. 
3.2.6 Western blot analysis 
MS-based quantitative proteomics has quantified a number of proteins expressed 
differentially in 14N-HAB/15N-HAB, 14N-HAB/15N-NAB, and 14N-LAB/15N-NAB comparisons. 
Relative protein levels of several selected proteins were analyzed by Western blot. Protein 
mixtures with equal protein content (10-30µg) were first resolved by SDS-PAGE. 
Subsequently, the separated proteins were transferred onto polyvinylidene fluoride (PVDF) 
membranes. Western blot analysis was performed with several selected antibodies. The 
membranes were then incubated with HRP-conjugated secondary antibody. ECL system 
and film were used for membrane visualization. ECL images were quantified by 
QuantityOne software (BioRad). 
3.2.7 Metabolomics 
The metabolomic analyses shown in this thesis were processed at the ‘Metabolomics Core’ 
of the University of California, Davis, CA, USA (Dr. Vladimir Tolstikov).  
3.2.7.1 Sample preparation 
Six mice from each animal line were employed in metabolic studies. 
The plasma samples were prepared by using the method described previously (Fiehn and 
Kind, 2007). Briefly, the plasma proteins were precipitated, and the metabolite extraction 
was obtained. An aliquot of plasma extract was dried down, and the other aliquots were 
frozen for recording purposes. The plasma was derivatized by first adding methoxyamine 
in an aprotic basic solvent and then adding a trimethylsilylating agent. The derivatized 
sample was analyzed by direct thermodesorption GC-TOF. 
The brain tissue samples were prepared as follows: First, the extraction solution was 
prepared by mixing acetonitrile, isopropanol, and water in the volume proportion 3:3:2. 
The pH of acetonitrile and isopropanol (pH7) was checked using wetted pH paper. The 
extraction solution mix was rinsed with small bubbles of argon for 5 min. The Argon line 
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was flushed out of air before being used for degassing the extraction solvent solution. The 
extraction solution was pre-cooled at -18°C to -22°C. Eppendorf tubes with two metal balls 
(3 mm diameter) containing frozen mouse brain samples were placed in a freezer 
pre-chilled to -80°C or with liquid nitrogen Eppendorf-holder of the grinder. Immediately 
afterwards the Eppendorf tubes were put back in liquid nitrogen. 10-50 mg of frozen 
mouse brain (hippocampus) was homogenized with 500-2.500 μl (or aliquot according to 
sample aliquot) extraction solution mix for 45 s in 25 ml conical polypropylene tubes in the 
homogenizer Tissue Master 125. The homogenate was centrifuged at 2500 rpm for 5 min. 
An aliquoted 250 or 500 μl of supernatant was evaporated in the Labconco Centrivap cold 
trap concentrator to complete dryness. The dried residue was then re-suspended with 500 
μl of acetonitrile : water (1:1 v/v) mixture and centrifuged for 2 min at 14000 rcf in the 
centrifuge Eppendorf 5415 D. The clear supernatant was for GC-TOF-MS analysis. Samples 
were dried in the Labconco Centrivap cold trap concentrator to complete dryness and, 
once dried, stored in darkness under argon. The dried samples were then derivatized for 
GC/MS profiling. Methyl oxime derivatives were produced by dissolving the dry extracts in 
20 μL freshly prepared omethylhydroxylamine·HCl (40 mg/mL in pyridine) and incubated 
at 30°C for 90 min while being shaken continuously. Subsequent trimethyl silylation was 
achieved by adding 80 μL of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), 
followed by continuous shaking for 30 min at 37°C. 
3.2.7.2 GC-MS data acquisition 
GC-TOF-MS analysis was performed by using an Agilent 6890 N gas chromatograph (Palo 
Alto, CA, USA) interfaced to a time-of-flight (TOF) Pegasus III mass spectrometer (Leco, St. 
Joseph, MI, USA). The mass spectrometer first was tuned according to the manufacturer’s 
manuals to achieve optimal parameters for ion lenses, detector voltage, and other settings. 
Automated injections were performed with a programmable robotic Gerstel MPS2 
multipurpose sampler (Mülheim an der Ruhr, Germany). The gas chromatograph (GC) was 
fitted with both an Agilent injector and a Gerstel temperature-programmed injector, a 
cooled injection system (model CIS 4) with a Peltier cooling source. An automated liner 
exchange (ALEX), designed by Gerstel, was used to eliminate cross-contamination from the 
sample matrix between sample runs. Multiple baffled liners for the GC inlet were 
deactivated with 1 μL injections of MSTFA. One microliter of each sample was injected in 
splitless mode, depending on the metabolite concentrations and eventual signal-to-noise 
ratios in the GC-MS profiles. The Agilent injector temperature was held constant at 250°C 
while the Gerstel injector was programmed (initial temperature 50°C, hold 0.1 min, 
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increased at a rate of 10°C/s to a final temperature of 330°C, hold time 10 min). Injections 
of 1 μL were made in split (1:5) mode (purge time 120 s, purge flow 40 ml/min). 
Chromatography was performed on an Rtx-5Sil MS column (30 m × 0.25 mm i.d., 0.25 μm 
film thickness) with an Integra-Guard column (Restek, Bellefonte, PA, USA). Helium carrier 
gas was used at a constant flow of 1 mL/min. The GC oven temperature program had an 
initial temperature of 50°C, with a 1 min hold time, and was ramped at 20°C/min to a final 
temperature of 330°C with a 5 min hold time. Both the transfer line and source 
temperatures were 250°C. The Pegasus III TOF (Leco, St. Joseph, MI, USA) mass 
spectrometer ion source operated at -70 kV filament voltage with ion source. After a 
solvent delay of 350 s, mass spectra were acquired at 20 scans per second with a mass 
range of 50 to 500 m/z. 
3.2.7.3 Data analysis 
The data were processed according to the methods described previously (Zou and Tolstikov, 
2008). The Xconvert program included in Xcalibur was used to convert the Xcalibur (*.raw) 
files to netCDF (*.cdf) format. Automatic peak finding, deconvolution, and alignment were 
performed using XCMS running on the open statistical platform R. Preliminary data were 
explored by unsupervised methods such as principle component analysis (PCA) and 
clustering. For PCA, a scree plot (to show the optimal number of eigenvalues), a score plot 
(to show the most important principal components and visually detect clusters), and a 
loading plot (to show positive and negative correlations of components) were included for 
each analysis by using the R package pcaMethods in the Bioconductor project. Cluster 
analysis of the PCA scores was performed with partitioning methods such as K-means 
using the function kmeans() in R package stats; hierarchical agglomerative methods such 
as Ward's method using the function hclust() in R package stats; multiscale bootstrap 
resampling using R package pvclust; and the model-based clustering approach using R 
package mclust, which assumes a variety of data models. Maximum likelihood estimation 
and Bayes criteria were applied to identify the most likely model and number of clusters. 
All calculations were performed in an R integrated development environment (IDE), 
RKWard, under Kubuntu 7.10, a Debian Linux operating system, on a quad core Dell 
OptiPlex 755 workstation (4 x 3.0 GHz CPU speed, 2 x 4 MB L2 cache, 8 GB RAM). The 
current versions of Kubuntu, R, Bioconductor, XCMS, pcaMethods, stats, pvclust, mclust, 
GALGO, and RKWard are free open source softwares (FOSS). 
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The MarkerView 1.1 Software (Applied Biosystems/MDS Sciex, Concord, Ontario, Canada) 
allows data from several samples to be compared so that differences can be identified. 
Typical applications include metabolomics, biomarker discovery, metabolite identification, 
impurity profiling, etc. In the current study, this software was used for data analysis in 
conjunction with the techniques described above. The program uses multivariate analysis 
techniques to compare samples and provides both supervised and unsupervised methods. 
Supervised methods use prior knowledge of the sample groups (for example, 
affected/altered vs. control) to determine the variables that distinguish the groups. In 
contrast, unsupervised methods allow the structure within the data to be determined and 
visualized. The two approaches can be combined, i.e. unsupervised methods can be used 
to determine the groups, and then supervised methods can be used to confirm the 
important variables. 
3.2.8 Pathway analysis 
The interactions between protein-protein, protein-metabolite, and metabolite-metabolite 
were analyzed with the software Pathway Studio (Ariadne Inc., MD). The differentially 
expressed proteins (>2 fold change, 2 out of 3 replicates, 10 peptides) and metabolites 
(P < 0.05) were uploaded and converted to the synonymous names compatible with the 
software database. The direct interactions among different entities were mapped by 
Pathway Studio. The confidence of each interaction can be evaluated by the number of 
references providing evidence. The enrichment of a sub-network can be calculated 
regarding any functional group. The enrichment of each Gene Ontology category was also 
obtained. Specific networks were generated for different purposes. 
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3.3 Results 
3.3.1 Animal experiments 
3.3.1.1 Bacterial diet feeding 
No discernible health effects were observed in the animals fed the bacterial diet compared 
with those fed a standard diet. After pregnancy detection, 4 days of free-choice feeding 
between the standard and bacterial diets provided enough time for animals to adapt 
gradually to the change of diet.  
Before weaning, no differences in overall food consumption were observed between dams 
and the offspring in any mouse line or diet. However, the animals fed bacterial diet 
showed lower body weights than the animals fed with standard chow (Figure 10). The 
reason for the lower body weight could be the different protein sources and nutritional 
composition of the two diets.  
 
Figure 10. Weight gain after weaning of animals fed with a bacterial or standard diet. 
Compared to standard-fed HAB animals (orange dotted line), bacterial-fed animals 
(red line) had gained less body weight at different developmental time points 
(++p<0.01 bacterial vs. control). 
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Figure 11. Anxiety-related behavior at post natal day 5 in the ultrasonic vocalization test 
(USV).  
3.3.1.2 Behavior test 
3.3.1.2.1 Ultrasonic vocalization (USV) 
The ultrasonic vocalization test (UVT) at PND 5 was used to predict the anxiety level at an 
early developmental stage. The HAB mice emitted significantly more ultrasound 
vocalization than the LAB mice. The ultrasound vocalization of the NAB mice was between 
that of the HAB and LAB mice (Figure 11). The USV results do not show a significant 
isotopic effect of the 15N/14N bacterial diet on any of the animal lines (Figure 11). The 
15N-fed NAB mice had a slightly higher USV level than the 14N–NAB mice; however, both 
were still within the control range. When compared with the USV data acquired from the 
animals fed the standard diet (Figure 11 b), the USV phenotypes of the different anxiety 
mouse lines did not demonstrate an effect of the bacterial diet. 
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3.3.1.2.2 Tail suspension test (TST) 
 
Figure 12. Depression-like behavior in the tail suspension test (TST). 
The tail suspension test (TST) evaluates the level of depression-like behavior. Independent 
of gender (separate data not shown), LAB mice displayed significantly less immobility time 
than HAB and NAB animals in the TST (Figure 12). However, a difference was observed 
between 15N- and 14N-fed HAB mice. The 15N diet showed an antidepressant-like effect, 
and HAB mice fed 15N had significantly less immobility time in the TST, implying a lower 
level of passivity in a hopeless situation. The comparison between the animals fed the 
standard diet and those fed the bacterial diet indicated that the group of 15N-fed HAB mice 
was the only one whose TST behavior was affected significantly by 15N feeding (Figure 12b), 
whereas 15N-HAB animals still showed considerably more depression-like behavior than 
LAB animals. All the other groups demonstrated constant TST behavior, indicating that 
there were no isotopic or dietary effects. Another 15N-labeled diet based on Spirulina 
protein has shown a similar effect on depression-like behavior in HAB mice (Frank et al., 
2009). Therefore, this effect appears to be diet independent. Since the 14N and 15N diets 
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are supposed to have identical ingredients, except for the nitrogen form, the reason for 
the TST variation between 14N- and 15N-HAB mice must be related to the 15N isotope. 
Although the phenotype we observed can involve a combination of different factors, the 
known factor in this study is the 15N isotope; hence, we assume that an isotope effect 
exists and that it can affect both animal behavior and protein expression. 
In order to avoid this isotope effect, an indirect comparison strategy was employed to 
analyze the protein expression differences between HAB and LAB mice (Figure 9).  
3.3.1.2.3 Elevated plus maze (EPM) 
 
Figure 13. Anxiety-related behavior and locomotion on the elevated plus maze (EPM).  
Elevated plus maze (EPM) data (percentage of time spent on the open arms) were used to 
evaluate the anxiety-like behavior level. As shown in Figure 13, the HAB mice spent less 
than 10% of the total testing time on the open arms of the EPM; by contrast, the LAB mice 
spent more than 50% of the time on an open arm. The time spent by NAB mice on an 
open arm was between that of the other two groups. Compared to mice fed the standard 
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diet, neither the anxiety behavior nor the locomotion of the EPM phenotypes (Figure 13b) 
were affected by either the bacterial diet or 15N isotope. 
3.3.2 Quantitative proteomics 
3.3.2.1 15N Incorporation rates 
The 15N incorporation rates in brain and plasma were determined on the basis of the 
peptides and proteins quantified by QuantiSpc. Figure 14 shows how incorporation rates 
increased during 15N feeding. The peptides mixed 1:1 were analyzed by MALDI-TOF; the 
mass spectra of tryptic peptides LGEYGFQNAILVR from plasma albumin (Figure 14a) and 
IWHHTFYNELR from brain beta actin (Figure 14b) are shown in Figure 14. In both cases, 
the 15N isotopic envelopes moved to the higher mass range during 15N labeling, indicating 
an increase in the 15N incorporation rate. By PND of sacrifice, day 56, the incorporation 
rates in both brain and plasma had reached over 90% (Figure 14c), which is sufficient for 
sensitive and accurate quantification by mass spectrometry. 
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Figure 14. 15N incorporation rate changes during 15N labeling. a: Tryptic peptide 
LGEYGFQNAILVR derived from mouse plasma albumin; b: Tryptic peptide IWHHTFYNELR 
derived from brain beta actin; c: The average 15N incorporation rate on different labeling 
days  
3.3.2.2 Glyoxalase-I in blood cells and brain 
Glyoxalase-I (Glo1) previously was identified and quantified by two-dimensional gel 
electrophoresis (2-DE) in both brain and red blood cells as a protein that is expressed 
differentially between HAB and LAB mice (Kromer et al., 2005) (Figure 15a), which was 
also confirmed by Western blot (Figure 15b). However, because of the technical limitations 
of the 2-DE platform mentioned in the introduction above, Glo1 was one of only a few 
protein candidates found by 2-DE to be differentially expressed between HAB and LAB.  
The SILAM labeling approach has given a much deeper insight into the proteome 
differences between HAB and LAB. A greater number of proteins were found to have 
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altered expression levels. Glo 1 was used to evaluate whether SILAM gives the same 
results as 2-DE. Our 14N-HAB/15N-HAB comparison showed that Glo 1 expression was not 
influenced by 15N isotopic feeding. Therefore, the 15N-HAB/14N-LAB red blood cells were 
used for direct comparison of Glo 1 expression, and HAB/LAB hippocampi were compared 
by using the indirect approach. Figure 15c shows the red blood cell Glo 1 tryptic peptide 
from three different biological replicates. In all instances, the LAB mice have a higher 
expression level than the HAB mice. Figure 15d shows the results of the HAB/LAB indirect 
comparison for tryptic peptide GLAFIQDPDGYWIEILNPNK. The left panel of Figure 15d 
illustrates that the expression levels of Glo 1 are quite comparable in HAB and NAB mice. 
However, the NAB and LAB comparison, shown in the right panel, reveals that the LAB 
mice have a higher expression level of Glo 1. By combining the two comparisons, one can 
conclude that HAB mice have a lower protein expression level than LAB mice. In summary, 
SILAM quantification results from both brain and red blood cells closely agree with 
previous 2-DE experiments.  
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Figure 15. Quantification of glyoxalase-I in red blood cells and brain. a: 2-DE 
quantification; b: Western blot quantification; c: Direct comparison between HAB and LAB 
blood cell Glo1; d: Indirect comparison between HAB and LAB hippocampal Glo1. 
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3.3.2.3 HAB/NAB and LAB/NAB comparison in cytosol and microsomes 
HAB/NAB and LAB/NAB hippocampal cytosol comparisons generated quantitative results 
for 2273 and 1962 proteins, respectively. In total, 2761 proteins were quantified by at least 
one experiment; 1509 proteins were quantified by both HAB/NAB and LAB/NAB 
experiments and used for the subsequent HAB/LAB indirect comparison. Of these 
quantified proteins, 230 were found to be expressed differentially (2 fold change, 2 out 
of 3 replicates, 10 peptides) in HAB and LAB hippocampal cytosol (Supplementary table 
1). 
HAB/NAB and LAB/NAB hippocampal microsome comparisons generated quantitative 
results for 2545 and 1956 proteins, respectively. In total, 3284 proteins were quantified by 
at least one experiment; 1254 proteins were quantified by both HAB/NAB and LAB/NAB 
experiments and used for the subsequent HAB/LAB indirect comparison. Of these 
quantified proteins, 143 were found to be expressed differentially (2 fold change, 2 out 
of 3 replicates, 10 peptides) in HAB and LAB hippocampal microsome (Supplementary 
table 2). 
The correlation between hippocampal protein regulation and KEGG pathways is shown in 
Figure 16, and between hippocampal protein regulation and GO cellular component in 
Figure 17. The pathways and categories enriched with proteins from the first and fifth bins 
are of great interest, since they show a change between HAB and LAB. Notably, synapse 
proteins are enriched in the first bin, implying a role of synapses in psychiatric disorders. 
3.3.2.4 HAB/NAB and LAB/NAB comparison in plasma 
HAB/NAB and LAB/NAB plasma comparisons generated quantitative results for 640 and 
647 proteins, respectively. In total, 974 proteins were quantified by at least one 
experiment; 355 proteins were quantified by both HAB/NAB and LAB/NAB experiments 
and used for the subsequent HAB/LAB indirect comparison. Of these quantified proteins, 
48 were found to be expressed differentially (2 fold change, 2 out of 3 replicates, 10 
peptides) in HAB and LAB plasma (Supplementary table 3). 
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Figure 16. Correlation between hippocampal protein regulation and KEGG pathways. The 
blue boxes at the top show protein regulation factors between HAB and LAB mouse lines. 
Proteins were divided into five bins and analyzed with respect to KEGG pathways. P values 
were transformed to z-scores, indicating bin-specific enrichments. (Due to the limited 
resolution the pathway names on the right are not legible; higher resolution figure is 
available in electronic file.)  
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Figure 17. Correlation between hippocampal protein regulation and GO cellular 
component. The blue boxes at the top show protein regulation factors between HAB and 
LAB mouse lines. Proteins were divided into five bins and analyzed with respect to GO 
cellular component categories. P values were transformed to z-scores, indicating 
bin-specific enrichments. (Due to the limited resolution the category names on the right 
are not legible; higher resolution figure is available in electronic file.)  
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3.3.2.5 Isotope effects: HAB/HAB comparison in cytosol and plasma 
The 14N-HAB/15N-HAB hippocampal cytosol comparison generated quantitative results for 
2969 proteins. Of those quantified proteins, 39 were found to be expressed differentially 
(2 fold change, 2 out of 3 replicates, 10 peptides) in 14N- and 15N-HAB hippocampal 
cytosol (Supplementary table 4). 
The correlation between hippocampal protein regulation and KEGG pathways is shown in 
Figure 18. It is clear that most of the protein population enrichments are in the 
intermediate bin, indicating a consistent expression level between 14N- and 15N-HAB. 
Notably, the pathway “long−term depression” is enriched with proteins from the second 
bin, implying differences in this pathway between 14N- and 15N-HAB, which is in 
accordance with the finding of the isotope effects on depression-like behavior.  
A similar analysis was performed for GO cellular component (Figure 19). Several categories, 
such as neurofilament, synaptosome, axon, and myelin sheath—which are highly relevant 
to psychiatric disorders—were found to be enriched in the fourth bin, indicating a 
difference between 14N- and 15N-HAB.  
The 14N-HAB/15N-HAB plasma comparison generated quantitative results for 788 proteins. 
Of these quantified proteins, 51 were found to be expressed differentially (2 fold change, 
2 out of 3 replicates, 10 peptides) in 14N- and 15N-HAB plasma (Supplementary table 5). 
3.3.2.6 HAB/NAB indirect comparison in cytosol and plasma 
14N-HAB/15N-HAB and 14N-HAB/15N-NAB hippocampal cytosol comparisons generated 
quantitative results for 2969 and 2273 proteins, respectively. In total, 3376 proteins were 
quantified by at least one experiment; 1906 proteins were quantified by both HAB/NAB 
and LAB/NAB experiments and used for the subsequent HAB/LAB indirect comparison. Of 
these quantified proteins, 132 were found to be expressed differentially (2 fold change, 
2 out of 3 replicates, 10 peptides) in HAB and NAB hippocampal cytosol 
(Supplementary table 6).  
14N-HAB/15N-HAB and 14N-HAB/15N-NAB plasma comparisons generated quantitative 
results for 659 and 640 proteins, respectively. In total, 1090 proteins were quantified by at 
least one experiment; 276 proteins were quantified by both HAB/NAB and LAB/NAB 
experiments and used for the subsequent HAB/LAB indirect comparison. Of these 
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quantified proteins, 53 were found to be expressed differentially (2 fold change, 2 out 
of 3 replicates, 10 peptides) in HAB and NAB plasma (Supplementary table 7). 
 
Figure 18. Correlation between hippocampal protein regulation and KEGG pathways. The 
blue boxes at the top show protein regulation factors between 14N- and 15N-HAB. Proteins 
were divided into five bins and analyzed with respect to KEGG pathways. P values were 
transformed to z-scores, indicating bin-specific enrichments. (Due to the limited resolution 
the pathway names on the right are not legible; higher resolution figure is available in 
electronic file.)  
Results 
52 
 
Figure 19. Correlation between hippocampal protein regulation and GO cellular 
component. The blue boxes at the top show protein regulation factors between 14N- and 
15N-HAB. Proteins were divided into five bins and analyzed with respect to GO cellular 
component categories. P values were transformed to z-scores, indicating bin-specific 
enrichments. (Due to the limited resolution the category names on the right are not 
legible; higher resolution figure is available in electronic file.)  
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3.3.3 Corticosterone assay 
The protein corticosteroid-binding globulin (CBG, IPI00116105) showed an expression 
difference between 14N- and 15N-HAB in plasma (Figure 25). CBG is the major transport 
protein for glucorticoids and progestins in the blood. Therefore, corticosterone 
concentrations were investigated in 14N- and 15N-HAB plasma. The free corticosterone was 
analyzed after filtering out binding corticosterone by ultrafiltration. The 15N-HAB mice 
showed significantly higher total corticosterone concentrations (Figure 20 a, P = 0.0182) 
and free corticosterone concentrations (Figure 20b, P = 0.0271) than 14N-HAB mice. 
 
Figure 20. Plasma corticosterone assay. a: Total corticosterone concentrations in 14N- and 
15N-HAB plasma; the 15N mice have a significantly higher level of corticosterone than the 
14N mice (P =0.0182); b: Free corticosterone concentrations in 14N- and 15N-HAB plasma; 
the 15N mice have a significantly higher level of corticosterone than the 14N mice (P = 0. 
0271) 
3.3.4 Western blot validation 
Western blot analyses were performed for several selected proteins to verify our 
MS-based quantitative data with a different strategy. Previous discussions (Mann, 2008) 
and empirical experience have indicated that the sensitivity of Western blot analysis relies 
largely on the specificity and reactivity of the commercial antibody. Moreover, a large 
number of experiments have shown that MS-based quantification in general is more 
sensitive than Western blot. Hence, the success rate of Western blot validation depends 
on the quality of the antibody, and we did not expect a 100% success rate. 
3.3.4.1 14N-HAB vs. 15N-HAB 
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3.3.4.1.1 Hippocampus 
Neurofascin (IPI00329927) is an axonal member of the L1 subgroup of the immunoglobulin 
superfamily and is implicated in neurite extension in the course of embryonic 
development. The MS-based data showed a significant increase in protein expression in 
14N-HAB mice (Figure 21a). However, the findings could not be validated by Western blot 
analysis, i.e. the difference between 14N- and 15N-HAB was not found on a global level. 
However, if we focus only on the individual animals analyzed by mass spectrometry 
(marked with a star), the 14N-HAB mice showed a tendency towards a higher level of 
neurofascin (Figure 21b). Besides the uncontrolled quality of the antibody, individual 
biological variance represents another challenge in validating MS results by Western blot. 
Neurofilaments, including neurofilament heavy polypeptide (Nefh, IPI00114241), are 
found specifically in neurons. Some studies have shown that Nefh can impair spatial 
learning and neuritis (Lalonde and Strazielle, 2003; Liberski et al., 1995). The MS-based 
data showed a significant protein expression increase in 14N-HAB mice (Figure 22a). 
However, the finding could not be validated by Western blot analysis, i.e. the difference 
between 14N- and 15N-HAB was not found on a global level. Similar to neurofascin, the 
individual 14N-HAB animals analyzed by mass spectrometry also demonstrated a tendency 
towards an elevated expression of Nefh in Western blot analysis compared to the 15N-HAB 
mice (Figure 22b). This protein appears also to show individual biological variance. 
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Figure 21. Quantification of 14N-HAB/15N-HAB neurofascin (IPI00329927) by mass 
spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N and 15N 
tryptic peptide GPEPDTIIGYSGEDLPSAPR; the peak areas are used for the 14N/15N signal 
quantification; b: The Western blot analysis of neurofascin for 14N- and 15N-HAB; bands 
marked with a star are from the animals that were used also for MS analysis; unlabeled bands 
are from the animals that were analyzed only by Western blot; c: The densities of protein 
bands from Western blot (b) are shown; a t test was performed to compare the 14N and 15N 
groups (P = 0.1967). 
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Figure 22. Quantification of 14N-HAB/15N-HAB neurofilament heavy polypeptide (Nefh, 
IPI00114241) by mass spectrometry and Western blot. a: Eluted chromatographic profiles for 
both 14N and 15N tryptic peptide HQADIASYQDAIQQLDSELR; the peak areas are used for the 
14N/15N signal quantification; b: The Western blot analysis of Nefh for 14N- and 15N-HAB; bands 
marked with a star are from the animals that were used also for MS analysis; unlabeled bands 
are from animals that were analyzed only by Western blot; c: The densities of protein bands 
from Western blot (b) are shown; a t test was performed to compare the 14N and 15N groups 
(P = 0.2509). 
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3.3.4.1.2 Plasma 
The endogenous function of major urinary protein 3 (MUP3, IPI00120832) within an 
animal is still unknown, but may involve regulating energy expenditure. The MS-based 
data showed a significant protein expression increase in 14N-HAB mouse plasma (Figure 
23a). The same change was also found by Western blot analysis (Figure 23b and c). Some 
other proteins from the same subfamily have also been quantified by MS and found 
differentially expressed between 14N- and 15N-HAB (MUP2, MUP4, MUP5). 
Complement C5 (C5, IPI00330833) is involved in the complement system, a biochemical 
cascade that complements the ability of antibodies to clear pathogens from an organism. 
The complement system has been found to be relevant to many diseases, particularly 
those of the central nervous system, such as Alzheimer's disease and other 
neurodegenerative conditions (McGeer and McGeer, 2001; Mukherjee and Pasinetti, 
2000). The MS-based data showed a significant protein expression increase in 14N-HAB 
mouse plasma (Figure 24a). The same change also was found in Western blot analysis 
(Figure 24b and c). Some other proteins from the same subfamily also have been 
quantified by MS as proteins expressed differentially between 14N- and 15N-HAB, including 
C6, C8, and C9. 
Corticosteroid-binding globulin (CBG, IPI00116105) is the major transport protein for 
glucocorticoids and progestins in the blood of almost all vertebrate species. CBG and 
glucocorticoids have been found to be relevant to psychiatric diseases (de Kloet et al., 
2007; Maes et al., 1996). The MS-based data showed a significant protein expression 
increase in 15N-HAB mouse plasma (Figure 25a). The same change also was found in 
Western blot analysis (Figure 25b and c). 
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Figure 23. Quantification of 14N-HAB/15N-HAB major urinary protein 3 (MUP3, IPI00120832) 
by mass spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N and 
15N tryptic peptide AGIYYMNYDGFNTFSILK; the peak areas are used for the 14N/15N signal 
quantification; b: The Western blot analysis of MUP3 for 14N HAB and 15N HAB; c: The densities 
of protein bands from Western blot (b) are shown; a t test was performed between the 14N and 
15N groups (P < 0.0001). 
Proteomic and metabolomic brain and plasma profiling of a trait anxiety mouse model 
59 
 
  
a 
c 
b 
14N HAB                                 15N HAB 
15N HAB 
14N HAB 
Figure 24. Quantification of 14N-HAB/15N-HAB complement C5 (C5, IPI00330833) by mass 
spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N and 15N tryptic 
peptide TDDPELPEENQASK; the peak areas are used for the 14N/15N signal quantification; b: The 
Western blot analysis of C5 for 14N-HAB and 15N-HAB; c: The densities of protein bands from 
Western blot (b) are shown; a t test was performed between the 14N and 15N groups (P < 
0.0001). 
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Figure 25. Quantification of 14N-HAB/15N-HAB corticosteroid-binding globulin (CBG, 
IPI00116105) by using mass spectrometry and Western blot. a: Eluted chromatographic 
profiles for both 14N and 15N tryptic peptide NTLISPVSISMALAMLSLSTR; the peak areas are used 
for the 14N/15N signal quantification; b: The Western blot analysis of CBG for 14N-HAB and 
15N-HAB; c: The densities of protein bands from Western blot (b) are shown; a t-test was 
performed between the 14N and 15N groups (P=0.0007). 
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3.3.4.2 HAB vs. LAB indirect comparison 
3.3.4.2.1 Hippocampus 
Several proteins (Transthyretin, Myosin, Carbonic anhydrase 2) that showed expression 
differences in the HAB/LAB hippocampal comparison were chosen for the Western blot 
analyses.  
Transthyretin (TTR, IPI00127560) is a serum and cerebrospinal fluid carrier of the thyroid 
hormone thyroxine (T4) and retinol. TTR has been reported previously to play important 
roles in both depressed patients (Sullivan et al., 1999) and suicide attempters (Schultz et 
al., 2008). In this HAB/LAB indirect comparison using MS data, HAB mice showed a higher 
expression level of TTR than LAB mice (Figure 26a and b). The same difference was found 
in Western blot analysis (Figure 26c and d), confirming the MS-based quantitative result.  
Myosin, heavy polypeptide 10 (Myh10, IPI00338604), is a member of the myosin family, a 
family of mostly motor proteins found in eukaryotic tissues. An earlier study showed that 
myosin can be controlled indirectly by excess glucocorticoids (Fukumoto et al., 2009), 
which are one of the main mediators of the stress reaction in the HPA axis. In this HAB/LAB 
indirect comparison using MS data, HAB mice showed a lower expression level of Myh10 
than NAB mice (Figure 27a and b). The same difference was found in Western blot analysis 
(Figure 27c and d), confirming the MS-based quantitative result. However, the LAB/NAB 
comparison could not be validated by Western blot. 
Carbonic anhydrase 2 (CA2, IPI00121534) catalyses the hydration of CO2 and the hydrolysis 
of esters. Complete absence of CA2 leads to mild mental retardation, cerebral calcification, 
osteoporosis, and renal tubular acidosis. For example, the inhibitor of carbonic anhydrase, 
topiramate, has been used to treat bipolar disorder, and topiramate often is used to 
augment psychotropics or to counteract the weight gain associated with numerous 
antidepressants (Arnone, 2005). In this HAB/LAB indirect comparison using MS data, HAB 
mice showed a higher expression level of CA2 than LAB mice (Figure 28a and b). The same 
difference was found in Western blot analysis (Figure 28c and d), confirming the MS-based 
quantitative result.  
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a                            b 
Figure 26．Quantification of HAB/LAB transthyretin (TTR, IPI00127560) by mass 
spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N-HAB 
and 15N-NAB tryptic peptide TSEGSWEPFASGK; b: Eluted chromatographic profiles for 
both 14N-LAB and 15N-NAB tryptic peptide TSEGSWEPFASGK; the peak areas are used for 
the 14N/15N signal quantification; c: The Western blot analysis of TTR for HAB, LAB, NAB; 
d: The densities of protein bands from Western blot (c) are shown; a t test was 
performed between groups (LAB vs. HAB: P = 0.0002; NAB vs. HAB: P = 0.0004) 
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Figure 27. Quantification of HAB/LAB Myosin, heavy polypeptide 10 (Myh10, IPI00338604), 
by mass spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N-HAB 
and 15N-NAB tryptic peptide DAAGLESQLQDTQELLQEETR; b: Eluted chromatographic profiles 
for both 14N-LAB and 15N-NAB tryptic peptide DAAGLESQLQDTQELLQEETR; the peak areas are 
used for the 14N/15N signal quantification; c: The Western blot analysis of Myh10 for HAB, LAB, 
NAB; d: The densities of protein bands from Western blot (c) are shown; a t test was 
performed between groups (NAB vs. HAB: P = 0.0009). 
a                            b 
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Figure 28. Quantification of HAB/LAB carbonic anhydrase 2 (CA2, IPI00121534) by mass 
spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N-HAB 
and 15N-NAB tryptic peptide AVQQPDGLAVLGIFLK; b: Eluted chromatographic profiles for 
both 14N-LAB and 15N-NAB tryptic peptide AVQQPDGLAVLGIFLK; the peak areas are used 
for the 14N/15N signal quantification; c: The Western blot analysis of CA2 for HAB, LAB, 
NA;. d: The densities of protein bands from Western blot (c) are shown; a t test was 
performed between groups (LAB vs. HAB: P = 0.0025; NAB vs. HAB: P = 0.0114). 
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3.3.4.2.2 Plasma 
As mentioned above, transthyretin (TTR, IPI00127560) is a serum and cerebrospinal fluid 
carrier of the thyroid hormone thyroxine (T4) and retinol. TTR is one of a few proteins 
found to be expressed differentially between HAB and LAB mice in both brain and plasma. 
In this HAB/LAB indirect comparison using MS data, HAB mice showed a higher expression 
level of TTR than LAB mice (Figure 29a and b). The same difference was found in Western 
blot analysis (Figure 29c and d) confirming the MS-based quantitative result. 
Serum amyloid P-component (SAP, IPI00309214) is a normal plasma constituent that has 
been found to be a biomarker for mild cognitive impairment and Alzheimer's disease 
(Nishiyama et al., 1996; Verwey et al., 2008; Yasojima et al., 2000). In this HAB/LAB indirect 
comparison using MS data, LAB mice showed a higher expression level of SAP than HAB 
mice (Figure 30a and b). The same difference was found in Western blot analysis (Figure 
30c and d), confirming the MS-based quantitative result.  
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Figure 29. Quantification of HAB/LAB transthyretin (TTR, IPI00127560) by mass 
spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N-HAB and 
15N-NAB peptide tryptic TAESGELHGLTTDEK; b: Eluted chromatographic profiles for both 
14N-LAB and 15N-NAB tryptic peptide TAESGELHGLTTDEK; the peak areas are used for the 
14N/15N signal quantification; c: The Western blot analysis of TTR for HAB, LAB, NAB; d: 
The densities of protein bands from Western blot (c) are shown; a t test was performed 
between groups (LAB vs. NAB: P < 0.0001; LAB vs. HAB: P < 0.0001; NAB vs. HAB: P = 
0.0015) 
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Figure 30. Quantification of HAB/LAB Serum amyloid P-component (SAP, IPI00309214) by 
mass spectrometry and Western blot. a: Eluted chromatographic profiles for both 14N-HAB 
and 15N-NAB tryptic peptide GRDNELLIYKEK; b: Eluted chromatographic profiles for both 
14N-LAB and 15N-NAB tryptic peptide GRDNELLIYKEK; the peak areas are used for the 
14N/15N signal quantification; c: The Western blot analysis of SAP for HAB, LAB, NAB; d: The 
densities of protein bands from Western blot (c) are shown; a t test was performed 
between groups (LAB vs. NAB: P = 0.0001; LAB vs. HAB: P = 0.0008) 
. 
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3.3.5 Metabolomics 
The data presented in this thesis kindly were analyzed by the ‘Metabolomics Core’ of the 
University of California, Davis, CA, USA (Dr. Vladimir Tolstikov). The results concerning the 
technical platform are presented with permission from Dr. Vladimir Tolstikov.  
3.3.5.1 Data processing 
GC-TOF-MS data were annotated prior to further analysis (Scholz and Fiehn, 2007). The 
GC-MS annotation procedure was automated and the data output generated as an Excel 
table (Scholz and Fiehn, 2007). Initial GC-TOF-MS peak detection and mass spectrum 
deconvolution were performed with ChromaTOF software (version 2.25, Leco). A reference 
chromatogram was defined that had a maximum of detected peaks over a signal/noise 
threshold of 20. This reference chromatogram was used for automated peak identification 
by means of mass spectral comparison to a standard NIST 05 library and in-house 
customized mass spectral libraries. Analytes spectra were searched against custom 
spectrum libraries and identified on the basis of the retention index and spectrum 
similarity match. A mixture of the retention time standards n-dodecane (RI 1,200), 
n-pentadecane (RI 1,500), n-nonadecane (RI 1,900), n-docosane (RI 2,200), n-octacosane 
(RI 2,800), n-dotriacontane (RI 3,200), and n-hexatriacontane (RI 3,600) was included in 
the final reagent volume (Wagner et al., 2003). Automated assignments of unique 
fragment ions for each individual metabolite were chosen as quantifiers and corrected 
manually where necessary. Relative quantification was performed on quantifiers with 
optimal selectivity. All known artifact peaks caused by column bleeding or phthalates and 
polysiloxanes derived from MSTFA hydrolysis were identified manually and removed from 
the results table. Since the purposes of the described studies were mainly clustering, 
classification, and prediction, metabolite annotation and identification were not required 
prior to data mining.  
GC-TOF-MS datasets were used after annotation. It is very important to search for and 
eliminate correlated variables introduced during sample preparation or as a result of the 
analytical methods, or both, especially for values close to the margins of measurements 
like overload, limits of detection, and background noise levels. Close proximity to these 
factors easily can generate false positive values characterized by a convincing P value that 
may not reflect the actual situation but rather the absence of the particular variable, 
which is not detected in a sample, or group of samples, since its level is below the current 
lower limit of detection of the instrument or method. When a biological question is 
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related to the highest variance in a dataset, PCA is a powerful technique to reduce, 
visualize, and explore dimensionality. 
Visualization methods often are the best way to discover interesting grouping information 
in data, whereas clustering methods provide mathematical rigor. Basically, there are three 
major categories of clustering methods: partitioning (clusters), hierarchical (trees), or 
probability model based (models). Partitioning methods map peaks into multiple 
disjointed clusters using a chosen criterion. K-means is the most popular partitioning 
method, although it requires the input of an initial clustering number. The K-means 
clustering algorithm chooses a pre-specified number of cluster centers to minimize the 
within-class sum of squares from those centers. Hierarchical methods construct a binary 
tree in which the root is a single cluster containing only one element and the leaves each 
contain only one element. A divisive tree is built top-down, and an agglomerative tree 
bottom-up. Recently, with the advances in methods, software, and interpretability of the 
results, probability model-based clustering methods have become increasingly popular. 
Probability modeling assumes that the data pool is a mixture with all of the labels lost and 
tries to find the most probable label for each data point. 
3.3.5.2 Plasma 
By using the strategy described previously, in mouse plasma 273 metabolites were 
detected, of which 94 compounds with a known chemical structure were identified. 
Concentrations of 31 known metabolites differed significantly (P < 0.05) between mouse 
lines (Table 2). For instance, the concentration of cholesterol in HAB plasma was much 
higher than in NAB and LAB plasma (Figure 31). Another metabolite that deserves 
attention is inositol. The HAB mice showed a higher level only for allo-inositol and not for 
other stereoisomers, such as myo-inositol (Figure 32). The PCA plots showed significant 
clustering and differentiation among groups (Figure 33). 
Table 2. Metabolite level comparisons (P < 0.05) in plasma between three mouse lines 
Metabolites P values 
HAB vs. LAB HAB vs. NAB LAB vs. NAB 
Threonic acid 0.003 0.040 0.968 
Pseudo uridine 0.002 0.688 0.001 
Malate 0.046 0.817 0.090 
Lysine 0.034 0.248 0.397 
Inositol myo- 0.002 0.785 0.005 
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Inositol allo- 0.045 0.079 0.864 
Indole-3-lactate 0.026 0.246 0.103 
Glutamic acid 0.000 0.299 0.004 
Fumaric acid 0.043 0.822 0.066 
Cholesterol 0.035 0.000 0.166 
Alanine 0.009 0.012 0.544 
3-hydroxypropionic acid 0.045 0.008 0.370 
3-hydroxy-3-methylglutaric acid 0.042 0.094 0.447 
Uric acid 0.180 0.110 0.012 
Tocopherol alpha 0.877 0.034 0.018 
Ornithine 4TMS 0.085 0.285 0.033 
Hydroxycarbamate 0.107 0.684 0.046 
Fructose 2 0.118 0.430 0.014 
Fructose 1 0.149 0.501 0.026 
Arabitol 0.223 0.207 0.023 
3,6-anhydrogalactose 0.992 0.057 0.023 
Valine 0.515 0.043 0.179 
Taurine 0.583 0.041 0.115 
Serine 0.357 0.027 0.395 
Pelargonic acid 0.516 0.045 0.208 
Methionine 0.118 0.003 0.215 
Leucine 0.368 0.029 0.192 
Isoleucine 0.707 0.037 0.096 
Glycine 0.495 0.029 0.098 
Ethanolamine 0.698 0.023 0.280 
1-monoolein 0.112 0.020 0.880 
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Figure 31. Variation of plasma cholesterol levels in the three mouse lines: 1,HAB; 2,LAB; 
3,NAB. 
  
a                            b 
Figure 32. Variation of plasma inositol levels in the three mouse strains: 1,HAB; 2,LAB; 
3,NAB. a: allo-inositol stereoisomer; b: myo-inositol stereoisomer 
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3.3.5.3 Hippocampus 
By applying our strategy to mouse hippocampi, 281 metabolites were detected, 129 of 
which were identified as having a known chemical structure. Concentrations of 14 known 
metabolites differed significantly (P < 0.05) between mouse lines (Table 3). For instance, 
the concentration of zymosterol, a cholesterol intermediate, was much higher in HAB brain 
than in LAB brain (Figure 34). The PCA plots showed significant clustering and 
differentiation among groups (Figure 35). 
  
a                              b 
Figure 33. PCA-DA scores and loading plots of the HAB, NAB, and LAB plasma metabolites. 
GC-TOF-MS data. a: Groups (HAB, NAB, LAB) are color coded as: 1, red: HAB; 2, green: LAB; 3, 
blue: NAB; the software MarkerView 1.0 was used; b: Loading plot showing resolved 
metabolites, annotated by BinBase (Scholz and Fiehn, 2007); chemical names are given for 
known metabolites; unidentified ones are labeled with numbers. (Due to the limited resolution 
the metabolite names are not legible; higher resolution figure is available in electronic file.) 
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Table 3. Metabolite level comparisons (P < 0.05) in hippocampi of the three mouse lines 
Metabolites P-values 
HAB vs. LAB HAB vs. NAB LAB vs. NAB 
1,2,4-benzenetriol 0.775  0.009  0.274  
2-hydroxybutanoic acid 0.032  0.756  0.007  
Dehydroascorbate 1 0.123  0.000  0.162  
Dehydroascorbate 3 0.132  0.000  0.186  
Ethanolamine 0.804  0.010  0.121  
FAD 0.128  0.001  0.389  
Fucose 1 + rhamnose 2 0.019  0.009  0.217  
Glycerol-beta-phosphate 0.365  0.012  0.143  
Inosine 0.128  0.556  0.042  
Palmitic acid butyl ester NIST 0.653  0.050  0.185  
Palmitoleic acid 0.101  0.046  0.573  
Threonic acid 0.067  0.048  0.269  
Xylose 1 0.297  0.008  0.327  
Zymosterol 0.914  0.038  0.079  
Figure 34. Variation of hippocampal zymosterol levels in the three mouse strains: 1,HAB; 
2,LAB; 3,NAB. 
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3.3.6 Pathway analysis 
The differentially expressed proteins and metabolites quantified from HAB/LAB/NAB mice 
as biomarker candidates were used to generate interaction maps with the Pathway Studio 
software. The proteins and metabolites were grouped on the basis of the Ariadne 
pathways, ontology (software built-in), GO cellular component, molecular function, and 
biological process. The P value of each biological event was calculated to assess the entity 
enrichment. Furthermore, sub-networks were created on the basis of the different target 
and interaction types. The enrichments also were assessed for statistical significance. 
Some of the top enriched categories are listed in Tables 4-11. Several well-known 
biological processes that may contribute to psychiatric disorders demonstrated high entity 
enrichments, such as oxidative stress, tricarboxylic acid cycle, glycinergic synaptic 
transmission, and long-term synaptic potentiation (LTP) (Figure 36). LTP is a critical neural 
process that likely underlies learning and memory formation (Bliss and Collingridge, 1993; 
Cooke and Bliss, 2006) and was another promising finding in this study. LTP has been well 
a                            b 
Figure 35. PCA-DA score and loading plots of the HAB, NAB, LAB hippocampal metabolites. 
GC-TOF-MS data. a: Groups (HAB, NAB, LAB) are color coded as: 4, purple: HAB; 5, green: LAB; 
6, red: NAB; the software MarkerView 1.0 was used; b: Loading plot showing resolved 
metabolites, annotated by BinBase (Scholz and Fiehn, 2007); chemical names are given for 
known metabolites ; unidentified ones are labeled with numbers. (Due to the limited 
resolution the metabolite names are not legible; higher resolution figure is available in 
electronic file.) 
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studied in neurodegenerative diseases, such as Alzheimer's disease (Rowan et al., 2003). It 
also has been found to influence anxiety (Marsch et al., 2007; Walther et al., 1998).  
Ariadne pathway and ontology analyses revealed several pathways that are significantly 
enriched with proteins and metabolites expressed differentially between animal lines 
(Table 4-5). These pathways may provide new insights into disease pathobiology. The 
tricarboxylic acid cycle (TCA cycle) showed a high entity enrichment in both the Ariadne 
Metabolic Pathways and ontology (Table 4-5) analyses. Twenty-five percent of the total 
ontology entities involved in the TCA cycle were found to be differentially expressed 
between the three mouse lines (Table 5, Figure 36d), indicating an important role of 
energy metabolism in anxiety.  
The notch pathway resulting from the Ariadne Signaling Pathways demonstrated a high 
entity enrichment (Table 6), implying its potential function in psychiatric disorders. The 
Notch signaling pathway is a highly conserved cell-signaling system present in most 
multicellular organisms (Artavanis-Tsakonas et al., 1999) and is very important for cell-cell 
communication as well as neuronal function (Gaiano and Fishell, 2002) and many diseases 
(Radtke et al., 2010; Tao et al., 2010). Some other pathways or ontologies, such as axon 
guidance, also have been found potentially to be involved in anxiety (Table 6). 
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Table 4. Ariadne metabolic pathways with P < 0.05 
Name 
Number of 
Entities 
Percent 
Overlap 
P value 
Tricarboxylic acid cycle 69 15 8.16E-06 
Branched chain amino acids metabolism 127 11 3.68E-05 
Serine and glycine metabolism 95 9 2.99E-03 
Ser/Gly/Thr/Cys metabolism 183 6 1.29E-02 
Folate biosynthesis 73 8 2.85E-02 
Bile acids metabolism 104 6 4.80E-02 
 
Oxidative stress                   Glycinergic synaptic transmission 
Long term synaptic potentiation               Tricarboxylic acid cycle 
Figure 36. Pathways enriched with proteins and metabolites. (Due to the limited resolution 
the protein/metabolite names are not legible; higher resolution figure is available in 
electronic file) 
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Table 5. Ariadne ontology with the 15 most significant P values. 
Name 
Number of 
Entities 
Percent 
Overlap 
P value 
Tricarboxylic acid cycle 39 25 1.21E-09 
Branced aminoacid metabolism 46 21 6.93E-09 
Actin-based cytoskeleton assembly 202 7 3.75E-06 
Actomyosin based movement 72 12 5.52E-06 
Microtubule sliding 156 7 2.54E-05 
ER to Golgi transport 47 12 1.89E-04 
ROCK1-2 2 100 3.26E-04 
Lipid transport 55 10 4.53E-04 
Asp/Lys/Thr/Met/Cys metabolsm 39 12 6.46E-04 
PAK 3 66 9.68E-04 
Protein folding 88 7 1.06E-03 
Aromatic aminoacid metabolism 125 6 1.93E-03 
Ubiquitin-dependent protein 
degradation 
166 5 3.20E-03 
Microtubule cytoskeleton assembly 148 5 5.45E-03 
PP2A 7 28 6.46E-03 
 
Table 6. Ariadne signaling pathways with the 10 most significant P values. 
Name 
Number of 
Entities 
Percent 
Overlap 
P value 
Notch pathway 1486 4 2.61E-06 
B-cell activation 1178 4 1.97E-05 
Insulin action 905 4 2.38E-05 
EphrinR -> actin signaling 216 7 3.21E-05 
Actin cytoskeleton regulation 539 5 4.77E-04 
T-cell activation 1100 4 5.47E-04 
Adipocytokine signaling 780 4 4.05E-03 
TNFRSF6 -> HSF1 signaling 15 20 5.96E-03 
EctodysplasinR -> AP-1 signaling 19 15 1.18E-02 
Axon guidance 1049 3 1.35E-02 
 
The GO biological process analyses revealed a number of categories that are significantly 
enriched with differentially expressed proteins and metabolites. The TCA cycle also was 
found as a “top hit” in this study (Table 7), confirming another result from Ariadne 
pathway analysis. Besides the TCA cycle, the fat metabolism-related categories, such as 
lipid transport (P = 5.65E-08), the cholesterol metabolic process (P = 9.17E-08), 
phospholipid efflux (P = 2.25E-07), cholesterol efflux (P = 1.66E-06), and the lipoprotein 
metabolic process (P = 3.56E-06), showed higher enrichments, indicating a potential 
correlation between fat metabolism and anxiety. Furthermore, proteins involved in 
oxidation reduction may play an important role in the response to oxidative stress, which 
is involved in many diseases, including many psychiatric disorders.  
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Table 7. Gene ontology biological process categories with the 20 most significant P 
values. 
Name 
Number of 
Entities 
Percent 
Overlap 
P value 
Metabolic process 858 4 1.43E-14 
Transport 1807 2 2.08E-08 
Lipid transport 94 10 5.65E-08 
Cholesterol metabolic process 75 12 9.17E-08 
Tricarboxylic acid cycle 24 25 1.44E-07 
Phospholipid efflux 14 35 2.25E-07 
Response to oxidative stress 137 8 2.26E-07 
Triglyceride metabolic process 33 18 1.09E-06 
Cholesterol efflux 20 25 1.66E-06 
Response to reactive oxygen species 22 22 2.77E-06 
Lipoprotein metabolic process 40 15 3.56E-06 
Cell motion 120 7 5.06E-06 
Response to axon injury 12 33 5.45E-06 
Acute-phase response 43 13 5.51E-06 
Protein transport 556 3 7.49E-06 
Intracellular protein transport 235 5 7.76E-06 
Response to carbohydrate stimulus 13 30 7.81E-06 
Anti-apoptosis 198 5 8.43E-06 
Interspecies interaction between 
organisms 
239 5 9.21E-06 
Oxidation reduction 702 2 1.86E-05 
 
The GO cellular component analyses indicated the localizations of proteins expressed 
differentially between HAB, NAB, and LAB mice (Table 8). Not surprisingly, cytoplasm had 
the largest number of proteins. The mitochondrial proteins also were more likely to differ 
between mouse lines; this is in accord with the findings on the TCA cycle because almost 
all the enzymes of the TCA cycle are located in the mitochondrial matrix. The TCA cycle 
first oxidizes acetyl-CoA to carbon dioxide and, in the process, produces reduced cofactors 
(three molecules of NADH and one molecule of FADH2) that are a source of electrons for 
the electron transport chain and a molecule of GTP that readily can be converted to ATP 
(Henze and Martin, 2003). 
The high-density lipoprotein particle and very-low-density lipoprotein particle were found 
to be highly enriched with differentially expressed proteins which is in agreement with GO 
biological process analysis, which found many differences in the expression of proteins 
related to fat metabolism. 
Another relevant group of proteins comes from axons, long, slender projections of a 
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neuron. Axons conduct electrical impulses away from the neuron's cell body and play a 
very important role in neuronal signal transmission. Axon dysfucntion previously has been 
reported to be closely related to schizophrenia (Benes et al., 1987; Eastwood et al., 2003; 
Pierri et al., 1999), depression (Hatt and Smith, 1976), and other psychiatric disorders. 
 
Table 8. Gene ontology cellular component categories with the 20 most significant P 
values. 
Name 
Number of 
Entities 
Percent 
Overlap 
P value 
Cytoplasm 5094 2 5.08E-29 
Cytosol 1197 5 8.22E-22 
Mitochondrial matrix 171 12 3.96E-16 
Mitochondrion 1253 4 1.54E-15 
Soluble fraction 428 6 7.67E-12 
Cytoskeleton 624 4 7.31E-09 
Stress fiber 36 22 1.29E-08 
High-density lipoprotein particle 25 28 1.86E-08 
Axon 137 9 2.05E-08 
Growth cone 61 14 6.92E-08 
Microtubule 270 5 3.70E-07 
Microtubule-associated complex 80 11 7.51E-07 
Perinuclear region of cytoplasm 188 6 8.35E-07 
COPII vesicle coat 7 57 8.39E-07 
Chylomicron 16 31 1.20E-06 
Very-low-density lipoprotein particle 17 29 1.68E-06 
Melanosome 88 10 1.69E-06 
Proteasome complex 33 18 3.16E-06 
ER-Golgi intermediate compartment 36 16 5.39E-06 
Protein complex 500 4 6.28E-06 
 
The GO molecular function analyses (Table 9) again demonstrated that the energy- and 
fat-related categories are enriched with proteins. For instance, a large number of proteins 
involved in ATP and ADP binding were found to be expressed differentially between HAB 
and LAB. The proteins relevant to phospholipid binding, lipid binding, lipid transporter 
activity, and cholesterol transporter activity were all highly enriched. Similarly, the 
oxidation-related proteins in the categories of antioxidant activity and oxidoreductase 
activity were all found to be highly enriched.  
Table 9. Gene ontology molecular function categories with the 20 most significant P 
values. 
Name Number of Percent P value 
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Entities Overlap 
Protein binding 7274 2 2.29E-20 
Catalytic activity 871 4 6.12E-14 
Motor activity 157 10 7.09E-11 
Nucleotide binding 2057 2 5.56E-10 
ATP binding 1750 2 8.58E-10 
Eukaryotic cell surface binding 23 30 6.54E-09 
Binding 1151 3 1.32E-07 
Hydrolase activity 1657 2 1.89E-07 
Microtubule binding 84 10 7.14E-07 
Phospholipid binding 64 12 9.07E-07 
Microtubule motor activity 99 9 2.87E-06 
Antioxidant activity 20 25 3.08E-06 
Actin binding 352 4 5.65E-06 
Lipid binding 169 6 6.15E-06 
Unfolded protein binding 146 6 1.04E-05 
ADP binding 26 19 1.23E-05 
Calmodulin binding 152 6 1.48E-05 
Lipid transporter activity 29 17 2.16E-05 
Oxidoreductase activity 730 3 2.44E-05 
Cholesterol transporter activity 16 25 3.19E-05 
 
The sub-network analyses were performed with two different methods. The interaction 
type of the first analysis was based exclusively on protein-protein or protein-metabolite 
binding. The second interaction map used all the other interaction methods, such as 
regulation, expression, etc. The sub-network analyses identified central proteins, 
metabolites, or even biological events and their interacting neighbor entities. The 
presence of a high enrichment of input proteins and metabolites in a particular network 
may indicate a potential correlation with the disease.  
The non-binding analyses demonstrated a number of networks that are highly enriched 
with proteins and metabolites expressed differentially between HAB and LAB (Table 10). 
The 20 networks with the most significant P values are shown in Table 10. 
Table 10. Sub-networks (connected by non-binding) with the 20 most significant P 
values. 
Central Entity 
Total Number 
of Neighbors 
Percent 
Overlap 
P value 
PD 98,059 23 66 2.39E-25 
Genistein 16 76 4.40E-22 
Dexamethasone 23 58 4.16E-21 
Cisplatin 10 90 1.11E-18 
Calcimycin 13 71 9.80E-17 
Nicotine 14 66 2.91E-16 
Wortmannin 11 75 1.75E-15 
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Cycloheximide 43 29 7.05E-15 
Okadaic acid 19 50 1.69E-14 
Rapamycin 10 72 1.05E-13 
Actinomycin D 10 72 1.05E-13 
Trichostatin A 10 72 1.05E-13 
Staurosporine 16 52 1.83E-13 
U0126 7 87 4.17E-13 
Diethylstilbestrol 165 11 5.01E-13 
Cilastatin sodium 8 77 1.85E-12 
Cyclosporine 9 70 6.11E-12 
Edetic acid 9 70 6.11E-12 
C.I. 77491 15 50 7.76E-12 
D-glucose 1518 3 8.27E-12 
 
 
Figure 37. Network of Ras/Raf/MEK/ERK pathway inhibition. The proteins shown in this 
figure interact with the metabolites that inhibit the Ras/Raf/MEK/ERK pathway. (Due to 
the limited resolution the protein/metabolite names are not legible; higher resolution 
figure is available in electronic file.) 
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Figure 38. Quantification of MEK and phosphorylated MEK by Western blot analysis. a: 
The Western blot analysis of MEK and p-MEK for HAB, LAB, and NAB; b: The densities of 
protein bands from Western blot (a) are shown; a t test was performed between groups 
(MEK comparisons: LAB vs. NAB: P < 0.0001; HAB vs. NAB: P = 0.0009 ; p-MEK comparisons: 
LAB vs. HAB: P = 0.0059; HAB vs. NAB: P = 0.0329) 
One notable pathway that deserves much attention is the signal transduction 
Ras/Raf/MEK/ERK(MAPK) pathway. Ras is a protein subfamily of small GTPases; Raf, MEK, 
and MAPK are all serine/threonine protein kinases. Activated Ras activates the protein 
kinase activity of Raf kinase; Raf kinase phosphorylates and activates MEK; and MEK 
phosphorylates and activates a mitogen-activated protein kinase (MAPK). A significant 
number of central entities, shown in Table 10, have been used to inhibit the 
Ras/Raf/MEK/ERK pathway, including but not limited to PD 98059 (Alessi et al., 1995; 
Dudley et al., 1995; Lazar et al., 1995; Pang et al., 1995), genistein (Akiyama et al., 1987), 
wortmannin (Ferby et al., 1996; Wymann et al., 1996), okadaic acid (Fujiki and Suganuma, 
2009; Garcia et al., 2003), staurosporine (Karaman et al., 2008), U0126 (Duncia et al., 1998; 
Favata et al., 1998), and SB 203580 (Cuenda et al., 1995) (Figure 37). To verify the 
involvement of this pathway in our anxiety mouse model, MEK and phosphorylated MEK 
(p-MEK) were quantified by Western blot (Figure 38). The results show that the NAB mice 
have a higher expression level of MEK than both HAB and LAB, and that the HAB and LAB 
mice have quite comparable MEK expression levels. However, the HAB mice showed a 
higher expression level of p-MEK than the LAB and NAB mice (Figure 38). 
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The Ras/Raf/MEK/ERK pathway transfers extracellular stimuli to the nucleus, resulting in 
diverse cellular responses such as proliferation, growth, differentiation, and apoptosis. The 
cascade pathways have been found to be relevant in different types of diseases, 
particularly cancers (Hoshino et al., 1999; Karreth and Tuveson, 2009; Sebolt-Leopold, 
2008). However, more recently, correlations between the Ras/Raf/MEK/ERK(MAPK) 
pathway and psychiatric disorders, such as depression, increasingly have become the focus 
of many studies, indicating that this pathway may be involved in the neuronal modulation 
of psychiatric disorders (Dwivedi et al., 2001; Feng et al., 2003; Gourley et al., 2008; Qi et 
al., 2008; Qi et al., 2009; Tiraboschi et al., 2004; Todorovic et al., 2009). Since a large 
number of Ras/Raf/MEK/ERK-related sub-networks were found in this analysis, another 
interaction map derived from the Ras/Raf/MEK/ERK pathway is shown below (Figure 39); 
all the entities in this map are part of the pathway and also have different levels of 
expression between the mouse lines.  
 
Figure 39. Network of the Ras/Raf/MEK/ERK pathway. (Due to the limited resolution the 
protein/metabolite names are not legible; higher resolution figure is available in electronic 
file.) 
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Another important finding is that dexamethasone (P = 4.16E-21) and the neighbors which 
it interacts with are highly enriched with proteins and metabolites expressed differentially 
between the animal lines (Table 10, Figure 40). Dexamethasone is a synthetic cortisol that 
acts as an anti-inflammatory and immunosuppressant and is used in cancer chemotherapy. 
Many studies have indicated that dysfunction of the HPA axis may lead to a depressive 
situation. Blood cortisol, which is secreted by the adrenal glands, can be used to assess the 
level of HPA axis activity. In depression patients, cortisol is secreted continuously, even 
though blood levels are already high. Therefore, the cortisol level is elevated in depression; 
the high levels usually decrease to a normal level once the depression disappears 
(Handwerger, 2009; Muller and Holsboer, 2006; Strohle and Holsboer, 2003; Yu et al., 
2008).  
 
Figure 40. Dexamethasone network. Proteins and metabolites shown in this figure 
interact with dexamethasone. (Due to the limited resolution the protein/metabolite 
names are not legible; higher resolution figure is available in electronic file.) 
Cortisol levels can be tested using the dexamethasone suppression test (DST). An 
individual is given a dose of dexamethasone before going to sleep at night, and blood 
cortisol levels are measured at different times on the following day. In a healthy person, 
the cortisol level drops at first but then returns to normal as the HPA axis compensates for 
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the dexamethasone in the blood. In depressed patients, cortisol secretion may not be 
reduced by the HPA axis or there may be no change at all after receiving dexamethasone. 
The sub-networks surrounding nicotine and rapamycin also were found to be enriched 
with proteins and metabolites expressed differentially between HAB, LAB, and NAB mice 
(Table 10). Nicotine is an alkaloid found in tobacco. Despite its toxicity and addictive 
properties, nicotine actually has demonstrated potential benefits in Alzheimer's and 
Parkinson's disease, as well as some mental disorders (Baron, 1996; Dome et al., 2009; 
Fagerstrom and Aubin, 2009; Quik et al., 2009). Rapamycin is an immunosuppressant drug 
used to prevent rejection in organ transplantation. It is the key element in the mammalian 
target of rapamycin (mTOR) pathway, which can influence neuronal development and 
plasticity (Jaworski and Sheng, 2006), resulting in the development of psychiatric disorders 
(Ehninger et al., 2009; Lang et al., 2009).  
The analyses of binding interactions also revealed a number of sub-networks of great 
significance and biological interest (Table 11). An obvious important one is glycinergic 
synaptic transmission (Table 11, Figure 36). Glycine is a major inhibitory neurotransmitter 
in, but not restricted to, the spinal cord and brainstem and has been shown to have a key 
function in the regulation of locomotor behavior (Kirsch, 2006; Legendre, 2001; Xu and 
Gong, 2010; Zafra et al., 1997). Several decades ago, glycine was found to be beneficial in 
depression treatment (Weinberg and Pittsburg, 1945 ).  
 
Table 11. Sub-networks (connected by binding) with the 20 most significant P values  
Central Entity 
Total Number 
of Neighbors 
Percent 
Overlap 
P value 
UGCGL1 10 100 9.07E-19 
Glycinergic synaptic transmission 10 90 4.35E-16 
ETFA 14 73 1.14E-15 
PSMD7 15 68 3.57E-15 
Reduction of virulence 9 90 1.76E-14 
Myelin maintenance 9 90 1.76E-14 
Microsporogenesis 9 90 1.76E-14 
AP2B1 19 55 1.26E-13 
SEC24B 26 44 2.58E-13 
ASPA 23 45 1.73E-12 
STRN 27 39 1.37E-11 
SYN2 27 39 1.37E-11 
PURB 28 37 2.16E-11 
Toluene catabolism 7 87 2.73E-11 
Carbon dioxide transport 7 87 2.73E-11 
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Spermine transport 7 87 2.73E-11 
Nav channel clustering 7 87 2.73E-11 
Humoral defense mechanism 7 87 2.73E-11 
Delayed-type hypersensitivity 7 87 2.73E-11 
SPTBN2 29 36 3.34E-11 
 
An additional analysis was performed to investigate the interaction between proteins and 
psychiatric disorders, with a focus on anxiety and depression. The correlation was built up 
on the basis of previous studies of depression and anxiety-related disorders. All the 
proteins shown in Figure 41 showed different expression levels between mouse lines on 
the basis of our MS-based data; their important roles in these psychiatric disorders have 
been the subject of much published resarch. For instance, a possible correlation with the 
anxiety phenotype previously was reported for both Glo1 and ApoE and was confirmed by 
the present study. 
 
Figure 41. Network of psychiatric disorders. The proteins shown in this figure are 
expressed differentially between HAB and LAB mice. These proteins have been reported 
previously to be relevant to psychiatric disorders. (Due to the limited resolution the 
protein/metabolite names are not legible; higher resolution figure is available in electronic 
file.) 
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3.4 Discussion 
By using the SILAM approach, we were able to identify and quantify a large number of 
proteins in a high throughput mode. As mentioned above, metabolic labeling enables us to 
mix the samples being compared at the earliest possible stage, reducing the potential 
variance generated during sample preparation. This study identified a lot more potential 
new biomarker candidates than had been found with the traditional 2-DE gel platform and 
thus helps improve our understanding of the anxiety mouse models as well as of the 
disorder as a whole.  
The stable isotope-labeled diet increased the costs of the whole experiment. However, 
labeling the whole animal allows all tissues to be harvested, and the labeled tissues are 
commonly used as the reference for mixing with case samples. Therefore, one labeled 
mouse enabled us to run numerous experiments on different tissues, making this 
approach actually relatively economical. 
3.4.1 Isotope effect 
As shown in this study, the 15N- and 14N-fed mice showed differences in both 
depression-like behavior and protein expression. The ingredients of the 14N and 15N diets 
are identical except for the nitrogen forms, and the only apparent difference between the 
two diets is the nitrogen source of the media used for bacterial culture. Although the 
observed effect can result from multiple factors, the isotope is the only known one; 
therefore, this effect is referred to as the isotope effect in this thesis.  
The underlying explanations for this isotope effect are still uncertain. One hypothesis is 
that the introduction of 15N may change the stability and synthesis rate of some proteins. 
Protein synthesis and degradation involve breaking and forming covalent peptide bonds, 
which are generated by the reaction between carboxyl and amine groups from two 
molecules. Two different types of isotope effects can be observed: the primary isotope 
effect happens at a chemical bond that is broken or formed, such as a peptide bond, 
where it affects the reaction rate; the secondary isotope effect results from isotope 
substitution involved in the side chain (Cassano et al., 2004; Cleland, 2003, 2005). 
In the SILAM approach, all the 14N atoms in an amine group are replaced by 15N. 
Furthermore, the nitrogen atoms at the side chains also are labeled with 15N. Heavier 
atoms normally result in more stable chemical bonds or lower vibration frequencies. 
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Therefore, more energy is required to break the 15N peptide bond. Since every peptide 
bond is modified during the SILAM experiment, this effect seems to be very pronounced. 
Actually, the vibrational frequencies of the affected bonds are highly dependent on the 
relative mass change. For instance, changing a hydrogen (H) atom to deuterium (D) results 
in a 100% increase in mass, whereas replacing 14N with 15N increases the mass by only 7%. 
The absolute mass increase of both H to D and 14N to 15N is 1 Dalton; however, the rate of 
a reaction involving a C-H bond is typically 6 to 10 times faster than the rate of a reaction 
involving a C-D bond, whereas an 14N reaction is only slightly faster than the corresponding 
15N reaction.  
As discussed above, 15N labeling may lead to a slight change in protein stability and protein 
synthesis and degradation rates. The influence of the 15N isotope may be amplified if the 
protein synthesis rate is the rate-limiting step in a biological process or if the activities of 
some enzymes are sensitive to their stabilities, resulting in biological responses. However, 
there is no evidence yet to support our hypothesis.  
Despite the unclear explanations for the isotope effects on the animals’ behavior and 
protein expression, a finding of interest is that the 15N diet showed an antidepressant-like 
effect in the HAB mice. Therefore, the differentially expressed proteins may be related to 
depression-like behavior, which may provide some hints for depression research. The 
pathobiology of this disorder will be discussed in the following sections.  
Even though the isotope influences protein expression to some degree, this is irrelevant 
when using 15N labeling tissue for quantitative proteomics. A typical approach—called 
indirect comparison in this study—is to use the 15N labeled material as the reference and 
to mix it with either case or control samples. These two proteomic experiments are then 
used to compare case and control samples. The biggest benefit of this approach is that any 
kind of dietary or isotopic effect can be avoided. Another benefit is that standard healthy 
animals can be used for labeling; furthermore, all the labeled tissues can be used in many 
different studies. By contrast, a labeled case animal may be used exclusively in only one 
study. However, a shortcoming of indirect comparison is that the number of overlapping 
proteins between two experiments is reduced, and the final protein quantification can 
employ only those overlapping proteins, leading to a smaller proteome coverage for 
quantification. However, the situation is improved by using multiple biological or technical 
replicates, or both.  
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3.4.2 Pathobiology of the anxiety phenotype 
Although the detailed pathogenesis of psychiatric disorders remains elusive, there is 
growing evidence for the involvment of several neural circuits and pathways in the brain. A 
single genetic, physiological or environmental lesion may not result in a psychiatric 
phenotype. Hence, systems biological analyses were performed in this study with both 
proteomic and metabolic data from trait anxiety mouse models. The strategies used 
enabled us to identify and quantify a great number of proteins and metabolites that are 
differentially expressed in HAB, LAB, and NAB mice. The interaction maps of protein and 
metabolite candidates were developed on the basis of various types of interaction. The 
results found several significant biological processes or pathways that showed high 
enrichment for candidate entities. These pathways help increase our understanding of 
anxiety. Some of the significant biological processes and pathways are highly related to 
psychiatric disorders (see further discussion below).  
3.4.2.1 Oxidative stress 
It is well known that the oxygen redox reaction is essential to and found everywhere in 
aerobic organisms. However, a disturbance in this normal redox state can have toxic 
effects through the production of peroxides and free radicals (molecules with unpaired 
electrons on an open shell configuration), leading to a higher chemical reactivity. Free 
radicals can damage all components of the cell, including proteins, lipids, and DNA (Davies, 
1995; Filomeni and Ciriolo, 2006). 
Oxidative stress has been thought to play an important role in the pathogenesis of various 
diseases, including psychiatric disorders. The brain is highly vulnerable to oxidative 
damage for the following reasons: first, the O2 consumption is high and hence more free 
radicals can be generated; and second, the antioxidant defense is modest, and third, a 
lipid-rich constitution provides a larger amount of substrates for oxidation (Halliwell, 2006; 
Valko et al., 2007).  
Oxidative stress has been found to be highly relevant to a number of neurological diseases, 
including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke (Kaur and 
Ling, 2008). Moreover, oxidative stress also has been associated with several psychiatric 
disorders, such as schizophrenia, bipolar disorder, and depression (Adibhatla and Hatcher, 
2009; Andreazza et al., 2008; Bouayed et al., 2009; Do et al., 2009; Ng et al., 2008; Tylec et 
al., 2007; Wood et al., 2009). In the present study, both 14N-HAB/15N-HAB and HAB/LAB 
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comparisons indicated a significant number of proteins responsible for responding to 
oxidative stress, and these proteins demonstrated expression differences between the 
mouse groups. Glo1 is an enzyme that modulates the level of oxidative stress and has 
been reported to be highly relevant to anxiety disorder by our research group as well as 
that of Hovatta (Hambsch et al., 2010; Hovatta et al., 2005; Kromer et al., 2005). However, 
the results of the two independent research groups are inconsistent: we found that Glo1 
was expressed at a higher level in low anxiety mice, while Hovatta found that 
overexpression of Glo1 resulted in an increase of anxiety-like behavior. The contradiction 
may partly be explained by the differences in the genotypes of the animals, but may not 
be limited to this explanation. Both results support the presence of abnormal Glo1 in 
anxiety-like behavior. Our finding is in accordance with that of another study focusing on 
mood disorder (which has a high comorbidity rate with anxiety disorders); this study also 
found that expression of Glo1 was lower in major depression and bipolar disorder patients 
than in healthy control subjects (Fujimoto et al., 2008).  
Further support for the involvement of oxidative stress in anxiety comes from the 
phospholipid transfer protein (PLTP) and alpha-tocopherol, the main isomer of vitamin E. 
Vitamin E is transferred by PLTP and is an antioxidant widely used in clinical therapies 
(Desrumaux et al., 2005). Complete PLTP deficiency is accompanied in mice by increased 
anxiety, as shown by fewer entries into and less time spent in the open arms of an 
elevated plus maze. Bouayed et al. found a positive relationship between peripheral 
oxidative status and level of anxiety in mice (Bouayed et al., 2007).  
Human studies on anxiety disorders, such as panic disorder and obsessive-compulsive 
disorder (OCD), also have indicated a correlation between oxidative stress and anxiety. 
Ersan et al. showed a significant relationship between OCD and oxidative stress and, 
consequently, an involvement of free radicals and of antioxidant defense (Ersan et al., 
2006). Kuloglu et al. reported that both panic disorder and OCD were associated with free 
radicals (Kuloglu et al., 2002a; Kuloglu et al., 2002b). 
There is a lot more evidence to support the correlation between oxidative stress and 
neuropsychiatric disorders (Bouayed et al., 2009; Masood et al., 2008; Rammal et al., 
2008a, b). Oxidative stress, like many other emotional stresses, also has a strong influence 
on anxiety behavior (Gingrich, 2005). All the published multi-dimensional data, including 
the OMICS data presented in this thesis, demonstrate that there is a link between 
oxidative stress and anxiety. These data imply that oxidative mechanisms play a key role in 
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pathogenic pathways in psychiatric disorders and antioxidants can be used as therapeutic 
targets for these diseases. 
3.4.2.2 HPA axis and hormones 
The role of the HPA axis in depression has been well studied for several decades (Pariante 
and Lightman, 2008). HPA axis activity is governed by the secretion of 
corticotropin-releasing factor (CRF), and vasopressin from the paraventricular nucleus of 
hypothalamus. CRF and vasopressin can in turn stimulate and regulate the secretion of 
adrenocorticotrophic hormone (ACTH) from the pituitary. ACTH further stimulates the 
secretion of the glucocorticoids (cortisol in humans and corticosterone in rodents) from 
the adrenal gland. Glucocorticoids then not only interact with their receptors in multiple 
target tissues but also act on the HPA axis (to suppress CRH and ACTH production) in a 
negative feedback cycle (Figure 42) (Herbert et al., 2006; Keck and Holsboer, 2001). The 
glucocorticoids, including synthetic forms such as dexamethasone, suppress CRF and ACTH 
synthesis and release. In this manner, glucocorticoids inhibit their own synthesis. Besides 
their peripheral functions, such as regulation of glucose metabolism, and their role in the 
immune system, the HPA axis and glucocorticoids also regulate neuronal survival, 
neurogenesis, memory, and emotions (Herbert et al., 2006). Excess glucocorticoids may 
impair or even damage the hippocampus, which may initiate and maintain a 
hypercortisolemic state, as found in some cases of depression (Nestler et al., 2002). A 
number of studies have shown that in depressed people the HPA axis is not suppressed by 
an oral dose of synthetic glucocorticoid dexamethasone; by contrast, in non-depressed 
people a small dose of dexamethasone can result in a reduced cortisol level, indicating a 
negative feedback inhibition of the HPA axis (Pariante and Lightman, 2008).  
The HPA axis mainly has been studied in depressive disorders. However, anxiety and 
depressive disorders are often comorbid and also commonly co-occur with other 
psychiatric disorders (Aina and Susman, 2006). Possible reasons for this comorbidity may 
relate to factors such as overlapping of symptoms, environment, and biology. Furthermore, 
anxiety also is a stress-related illness, and obviously stress can greatly affect the HPA axis. 
Therefore, HPA dysfunction also has been associated with anxiety by a number of studies 
(Cameron, 2006; Young et al., 2004).  
The 15N-labeled diet used in this study showed an antidepressant-like effect in HAB mice. 
Although we do not have a clear idea how the 15N diet reduces depression-like behavior, 
we consider it to be an antidepressant. Our finding is in good agreement with that of an 
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earlier study in which the effects of acute and subchronic treatment with different 
antidepressants (amitriptyline, fluoxetine, mirtazapine, St John’s wort extract) on the 
brain/plasma distribution of corticosterone were investigated in mice (Weber et al., 2006). 
Significantly elevated plasma and brain corticosterone levels were found after one single 
oral treatment with fluoxetine, mirtazapine, or St John’s wort extract. However, in 
subchronic treatment, only fluoxetine and St John’s wort extract significantly elevated 
plasma and brain corticosterone levels. Mirtazapine and amitriptyline showed no effects. 
However, earlier studies showed inconsistent results concerning the effect of fluoxetine on 
plasma corticosterone (Stout et al., 2002). A possible explanation for the observation in 
our study is that the antidepressant may increase cortisol secretion by enhancing 
serotoninergic and noradrenergic neurotransmission (Schule et al., 2004). Furthermore, 
the levels of corticosteroid-binding globulin (CBG), which is responsible for binding and 
transferring corticosteroid, were found to be higher in 15N-fed mice than in 14N-fed mice. In 
other words, the 15N antidepressant-like effect can result in both increased corticosterone 
and CBG. Although it is unclear whether increased CBG is a result of increased 
corticosterone or another cause, this finding is in accordance with that of a previous study 
in which positive associations were observed between CBG and cortisol levels following 
the Trier Social Stress Test (TSST) (Kumsta et al., 2007).  
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Figure 42. Regulation of the Hypothalamic-Pituitary-Adrenal Axis. (Reproduced from 
(Nestler et al., 2002)).  
3.4.2.3 Neurotransmission 
Neurotransmission is an electrical movement across synapses caused by the propagation 
of nerve impulses by a neurotransmitter. Anxiety disorders may involve decreased 
inhibitory signaling by gamma amino butyric acid (GABA) or increased excitatory signaling 
by glutamate (Martin et al., 2009). Currently, the mainstays of anxiety therapies are 
benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) (Gingrich, 2005), both 
of which are targeted at neurotransmitter pathways. Benzodiazepines interact with the 
receptor A of gamma amino butyric acid (GABA), an inhibitory neurotransmitter in the 
mammalian central nervous system that plays a role in regulating neuronal excitability. 
SSRIs increase the extracellular level of the neurotransmitter serotonin, also known as 
5-hydroxytryptamine (5-HT), by inhibiting its reuptake into the presynaptic cell and thus 
increasing the level of serotonin available to bind to the postsynaptic receptor. This implies 
that neurotransmission plays an essential role in anxiety disorders.  
The two principal subtypes of postsynaptic GABA receptor complexes, the ionotropic 
GABA-A and metabotropic GABA-B receptors, play important roles in the brain and are a 
target for a variety of endogenous and exogenous modulators (Kalueff and Nutt, 2007; 
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Mombereau et al., 2004; Nutt and Malizia, 2001). GABA-A receptors are ligand-gated ion 
channels, and activated GABA-A could hyperpolarize the neuronal membrane, reducing 
neuron excitability and leading to inhibitory actions of GABA. GABA-B receptors may be 
involved in modulating the generation of excitatory postsynaptic potential and long-term 
potentiation (Chang et al., 2003). Both GABA-A and -B receptors have been shown to be 
involved in the regulation of neuronal excitability and rapid changes in fear arousal, such 
as sleep, anxiety, panic, and the acute stress response (Brambilla et al., 2003; Kalueff and 
Nutt, 2007). 
Our study identified a number of candidate proteins associated with GABAergic 
neurotransmission. Moreover, glycinergic synaptic transmission was found to be enriched 
with proteins and metabolites expressed differentially between mouse lines. Both glycine 
and GABA are two essential inhibitory neurotransmitters in the central nervous system. 
Although glycine’s involvement in psychiatric disorders is less understood than GABA’s, 
co-localization and release of GABA and glycine is widespread in inhibitory neurons of the 
brain and spinal cord, and GABA even acts as a co-agonist to modify the response of 
glycine receptors (Lu et al., 2008). Furthermore, glycine is a requisite co-agonist of 
glutamate, the most abundant excitatory neurotransmitter in the vertebrate nervous 
system (Laube et al., 1993; Lester et al., 1993). Therefore, it is reasonable to assume an 
important role of glycinergic transmission in psychiatric disorders. Indeed, studies have 
found that glycine exerts inhibitory effects in certain areas of the brain, resulting in 
significant anxiety relief (Chojnacka-Wojcik et al., 2001; Young et al., 1974).  
3.4.2.4 Ras/Raf/MEK/ERK pathway  
The Ras/Raf/MEK/ERK pathway is a signal transduction pathway involved in metazoan 
development; it controls many biological processes, including metabolic processes, the cell 
cycle, cell migration, and cell shape as well as cell proliferation and differentiation 
(Schlessinger, 2000).  
The receptor tyrosine kinases (RTKs), such as the EGF receptor, first stimulate the exchange 
of GTP for GDP on the small G protein Ras, which is activated by the Grb2/Sos complex. 
Then, the Ras interacts with Raf to stimulate intracellular processes. Activated Raf 
stimulates MAP-kinase-kinase (MAPKK, MEK) by phosphorylating a key Ser residue. 
MAPKK then phosphorylates and activates MAPK (ERK). Activated MAPK phosphorylates a 
variety of cytoplasmic- and membrane-linked substrates. In addition, MAPK is transferred 
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rapidly into the nucleus, where it phosphorylates and activates transcription factors 
(Figure 43).  
The Ras/Raf/MEK/ERK pathway has been found to be highly related to diverse diseases, 
especially cancers (Dhillon et al., 2007; Hoshino et al., 1999; Roberts and Der, 2007). Raf 
has attracted much attention since the Raf gene was found to be mutated in a large 
percentage of malignant tumors (Wan et al., 2004). Furthermore, Ras, Raf, and MEK have 
been used as drug targets in cancer for many years (Kohno and Pouyssegur, 2006). In 
contrast to its relevance in cancer, the importance of the Ras/Raf/MEK/ERK pathway in 
psychiatric disorders is relatively poorly understood; however, it is increasingly becoming a 
focus of research in psychiatry.  
As discussed above, the HPA axis and the hormones it controls are of great importance in 
psychiatric disorders, including depression and anxiety. One hypothesis is that CRF acts as 
a ligand that can bind to and phosphorylate the CRF receptor and eventually may activate 
the Ras/Raf/MEK/ERK pathway (Hauger et al., 2006; Hillhouse and Grammatopoulos, 2006; 
Sananbenesi et al., 2003).  
In this study, a number of enriched sub-networks were found to be relevant to the 
Ras/Raf/MEK/ERK pathway. Western blot results showed that activated MEK is expressed 
at a higher level in high anxiety mice, which is in accordance with the findings of a 
previous study in which mice deficient in CRF2 displayed an increased anxiety level and 
also an increased hippocampal level of activated MEK (Todorovic et al., 2009). 
Furthermore, inhibition of the Ras/Raf/MEK/ERK pathway by the MEK inhibitor U0126 was 
found to decrease dramatically the depression-like behavior in both wild-type and mutant 
mice, indicating an involvement of this pathway in psychiatric disorders (Todorovic et al., 
2009). Some inconsistent findings were that activation of ERK may result in depression or 
anxiety-like behavior (Qi et al., 2008; Qi et al., 2006; Qi et al., 2009). This contradiction can 
be partly explained by the finding that region-specific manipulation of the 
Ras/Raf/MEK/ERK pathways may generate quite different behavioral phenotypes 
(Todorovic et al., 2009). 
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Figure 43. Schematic representation of the Ras/Raf/MEK/ERK signaling cascade. 
(Reproduced from (Roberts and Der, 2007)) 
In summary, the pathology of psychiatric disorders is not yet fully understood. However, it 
is well accepted that psychiatric disorders probably arise from a combination of factors, 
including genetic vulnerabilities and environmental stressors. A typical biological study 
focusing on a particular protein or pathway is normally insufficient to deepen the 
understanding of the pathophysiology of a disease. On the basis of our OMCIS data, we 
have found a number of proteins and metabolites that are involved in some important 
pathways and that could provide a new approach in psychiatric disorder research. As 
demonstrated in this thesis, anxiety probably is caused by several pathways. A simple 
hypothesis could be that oxidative stress damages the brain and neurotransmission and 
also stimulates the HPA axis and hormone excretion. CRF also may be involved in the 
Ras/Raf/MEK/ERK signaling cascade. Any dysregulation in this complex network may 
contribute to anxiety disorders.
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4 Technology development  
The previous section has demonstrated that methods involving stable isotope metabolic 
labeling result in high quantitative accuracy, since they allow the combination of two or 
more samples before workup. Unfortunately, stable isotope incorporation rates in 
metabolic labeling experiments using mammalian organisms usually do not reach 100%. 
As a consequence, protein identifications in 15N database searches with mass 
spectrometry data have poor success rates. In this section, we report on a strategy that 
significantly improves the number of 15N-labeled protein identifications and results in a 
more comprehensive and accurate relative peptide quantification workflow.  
At present most quantitative proteomics investigations are restricted to the analysis of 
protein expression differences between two or more sample specimens. With each 
analysis a static snapshot of a cellular state is captured with regard to protein expression. 
However, any information on protein turnover cannot be obtained using classic 
methodologies. Protein turnover, the result of protein synthesis and degradation, 
represents a dynamic process, which is of equal importance to understanding physiological 
processes. Therefore a protein turnover analysis method was developed using the 
15N-labeled diet as an isotopic tracer. Unlike the 15N complete labeling strategy used for 
relative quantitation, adult mice were fed with the labeled diet for limited time periods 
and the resulting partially labeled proteins digested and subjected to tandem mass 
spectrometry. Results are presented reflecting the dynamics for a great number of 
proteins from mouse brain and plasma. 
4.1 A mass spectrometry data search method for improved 
15N-labeled protein identification  
4.1.1 Introduction 
Modern quantitative proteomics greatly benefits from both high resolving mass 
spectrometers and stable isotope labeling. In this regard global metabolic labeling with 15N, 
as well as ‘Stable Isotope Labeling with Amino Acids in Cell Culture’ (SILAC) (Kruger et al., 
2008; Ong et al., 2002), are the gold standards in terms of accuracy since the control and 
case samples are combined prior to any sample preparation. This avoids the risk of 
introducing artificial variance due to inconsistent sample preparation. The 15N labeling 
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technology has been applied successfully to cells in culture (Conrads et al., 2001; Ishihama 
et al., 2005), plants (Huttlin et al., 2007; Nelson et al., 2007; Palmblad et al., 2007; Schaff 
et al., 2008), Drosophila melanogaster (Krijgsveld et al., 2003), Caenorhabditis elegans 
(Dong et al., 2007; Krijgsveld et al., 2003), and mammals (McClatchy et al., 2007a; Wu et 
al., 2004). 
Proteins are labeled with 15N during their synthesis. However, the 15N incorporation rates 
typically do not reach 100% due to residual 14N that is left in the diet and/or organism. 
Incomplete 15N labeling will result in a rather complex peptide isotopologue distribution 
during mass spectrometry analysis, which affects both peptide identification and 
quantification. Therefore, a modified method for 15N-labeled protein identification was 
considered in the present study.  
4.1.2 Material and methods 
4.1.2.1 Methods 
For protein identification using mass spectrometry data, the expected and measured 
monoisotopic peptide peak values need to coincide during the first step of the database 
search. Hence, during mass spectrometry data acquisition the instrument needs to select 
the correct 15N monoisotopic peak for subsequent fragmentation and MS/MS analysis. For 
incompletely labeled peptides the 15N isotopologue envelope is different from the natural 
14N envelope. If the 15N monoisotopic peak does not represent the most intense signal, it is 
typically not chosen as precursor ion for fragmentation. Instead the most intense peak 
that is not made up of only the 15N isotope is selected for fragmentation. For 15N 
incorporation rates of approximately 90% the mass of the most intense peak is generally 1 
Da smaller than that of the fully labeled 15N monoisotopic peak (Figure 44). This deviation 
results in a low success rate for 15N protein identification using default search parameters 
and a 15N protein database.  
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Figure 44. Isotopologue distributions of 15N labeled peptide TFTTQETITNAETAK, 
C70H114N18O28. a: observed isotopologue distribution, in which the most intense peak is 1 
Da smaller than the 15N monoisotopic peak and therefore subjected to fragmentation 
during MS/MS analysis. b: theoretical isotopogue distributions of the same peptide with 
90% and 100% 15N enrichment.  The mass of the most intense peak for 90% 15N 
incorporation is 1Da smaller than that for 100% incorporation. 
In a tryptic protein digest every identified peptide contains at least one arginine or lysine 
residue with the exception of the C-terminal peptide. Here we introduce a hypothetical 
-0.997035 Da (Δmass=14N-15N), simplified as -1 Da, variable modification for arginine and 
lysine residues to correct for non-monoisotopic peak selection in MS/MS analysis during 
mass spectrometry data acquisition. Amino acid modifications can be easily included in 
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MASCOT (Perkins et al., 1999) or SEQUEST (Eng et al., 1994) database searches. By 
introducing the -1 Da variable modification for arginine and lysine residues, both the all 
15N and n-1 15N signals will be considered in the database search. For the MS/MS fragment 
ions no modification edits are necessary, since all isotopologue peaks in close proximity to 
the selected precursor ion will be included during fragmentation.  
4.1.2.2 Experiments 
The animal studies were conducted in accordance with the“Guide for the Care and Use of 
Laboratory Animals of the Government of Bavaria”. CD1 mice were fed for 56 days starting 
in utero with either U-15N-SILAM-Mouse or U-14N-SILAM-Mouse diets (Silantes GmbH, 
Munich, Germany) (McClatchy et al., 2007a; Wu et al., 2004). The 15N incorporation rates 
determined by MALDI-TOF analysis and the in-house software QuantiSpec (Haegler et al., 
2009b) were approximately 90% and 98% for brain and plasma proteins, respectively. 15N 
and 14N mouse hippocampal protein extracts were mixed at a ratio of 1:1 based on 
Bradford assay quantification. The protein mixture was resolved by SDS-PAGE (4-12%) and 
the gel stained with Coomassie blue. The gel lane containing the separated proteins was 
cut into 2 mm-wide pieces and each piece subjected to in-gel tryptic digestion 
(Shevchenko et al., 2006). Gel pieces were destained twice with 100 μL 50 mM 
NH4HCO3/acetonitrile (1:1, vol/vol) for 30 min, and disulfide bonds reduced with 10 mM 
DTT in 50 mM NH4HCO3 at 56°C for 30 min, and then alkylated with 55 mM iodoacetamide 
in 50 mM NH4HCO3 in the dark for 30 min. Subsequently, 12.5ng/μl trypsin in 25 mM 
NH4HCO3 was added to saturate and cover gel slices. The enzymatic reaction was carried 
out at 37°C overnight. After the digestion, the peptides were extracted from the gel pieces 
by adding 5% formic acid at 37°C for 30 min. The gel pieces were spun down and the liquid 
collected. The extraction was repeated twice. Finally, the extracted digest peptide mixture 
was lyophilized to dryness, dissolved in 10 μL 0.1% formic acid and then analyzed by 
LC-MS/MS with an ORBITRAP (Thermo Fisher Scientific, Bremen, Germany) analyzer. In 
addition, 15N and 14N mouse plasma proteins were mixed at a 1:1 ratio, and seven high 
abundant proteins were immunodepleted using the IgY-M7 cartridge (GenWay Biotech 
Inc., San Diego, CA) according to the product manual. The flow-through fraction was 
processed using the same workflow as for the brain samples.  
4.1.2.3 Data process 
For SEQUEST database analysis the ORBITRAP Raw files were searched against a 
concatenated forward / reversed IPI-mouse database v 3.46. The Raw files were also 
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converted to mzData files with Bioworks 3.3.1 SP1 (Thermo Fisher Scientific Inc., Waltham, 
MA), and then searched against forward IPI-mouse database v 3.46 with activation of the 
Decoy checkbox in MASCOT v 2.2. The 14N database search was performed by using the 
following parameters: 20 ppm mass tolerance for the MS scan, 1 Da for the MS/MS scan, 
fixed carbamidomethylation for cysteine and variable oxidation for methionine, one 
miscleavage. The 15N database search was executed twice using two different sets of 
parameters. The first search was done with the same parameters as for the 14N search but 
using 15N amino acid masses. The second search employed an additional -1 Da variable 
modification for arginine and lysine residues. Assembly and removal of redundant proteins 
based on their accession numbers were performed by in-house written Perl scripts. The 
SEQUEST results were filtered using peptide XCorr >1.9 for 1+ charged ions, >2.7 for 2+ 
charged ions, >3.5 for 3+ or above charged ions, and DeltaCN >0.08 . MASCOT results were 
filtered using a fixed significance threshold of p<0.01, and MASCOT score > 20. The False 
Discovery Rate (FDR) was then determined by calculating the ratio of the number of 
peptides identified from decoy and forward database searches (Wang et al., 2009). 
Relative quantification of the peptide pair signals was performed with the ProRata 
software (Pan et al., 2006) based on the SEQUEST identification results. Briefly, the ion 
chromatograms were extracted for both labeled and unlabeled isotope envelopes 
according to the identified amino acid sequence, and the ratio of areas of labeled and 
unlabeled chromatographic peaks were used for peptide quantification. 
4.1.3 Results 
The above mass spectrometry data search strategy significantly improves 15N protein 
identification success for the brain protein mass spectrometry dataset, with the number of 
proteins approaching those of the 14N database search results (Table 12). The conventional 
SEQUEST search parameters and a 15N database resulted in 798 identified peptides 
corresponding to 525 proteins. When using the modified search method, we identified 
10525 peptides corresponding to 1586 proteins, 1203 of which were only identified by the 
latter method. The FDR also greatly improved due to the modified database search 
method. Together with 14N search results the total number of identified proteins for the 
brain mass spectrometry dataset is 2681 with the modified method; 1294 proteins were 
identified by both 14N and 15N database searches. The 15N/14N database search results 
overlap is only 283 proteins when the conventional method is used. Moreover, the average 
number of identified peptides for a given protein also increases with our method (Table 
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12). The MASCOT search results also demonstrate the advantage of the modified 15N 
database search method, with an increase of the identified 15N peptide number from 3892 
to 22713, and a decrease of the FDR from 8.42% to 2.02% (Table 12). 
Table 12. Number of peptides and proteins identified by different search methods 
search mode  
SEQUEST  MASCOT 
peptidesa) proteinsb) 
peptide 
FDR 
 
peptidesc) proteinsb) 
peptide 
FDRd) 
Brain        
14N and 15N unmodified  32102 2631 -  42685 3205 - 
14N and 15N modified  41829 2681 -  61506 3353 - 
14N 31304 2389 0.40%  38793 3083 3.57% 
unmodified 15N 798 525 45.74%  3892 948 8.42% 
modified 15N 10525 1586 10.92%  22713 1616 2.02% 
Plasma        
14N and 15N unmodified  25209 873 -  37372 1145 - 
14N and 15N modified  26514 892 -  37225 1093 - 
14N 13414 663 0.19%  19346 896 6.08% 
unmodified 15N 11795 702 1.66%  18026 741 3.34% 
modified 15N 13100 725 2.41%  17879 662 2.37% 
a) Number of redundant peptides with SEQUEST XCorr >1.9 for charge state 1+, >2.7 for 
charge state 2+, >3.5 for charge state 3+ or above, and DeltaCN >0.08 
b) Number of non-redundant proteins 
c) Number of redundant peptides with MASCOT significance threshold p<0.01, MASCOT 
score > 20 
d) FDR based on the peptide matches above identity threshold calculated by MASCOT 
 
 
The proteins in plasma show higher 15N incorporation rates, which is a reflection of their 
higher metabolic turnover rates compared to brain proteins. The almost 100% 15N 
incorporation rates resulted in a greater success rate for monoisotopic peak selection. 
Therefore, the plasma 15N protein identification numbers using the modified database 
search method did not improve as much as it did for the brain proteins. However, there 
were still 1305 peptides and 25 proteins exclusively identified by SEQUEST with the 
modified 15N database search method. The majority of large peptides could only be 
identified by the new database search method, since their isotopologue distributions are 
more affected by small amounts of residual 14N. Using SEQUEST the modified method 
identified 408 peptides > 3 kDa, whereas the conventional method resulted in only 23 
peptides. Similarly, 969 peptides and 252 peptides, respectively, were found to be > 2.5 
kDa with the modified and conventional search methods. MASCOT results show no 
significant advantage of our modified method for highly labeled plasma proteins.  
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4.1.4 Discussion 
As has been reported by others (Balgley et al., 2007; Elias et al., 2005; Kapp et al., 2005) 
the number of identified peptides depends on the search engine and score threshold. For 
a given search engine, be it SEQUEST or MASCOT, a 15N database search benefits from the 
presented modified method in terms of peptide identification number, when the labeling 
percentage is not close to 100%. The observed FDR for 15N identifications using the 
conventional method appears to be relatively high, a finding that has been reported by 
others (Nelson et al., 2007). This is probably due to the increased complexity of the 15N 
isotopomer and isotopologue patterns, making the correct monoisotopic peak selection 
during data acquisition and peak mapping during database search less likely. Furthermore, 
for a 1:1 14N/15N protein mixture, the ratio of MS/MS spectra from 14N and 15N precursors 
should also be approximately 1:1. As a consequence, a great number of 15N 
peptide-derived data submitted to either 14N or 15N database searches will result in a 
significant number of false positive identifications. This situation gets worse the lower the 
15N incorporation rates are since the spectra get even more complex. For our 98% labeled 
plasma dataset, the 15N FDR for SEQUEST and MASCOT searches is low. However, for 90% 
labeled brain proteins our modified search method using SEQUEST or MASCOT decreases 
the 15N FDR by approximately 75% compared to the conventional search method. The 15N 
search continues to show a much higher FDR than a 14N search for SEQUEST if a fixed 
threshold filtering is applied. The difference between SEQUEST and MASCOT searches are 
most likely due to decoy search and threshold filtering methods. MASCOT shows a higher 
compatibility with lower % 15N incorporation data. 
The modified search method also facilitates relative protein quantification. Although 
existing algorithms like Census (Park et al., 2008) or ProRata (Pan et al., 2006) are able to 
quantify the paired 14N and 15N peptides from either 14N or 15N search results, a greater 
number of identified peptides and proteins provide better statistical quantification values. 
With the conventional search method, peptide and protein quantification is predominantly 
based on the identified 14N peptides since the number of 15N identifications is low. This 
results in a loss of information in cases where the 15N signal has a higher intensity than the 
corresponding 14N signal, the latter thus not being subjected to fragmentation. As a result, 
peptide signal comparison and quantification are not possible in those cases. With the 
present method, the greater number of identified and quantified 14N and 15N peptide pairs 
from the same protein results in increased accuracy, especially in cases where only a few 
peptides are identified for a protein.  
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Gouw and colleagues have introduced another method for dealing with 15N-labeled mass 
spectrometry data (Gouw et al., 2008). In this case precursor selection was corrected. 
However, this leads to a doubling of database search time and post-search alignment is 
required. Our method can be performed with a single database search and no 
post-alignment is necessary since the -1 Da correction can be introduced at the database 
search step.  
We should also emphasize that the deviation between the most intense peak and 15N 
monoisotopic peak varies not only with the rate of 15N incorporation but also peptide 
length, both of them affecting isotopologue distribution. This becomes evident from a 
theoretical simulation of both parameters (Figure 45). Averagine is an imaginary average 
amino acid with the molecular formula C4.9384H7.7583N1.3577O1.4773S0.0417, which represents the 
statistical occurrence of the 20 common amino acids in the Protein Identification Resource 
(PIR) protein database (Senko et al., 1995). Peptides with different averagine residue 
numbers and 15N incorporation rates result in isotopologue patterns with varying mass 
deviations between the 15N monoisotopic peak and the most intense peak. These mass 
deviations can be calculated for every hypothetical peptide. If the 15N monoisotopic peak 
and most intense peak coincide this difference is zero. A mass correction in the database 
search becomes necessary for all the peptides with negative deviation shown in Fig. 2. 
When the 15N incorporation rate is equal or greater than 90%, the -1Da variable 
modification works well, and extended modifications, such as -2 Da, do not generate more 
peptide identifications (data not shown). The modification can be adjusted (e.g. -2 Da) in 
cases of lower 15N incorporation rates. Searches with more than one modification can also 
be performed in parallel if necessary. The presented method can also be applied to other 
global metabolic labeling techniques, including 13C and 2H isotopes, when the 
incorporation rates are less than 100%. Alternatively, the hypothetical -1 Da variable 
modification can also be used for peptide C- or N-termini. One advantage of choosing 
arginine and lysine residues for the variable modification is that the mass shift of long 
peptides resulting from missed cleavage will be automatically adjusted to -2 Da or greater. 
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Figure 45. The mass shift between the most intense peak and 15N monoisotopic peak.  
The peptides illustrated are hypothetical and consist of a different number of averagine 
residues.  Averagine has the molecular formula C4.9384H7.7583N1.3577O1.4773S0.0417, which is 
based on the statistical occurrence of the 20 common amino acids in the PIR protein 
database. 
4.2 Proteome scale turnover analysis in living animals using 
stable isotope metabolic labeling  
4.2.1 Introduction 
Proteomics continues to generate valuable protein identification and quantitation 
information for many cell types and species. A particular focus of current proteomics 
efforts is the quantitative assessment of relative as well as absolute protein expression 
levels. Methods based on stable isotope labeling and label free approaches are employed 
using mass spectrometers of high resolving power and accuracy (Aebersold and Mann, 
2003; Ong and Mann, 2005). Although these studies provide valuable protein 
identification and quantitation information they only represent “snapshot” pictures of a 
cellular state that capture the proteomic state of affairs at a given time. However, the 
proteome is a highly dynamic and tightly regulated entity that is constantly changing and 
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adapting to its environment. The protein amount represents the final outcome of the 
protein synthesis and degradation process resulting in expanded, contracted or unchanged 
protein pools.  
Previous studies have found only weak correlations between mRNA and protein levels 
(Chen et al., 2002; Griffin et al., 2002; Ideker et al., 2001). A potential reason for these 
discrepancies is differential protein turnover that impacts on the overall protein levels in 
the cell. Since the overall amount of a protein depends on its synthesis and degradation 
upcoming changes in protein levels are apparent at a much earlier time point using 
turnover analysis when those changes are not yet reflected by the total protein amount. 
This paradigm has great significance for biomarker discovery since it would allow the 
detection of upcoming protein changes at a much earlier time point. Several reports 
confirm this hypothesis. Rao et al. have found that 5 proteins were upregulated in 
Mycobacterium tuberculosis bacteria grown in high iron medium. However, higher 
turnover rates were found for 24 proteins in the same experiment (Rao et al., 2008). In 
another study, Pupim et al. found that in chronic hemodialysis patients, nutritional 
interventions do not or only slightly affect the concentration of serum albumin, whereas 
turnover of the protein was significantly changed (Pupim et al., 2004). 
Protein turnover analysis is typically performed by administering either radiolabeled or 
stable isotope labeled tracers, mostly amino acids, which are incorporated into proteins 
during synthesis. The rate of the gain or loss of a tracer provides a measure of protein 
dynamics. Among other disadvantages the primary shortcoming of turnover determination 
with the help of radioisotopes is that these methods are restricted to the assessment of 
whole-body protein. Individual protein dynamics can only be achieved after protein 
purification rendering this method inefficient for high throughput analyses (Afify, 2002; 
Marshall et al., 2005; Rechinger et al., 2000). For this and also safety reasons the stable 
isotope tracer method is now preferred for protein turnover studies, and has become 
feasible with the availability of mass spectrometers that have high resolution and accuracy.  
Studying protein dynamics in cultured cells is a rather straightforward process. In this case, 
after changing the cell culture media the precursor pool is rapidly converted from an 
unlabeled to a labeled state or vice versa, so that the media relative isotope abundance 
(RIA) of the tracer represents the precursor RIA in the cell. Hence the newly synthesized 
protein will be labeled with a known RIA, and no RIA calculations are required (Pratt et al., 
2002).  
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An RIA of 1, however, can only be achieved in cell culture experiments and is difficult to 
realize in living animals due to the presence of internal unlabeled amino acids resulting 
from the degradation of pre-existing proteins. Living animals can be labeled by 
intravenously injecting the isotope tracer by either continuous infusion (Caso et al., 2001; 
Walrand et al., 2004) or a flooding dose (Bregendahl et al., 2004). In both cases, however, 
measuring protein turnover of individual proteins in a high throughput manner is not 
possible (Doherty and Beynon, 2006a). Furthermore, the sudden intake of the isotope 
tracer by intravenous injection may alter protein synthesis and lead to artificial protein 
turnover data (Smith et al., 1998b). Alternatively, the isotope tracer can be administered 
orally with the diet (Doherty et al., 2005) or water (Rachdaoui et al., 2009) resulting in a 
more natural labeling of the animals. 
All the current methods for protein dynamics measurement require data on precursor RIA, 
which especially in living animals is difficult to measure precisely. We have developed a 
new approach which enables monitoring individual protein turnover rates in complex 
mixtures. A diet, in which all the 20 amino acids are fully 15N-labeled was used as the 
tracer. This is in contrast to other methods that either use single labeled amino acids as 
tracers or heavy water where mainly labeled nonessential amino acids are generated. In 
both instances only low overall RIAs are achieved. The all amino acid labeled diet that we 
have used significantly amplifies protein labeling efficiency and results in greater data 
accuracy. Even early on during the labeling process when the precursor RIA is still relatively 
low, peptides derived from newly synthesized proteins will rarely consist of only unlabeled 
amino acids. 
The mass spectrometry signal of a labeled peptide derived from a newly synthesized 
protein overlaps with the peptide signal from pre-existing unlabeled protein. To distinguish 
the labeled/newly synthesized from the unlabeled/pre-existing peptide populations we 
developed the algorithm ProTurnyzer (Protein Turnover Analyzer). The algorithm is based 
on the hypothesis that the monoisotopic (all 14N) peptide only originates from the 
pre-existing protein population and hence the knowledge of precursor RIA is not required 
for protein turnover analysis. Here we present protein turnover data from bacteria and 
mice that demonstrate the validity of the method. 
4.2.2 Material and methods  
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4.2.2.1 Material 
Standard rodent diet (Harlan Laboratories, Inc., Indianapolis, IN) and bacterial 
protein-based rodent diet (Silantes GmbH, Munich, Germany) were used for all 
experiments. Two isotopic forms of the bacterial diet were used: natural isotope 14N and 
15N-enriched. Media for E. coli culture were 14N (Spectra 9-U) and 15N-enriched (Spectra 
9-N, >98%) (Cambridge Isotope Laboratories, Inc., Andover, MA). All other chemicals were 
from Sigma-Aldrich (St. Louis, MO), Merck (Darmstadt, Germany) and BioRad (Hercules, 
CA).  
4.2.2.2 Animal experiments 
Twelve 8-week old DBA/2 male mice were divided into 6 groups. For adaptation to the 
bacterial protein diet the animals were first fed 14N bacterial diet for 4 days. Two mice only 
fed with the 14N bacterial diet were then sacrificed. Blood was taken by cardiac puncture, 
and the plasma was obtained by centrifuging the blood in an EDTA pre-added tube at 
1,300 × g for 10 min. The remaining body blood was removed by 0.9% saline perfusion. 
The plasma and organs were snap-frozen in liquid nitrogen and the samples stored at 
-80°C for further usage. The food supply for the remaining mice was switched to 
15N-labeled bacterial diet and 2 mice each were sacrificed after 1, 2, 4, 7, and 14 days of 
feeding with the labeled diet (Figure 46). Organs and blood were isolated. The animals did 
not show any discernible health effects compared to animals fed with a standard diet. 
 
Figure 46. 15N feeding protocol for DBA/2 mice. 
4.2.2.3 E.coli experiments 
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14N (Spectra 9-U) and 15N-enriched (Spectra 9-N, >98%) media were used for bacterial 
cultures. 20%, 40%, and 60% 15N-labeled media were generated by mixing the 14N and 15N 
media at 80 : 20, 60 : 40, and 40 : 60 ratios, respectively. Single E. coli clones were 
pre-cultured in 2 ml of natural, 20%, 40%, or 60% 15N-labeled media for 6 h at 37°C with 
shaking at 220 rpm. Then the bacteria were expanded into 100 ml of the same media 
containing 100 μg / ml ampicillin and incubated overnight at 37°C with shaking at 220 rpm. 
The bacterial pellets were obtained by centrifuging the cultures at 5,000 rpm for 15 min at 
4°C.  
4.2.2.4 Sample preparation 
Mouse plasma protein concentrations from days 0, 1, 2, 4, 7 were measured by Bradford 
assay. Mouse cerebella from days 0, 2, 4, 7, 14 were put into ice-cold 5× buffer of 250 mM 
sucrose, 50 mM Tris - HCl (pH 7.4), 5 mM MgCl2, 1 mM DTT, 25 µg / ml
 Spermine, 25 µg / 
ml Spermidine and protease inhibitor cocktail tablet (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland), and then homogenized with a Teflon-glass dounce homogenizer and an 
electric drill at 1,200 rpm for 3 min. The homogenates were centrifuged at 20,000 g for 30 
min at 4°C and the supernatants collected. The protein concentrations were estimated by 
Bradford assay. 
The E. coli pellets were sonicated in lysis buffer consisting of 100 mM Tris-HCl (pH 8), 150 
mM NaCl, 1 mM EDTA to break the bacterial cells. The lysates were then centrifuged at 
13,000 rpm for 12 min and the supernatants containing the soluble proteins were 
collected. The protein concentrations were estimated by Bradford assay. The 14N- and 
differently 15N-labeled E. coli populations were mixed to obtain defined E. coli mixtures 
with different labeled/unlabeled ratios according to their protein concentrations (Table 13). 
The labeled protein fractions consisted of 3 populations with different 15N incorporations 
in order to simulate newly synthesized proteins exposed to different 15N amounts. 
The mouse brain, mouse plasma, and E. coli protein mixtures were resolved by SDS-PAGE 
and the gel stained with Coomassie Brilliant Blue. The gel lane containing the separated 
proteins was cut into 2 mm-wide pieces, and several selected pieces subjected to in-gel 
tryptic digestion. Gel pieces were destained twice with 100 µL 50 mM NH4HCO3 / ACN (1 : 
1, vol / vol) for 30 min, and disulfide bonds reduced with 10 mM DTT in 50 mM NH4HCO3 
at 56°C for 30 min, and then alkylated with 55 mM iodoacetamide in 50 mM NH4HCO3 in 
the dark for 30 min. Subsequently, 12.5 ng / µL trypsin in 25 mM NH4HCO3 was added to 
saturate and cover gel slices. The enzymatic reaction was carried out at 37°C overnight. 
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After digestion, the peptides were extracted from the gel pieces by adding 5% formic acid 
at 37°C for 30 min. The gel pieces were spun down and the liquid collected. The extraction 
was repeated twice. Finally, the extracted peptide mixture was lyophilized to dryness and 
dissolved in 10 µL 0.1% formic acid. 
4.2.2.5 HPLC and mass spectrometry 
The peptide mixtures were analyzed by nanoHPLC (Eksigent Technologies, Inc., Dublin, CA) 
coupled to an LTQ-Orbitrap (Thermo Fisher Scientific, Bremen, Germany) hybrid mass 
spectrometer. The C18 reverse-phase columns were made by packing PicoFrit emitters 
(New Objective, Inc., Woburn, MA) using a methanol slurry of reverse-phase ReproSil-Pur 
C18-AQ 3µm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) under a constant 
100 bar pressure. The packed columns were cut to approximately 15 cm length. Peptides 
were separated at a 200 nl/min flowrate using a gradient of 2-98% solvent B (98% ACN in 
water, 0.1% FA) over 130 min. The eluates were on-line electrosprayed into the mass 
spectrometer via a nanoelectrospray ion source (Thermo Fisher Scientific, San Jose, CA). 
The LTQ-Orbitrap was running in positive ion, top 5 data-dependent acquisition mode. For 
full scans in the Orbitrap, the target ion value was 1,000,000 and the maximal injection 
time was 500 ms at a resolution of r=60,000 at m/z 400. The MS full scan range was 
380-1600 m/z. The 5 most intense peaks in the MS scan were fragmented in the LTQ by 
collision-induced dissociation with a target value of 10,000 ions and injection time of 250 
ms. Former precursor ions selected for MS/MS were dynamically excluded for a period 
ranging from 30 to 60 s. 
The mass spectrometric conditions were: spray voltage, 2.1 kV; no sheath and auxiliary gas 
flow; ion transfer tube temperature, 200°C; normalized collision energy using wide-band 
activation mode, 35% for MS2. 
4.2.2.6 Free amino acid analysis 
We analyzed tissue free amino acids to investigate the enrichment of the precursor pool 
for protein synthesis. Although aminoacyl-tRNA is the actual precursor (Caso et al., 2002; 
Johnson et al., 1999; Martini et al., 2004), previous studies have shown that the tissue free 
amino acid pool is a valid surrogate for measuring the enrichment, while being accessible 
much more easily (Davis et al., 1999). Mouse plasma and brain extract were prepared 
using a cation-exchange extraction and derivatization with propyl chloroformate using the 
EZfaast amino acid analysis kit (Phenomenex, Torrance, CA). Prior to extraction the 
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samples were spiked with a mixture of internal standards homoarginine, methionine d3, 
and homophenylalanine supplied with the kit. Extraction and derivatization were 
performed according to the manufacturer’s manual. Derivatized amino acids were 
separated in 15 min in gradient mode using a reversed phase Kinetex 2.1 x 150 mm 1.7 um 
C18 column (Phenomenex) at 0.25 mL/min flow rate on an ACQUITY UPLC system (Waters, 
Milford, MA). The column was thermostated at 40°C. Mobile phase A was 10 mM 
ammonium formate in water, mobile phase B was 10 mM ammonium formate in 99.5% 
methanol. The following gradient program was used: 0 min – 40% B, 10 min – 75% B, 12 
min – 75% B with subsequent equilibration at 40% B for 3 min. The amino acid samples 
were held in an autosampler at 15°C. Injection volume was 5 μL and each sample was 
injected twice. The UPLC was coupled to an Exactive benchtop Orbitrap mass 
spectrometer (Thermo Fisher Scientific). The mass spectrometer operated in positive 
electrospray ionization mode at 50,000 FWHM resolution (2 scans/s), 250 ms maximum 
inject time and balanced AGC target (10e6 ions) scanning in m/z 195-505 mass range. The 
following tune parameters were used: 3.5 kV spray voltage, 275°C capillary temperature, 
40, 8 and 1 arbitrary units of sheath, auxiliary and sweep gas (nitrogen), 60 V capillary 
voltage, 100 V tube lens voltage, 20 V skimmer voltage. The data analysis was performed 
using LCquan software (Thermo Fisher). Theoretical masses of natural and 15N labeled 
derivatized amino acids were calculated using Xcalibur software and a 2 mmu window was 
used to ensure selective detection. Eight level calibration curve was built at concentration 
levels 6 nM, 20 nM, 60 nM, 2,00 nM, 600 nM, 2,000 nM, 6,000 nM, and 20,000 nM with 
1/X weighting factor. Calibration curve was linear with R^2 at least 0.95. Calibrators were 
spiked with internal standards at the same level as the samples. Therefore a response 
factor (area ratio of analyte peak to internal standard peak) was calibrated to 
concentration levels. Calibration standards of natural amino acids were supplied with the 
kit. The samples were 10 fold diluted compared to the calibration standard to avoid 
column and detector saturation problems for abundant amino acids. Concentration of 
15N-labeled amino acids was calculated under the assumption that the response factor is 
the same for natural and 15N-labeled amino acids. 
4.2.2.7 Data processing 
The LTQ-Orbitrap raw files were converted to universal mzXML format using ReAdW 
(http://tools.proteomecenter.org/software.php). The raw MSn data were converted to 
mzData files with Bioworks 3.3.1 SP1 (Thermo Fisher Scientific, Waltham, MA), and then 
searched against IPI-mouse database v 3.57 (20 ppm mass tolerance for the MS scan, 0.8 
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Da for the MS/MS scan, fixed carbamidomethylation for cysteine, and variable oxidation 
for methionine) or SwissProt15.3 E.Coli database (20 ppm mass tolerance for the MS scan, 
1 Da for the MS/MS scan, fixed carbamidomethylation for cysteine, and variable oxidation 
for methionine) with activation of the Decoy checkbox using MASCOT v 2.2 (Perkins et al., 
1999). MASCOT results were exported as xml files with a filtering threshold of p<0.001 and 
score>20. MASCOT xml and mzXML files were subsequently used for ProTurnyzer analysis.  
4.2.2.8 ProTurnyzer 
The in-house developed software ProTurnyzer was written in Java. All peptide IDs are read 
from the MASCOT files and for each ID the sequence and identification scan (MS/MS scan) 
are stored. The expected isotopologue distributions (masses and frequencies) of the 
peptides are calculated based on the respective sequence and natural frequencies of the 
isotopes. For each peptide, additional theoretical masses are calculated to account for 
additional peaks of isotope enriched (labeled) molecules. For each mass extracted ion 
chromatograms (XICs) were created by extracting peak intensities from the raw data from 
scans within an elution time window of 60 s before and after the corresponding MS/MS 
scan. The chromatographic peak of the peptide was determined by local minima of the XIC 
of the monoiostopic ion. In general there is no need for de-noising and smoothing before 
peak extraction on modern mass spectrometers such as the LTQ Orbitrap due to their high 
resolution and accuracy. 
The following equations formally describe the algorithm to estimate the fractional 
synthesis rate of an identified peptide. 
Let mp be the theoretical mass of the pth isotopic peak and 𝑝 ∈  0, . . . , 𝑁, . . . , 𝑀 . The first 
N + 1 masses are calculated based on natural isotope abundances comprising all natural 
isotopologues, whose frequency is at least 10%. The remaining M − N masses correspond 
to additional theoretical masses of all peaks that might arise from isotopic enrichments in 
a given range. These additional masses are defined by 
 𝑚𝑝 = 𝑚𝑝−1 + 𝑑 for 𝑝 ∈  𝑁 + 1, . . . , 𝑀 , (1) 
where d is the constant mass difference between the 15N and the 14N isotopes. In other 
words, the additional masses arise by replacing a 14N atom with a 15N atom until the 
percentage of heavy nitrogen atoms reaches a user defined maximum. 
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Let ip be the total measured intensities of the pth isotopic peak, which is derived by 
summing up all extracted ion intensities for that particular mass across the 
chromatographic peak of the peptide. Simple summation results in a weighted average of 
the relative isotopologue intensities. Based on ion statistics, the most intense scans 
(highest weight) should also most accurately reflect the true relative intensities. The total 
peptide intensity T is then simply the sum of all intensities arising from both natural and 
labeled molecules, denoted by Tnat and Tlab, respectively 
 𝑇 = 𝑇𝑛𝑎𝑡 + 𝑇𝑙𝑎𝑏  (2) 
From the extracted data the amount of total unlabeled signal can be calculated by 
 
𝑇𝑛𝑎𝑡 =
𝑖0
𝑓0
 (3) 
where i0 and f0 are the extracted intensity and calculated theoretical fractional frequency 
of the monoisotopic peak, respectively. The labeled peptide fraction LPF is then defined as 
the proportion of the labeled peptide signal to the total peptide signal, i.e. 
 
𝐿𝑃𝐹 =
𝑇𝑙𝑎𝑏
𝑇
=
𝑇 − 𝑇𝑛𝑎𝑡
𝑇
= 1 −
𝑇𝑛𝑎𝑡
𝑇
 (4) 
In order to determine actual rates, protein degradation has to be taken into account as 
well. Assuming steady state conditions (amount of synthesis = amount of degradation), the 
labeled peptide fraction measured after labeling duration t, LPFt, can be described by an 
exponential equation 
 𝐿𝑃𝐹𝑡 = 1 − 𝑒
−𝜆𝑡  (5) 
Where  is the degradation/synthesis rate constant. Rearranging yields the final equation 
to estimate the FSR, which is independent of the labeling duration 
 
𝐹𝑆𝑅 = 𝜆 =
−ln⁡(1 − 𝐿𝑃𝐹𝑡)
𝑡
 (6) 
For further analysis, in case the required conditions are met, the LPF values can be 
converted into fractional synthesis rates using equation (6). However, even if steady state 
cannot be assumed, relative differences in protein turnover between two states can be 
readily derived from the LPF.  
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4.2.2.9 Western blot 
Relative protein levels of α-tubulin from 14 d labeled brain, and liver carboxylesterase 1 
from 1 d labeled plasma were analyzed by Western blot. Protein mixtures with equal 
protein content (10 µg) were first resolved by SDS-PAGE. Each sample was loaded three 
times. Subsequently, the separated proteins were transferred onto polyvinylidene fluoride 
membranes. Western blot analysis was then performed with anti-α-tubulin (1:5000, CP06, 
Oncogene Research Products, La Jolla, CA) and anti-liver carboxylesterase 1 (1:500, 
ab52941, Abcam plc., Cambridge, UK) antibodies, respectively. The membranes were then 
incubated with HRP-conjugated secondary antibody. ECL system and film were used for 
membrane visualization. Quantification of ECL images was done using Quantity One 
software (BioRad). 
4.2.2.10 Gene ontology and pathway analysis 
Brain proteins derived from 7 day labeled mice were sorted by FSR in ascending order and 
divided into four equal bins. The GO (Ashburner et al., 2000) analysis was performed using 
the methods described previously (Pan et al., 2009) using R (Team, 2009) and the GOstats 
(Falcon and Gentleman, 2007) package. Briefly, for each bin the p-values for each GO 
category were calculated by the conditional hypergeometric test using the quantitative 
proteome as a background. After obtaining the p-value for each category and bin, GO 
categories were filtered based on their p-values. Categories with no significant enrichment 
(p<0.05) in any bin were filtered out. Those categories which did not have a p-value for a 
bin after filtering were provided a conservative p-value of 1. Finally, the p-values were 
transformed with the equation x = -log10 p, and the z-scores were calculated by 
[x-mean(x)]/sd(x). For the KEGG (Kanehisa et al., 2004) analysis the mouse proteins were 
mapped to the KEGG ortholog level. This allows an interspecies comparison for further 
investigations. Afterwards the hypergeometric test was calculated using R. The background 
of the test was set to all mouse proteins in KEGG with at least one pathway entry (3319). 
Similar to the GO analysis the p-values were transformed into z-scores. 
4.2.3 Results 
4.2.3.1 ProTurnyzer 
The determination of protein turnover with the newly developed ProTurnyzer algorithm is 
based on the assumption that for peptides derived from co-existing labeled and unlabeled 
proteins, the monoisotopic peptide population almost exclusively originates from the 
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pre-existing protein fraction. This is evident from the following calculations. The 
probability of observing monoisotopic tryptic peptides is influenced by the total number of 
atoms N of each element and its corresponding heavy isotope percentage in the precursor 
pool p during protein synthesis. The greater N and/or p are, the lower is their contribution 
to the monoisotopic fraction. For example, for a hypothetical peptide consisting of 10 
averagines (Senko et al., 1995) that is synthesized under unlabeled conditions, the 
probability of generating a monoisotopic peptide is 53.4% (Figure 47a). In contrast, if the 
precursor pool is labeled with 10% 15N, the probability of synthesizing a monoisotopic 
peptide is reduced to 13.6% (Figure 47b). In case of a 20% 15N-labeled precursor pool, the 
monoisotopic peptide level decreases to only 3% (Figure 47c). Although an in silico tryptic 
digestion of all proteins from a typical protein database results in a relatively large number 
of small peptides (Elias and Gygi, 2007), only very few peptides smaller than 10 amino 
acids in sequence are typically identified during a shotgun mass spectrometry experiment. 
Commonly identified tryptic peptides have an average length of approximately 15 amino 
acids (Wang et al., 2010) and the newly synthesized labeled peptides are mainly 
non-monoisotopic in nature. For instance, a 15 averagine peptide only contains 0.4% 
monoisotopic signal when labeled with 20% 15N (Figure 47g). In summary, unless a peptide 
has a very short sequence and a low 15N% incorporation, the newly synthesized fraction is 
mainly made up of the non-monoisotopic species. Thus, for the majority of commonly 
identified peptides, the newly synthesized fraction will have a negligible monoisotopic 
signal (Figure 47d, h). 
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Figure 47. Theoretical isotopologue distributions for peptides consisting of 10 (a,b,c,d) or 
15 (e,f,g,h) averagine residues with natural (a,e), 10% (b,f) and 20% 15N (c,g) content. The 
monoisotopic peptide signal disappears rapidly with increasing peptide length and/or 15N 
incorporation. Spectra d and h show mixed peptide populations, consisting of natural, 10% 
15N, 20% 15N populations at a ratio of 60:20:20. The example demonstrates that the 
monoisotopic peptide signal mainly represents the natural protein population. M0 
represents the monoisotopic peptide. Mx the peptides containing x heavy isotopes.  
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Figure 48. The free amino acid relative isotopic abundance in mouse brain and plasma 
during 15N labeling. A rapid increase of the 15N label is observed in plasma whereas in 
brain tissue the 15N incorporation is somewhat delayed.  
To verify the above assumption we analyzed free amino acids in tissue and plasma for 15N 
enrichment of the precursor pool in living mice. Prior to feeding the animals with the 
15N-labeled diet only 14N amino acid signals were detectable. After feeding the 15N-labeled 
diet for 14 days, the 15N amino acid signal increased from 0% to 66% in brain tissue and 
from 0% to 84% in plasma (Figure 48). Since diet-based amino acids can get into plasma 
more rapidly, the 15N amino acid quantity increased at a relatively high rate at the 
beginning of labeling (47% on day 1). The plasma proteins which are mostly synthesized in 
the liver incorporate labeled amino acids without much delay resulting in mainly 
non-monoisotopic signals for almost all tryptic peptides. Previous studies have shown that 
brain has lower amino acid concentrations since free amino acids cannot enter it directly 
due to the blood brain barrier (Hawkins et al., 2006). This is the reason for the low 15N 
increase in brain compared to plasma. On day 1 the free 15N amino acid levels were 
approximately 10% and increased to 66% on day 14 (Figure 48). Since essential amino 
acids cannot be synthesized de novo by the organism, they must be obtained from the diet. 
Therefore, the essential amino acid 15N% should increase at a faster rate than the one for 
non-essential amino acids. This was indeed the case for the plasma samples on days 1, 2 
and 4 whereas in the brain samples the difference was insignificant (data not shown). 
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Figure 49. Isotopologue distributions of plasma albumin peptide TCVADESAANCDK (a, b, 
c, d) and brain heat shock protein 70kDa peptide LDKSQIHDIVLVGGSTR (e, f, g, h) at 
different labeling times as determined by mass spectrometry followed by ProTurnyzer 
analysis. The yellow part of the bars represents the peptide derived from pre-existing 
protein, and the purple part the peptide derived from newly synthesized protein. With 
increasing labeling time the newly synthesized protein fraction steadily increases whereas 
the pre-existing protein fraction disappears. The average mass of the peptide derived from 
newly synthesized protein increases along with the precursor pool RIA. 
Table 13. E.Coli protein mixtures labeled to different extents with 15N. 
 
15N content 
Proportion (%) 
in mixture 
Theoretical 
15N labeled 
fraction (%) 
Measured 15N 
labeled 
fraction 
(mean±S.E. %) 
Mixture 1 Natural 40 60 61.18±1.34 
Technology development 
119 
20% 10 (n=82) 
40% 20 
60% 30 
Mixture 2 
Natural 60 
40 
38.92±1.09 
(n=116) 
20% 13.3 
40% 13.3 
60% 13.3 
 
 
Figure 50. Mass spectra of E.Coli protein carbamoyl-phosphate synthase peptide 
ELLIDESLIGWK. a, c: theoretical isotopologue distributions of the peptide in mixtures 1 (a) 
and 2 (c) (see Table 13 for compositions). b, d: observed mass spectra of the peptide 
following ProTurnyzer analysis. The yellow part of the bars represents the natural peptide 
and the purple part the labeled peptide fractions.  
 
In order to validate the ProTurnyzer algorithm for calculating the protein fractional 
synthesis rate (FSR), we performed experiments with predefined 15N-labeled protein 
mixtures derived from E.coli cultures (Table 13). The objective here was to distinguish 
labeled and unlabeled peptide populations based on the mass spectrometry isotopologue 
patterns. In the example, the observed isotopologue distribution of E.Coli 
carbamoyl-phosphate synthase tryptic peptide ELLIDESLIGWK is close to the predicted 
isotopologue distribution calculated based on the differentially labeled protein mixtures 
(Figure 50). The ProTurnyzer algorithm is able to distinguish the labeled and unlabeled 
fractions (Figure 50b, d) and the average % of labeled peptide in mixtures 1 and 2 was 
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calculated to be 61.18±1.34% and 38.92±1.09%, respectively (Table 13), which is in good 
agreement with the expected values (60% and 40%, respectively). These data demonstrate 
that ProTurnyzer succeeds in capturing the labeled fraction of an isotopologue pattern 
from labeled and unlabeled peptide mixtures without prior knowledge of the precursor 
pool RIA. 
4.2.3.2 Protein turnover analysis in living mice 
Mice were fed a 15N-labeled diet for several days to analyze brain tissue and plasma 
protein turnover. Figure 49 shows tryptic peptide isotopologue distributions for plasma 
albumin and brain heat shock protein 70 kDa at different labeling times. The yellow part of 
the bars represents the unlabeled peptide fraction derived from pre-existing protein. The 
purple part represents the peptide fraction that is newly synthesized from 15N-labeled 
amino acids in the precursor pool. The gain of purple and loss of yellow signals reflect the 
protein turnover progress. The average peptide mass of the purple signal increases over 
the course of 15N labeling, reflecting an increased 15N amino acid incorporation into the 
precursor pool. At an early labeling time the newly synthesized proteins have a low 15N 
content and the tryptic peptide isotopologue signal overlaps with the one from the 
pre-existing protein. Despite this low 15N content ProTurnyzer is still able to distinguish the 
mixed peptide populations. Our data show that the FSR calculated for the albumin peptide 
TCVADESAANCDK is approximately 15%/day, which is in good agreement with the 
4.96%/8h value reported using the H2
18O labeling method (Rachdaoui et al., 2009). 
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Figure 51. Liver carboxylesterase (a,b,c) and alpha-tubulin (d,e,f) ProTurnyzer(a,b,d,e) 
and Western blot analyses (c,f) in two mice of the same strain. a, b: ProTurnyzer analysis 
results for carboxylesterase peptide EGASEEETNLSK from 1-day labeled mouse plasma. d, e: 
ProTurnyzer results for alpha-tubulin peptide NLDIERPTYTNLNR from 14-day labeled 
mouse brains. The purple part of the bars represents peptide derived from newly 
synthesized protein. In both cases, mouse 2 (corresponding to spectra b and e) shows a 
faster turnover rate than mouse 1 (corresponding to spectra a and d). No difference in 
protein amount is detected by western blot (c, f) between the two animals (analyzed in 
triplicate). 
In another set of studies we investigated the correlation between protein turnover and 
quantity. Liver carboxylesterase N (IPI00138342) from 1-day labeled plasma and tubulin 
alpha (IPI00117350) from 14-day labeled brain tissue showed different turnover rates 
between two animals (Figure 51a, b, d, e). At the same time western immunoblots 
showed no detectable change in the two proteins’ expression levels (Figure 51c, f) 
implying that protein synthesis can vary without an obvious change in overall protein 
expression. It also demonstrates that protein turnover is a more sensitive measure for 
detecting biological variability. 
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Figure 52. Correlation between brain protein turnover and KEGG pathway (a) and gene 
ontology cellular component (b). The blue graph on top displays protein FSR distribution 
from 7-day labeled brain tissue. Proteins were divided into four equal bins and analyzed 
with respect to KEGG pathways and GO categories. P-values were transformed to z-scores 
indicating bin specific enrichments (Due to the limited resolution the pathway and 
category names on the right are not legible; higher resolution figure is available in 
electronic file.). 
Based on their FSRs brain proteins from 7-day labeled brain tissue were divided into equal 
four bins. Proteins in each bin were analyzed independently with respect to enrichment in 
GO categories cellular component, molecular function, biological process, as well as KEGG 
pathways. Only categories with at least one bin of statistical significance larger than 95% 
(p-value<0.05) are shown. KEGG pathway analyses (Figure 52a) reveal that pathways 
citrate cycle (TCA cycle) (p=7.6E-17), valine, leucine and isoleucine degradation (p=5.8E-15) 
and butanoate metabolism (p=2.5E-12) are enriched with proteins from the first bin with 
low FSRs. In contrast, proteasome (p=1.7E-5), fatty acid biosynthesis (p=3.9E-4) and 
aminoacyl-tRNA biosynthesis (p=5.0E-4) are enriched with proteins from the fourth bin, 
implying high turnover rates. The GO analysis on cellular components (Figure 52b) 
demonstrates that proteins in the mitochondrion (p=7.1E-15), mitochondrial inner 
membrane (p=6.3E-12), mitochondrial envelope (p=8.3E-11), and organelle membrane 
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(p=4.2E-9) are enriched in the first bin, and proteins in the nucleus (p=2.0E-5) and 
endoplasmic reticulum (p=7.0E-4) are enriched in the fourth bin. Our results are in 
agreement with a previous study (Takizawa and Yamashita, 1989) that also found shorter 
biological half lives for nuclear compared to mitochondrial proteins. GO biological process 
and molecular function analyses also demonstrate differences in protein turnover. Proteins 
relevant to oxidation/reduction (p=3.4E-5), acetyl-CoA metabolic process (p=4.7E-5), and 
hyaluronic acid binding (p=0.001) and oxidoreductase activity (p=0.004) are enriched in 
the first bin, indicating slow turnover rates. The proteins relevant to protein metabolic 
process (p=2.7E-4), cellular biopolymer metabolic process (p=8.3E-4), and protein binding 
(p=1.7E-4), DNA binding (p=4.7E-4), unfolded protein binding (p=6.7E-4) and ATP binding 
(p=7.9E-4) are enriched in the fast turnover bin (Figure 53, 54). 
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Figure 53. Correlation between brain protein turnover and gene ontology biological 
process. The blue graph on top displays protein FSR distribution from 7-day labeled brain 
tissue. Proteins were divided into four equal bins and analyzed with respect to KEGG 
pathways and GO categories. P-values were transformed to z-scores indicating bin specific 
enrichments. 
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Figure 54. Correlation between brain protein turnover and gene ontology molecular 
function. The blue graph on top displays protein FSR distribution from 7-day labeled brain 
tissue. Proteins were divided into four equal bins and analyzed with respect to KEGG 
pathways and GO categories. P-values were transformed to z-scores indicating bin specific 
enrichments. 
4.2.4 Discussion 
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We introduce a new straightforward method for the global analysis of individual protein 
turnover in live organisms that unlike other protein turnover analysis methods (Doherty 
and Beynon, 2006b) does not require precursor pool RIA knowledge. Our method is based 
on the hypothesis that tryptic peptides derived from newly synthesized proteins are 
essentially devoid of any monoisotopic peptides. This is attributable to the fully 15N 
labeled dietary tracer, which significantly increases labeling efficiency. We show that for an 
average sized tryptic peptide with a low 15N incorporation the monoisotopic peptide signal 
is mostly derived from the pre-existing protein population (Figure 47h). We also 
demonstrate that the free amino acid RIA increases rapidly for plasma proteins, and 
somewhat slower in the brain. As a consequence the newly synthesized protein fraction 
can be distinguished from the pre-existing fraction already early on in the labeling process 
(Figure 49). 
Other methods for protein turnover analysis in live organisms that rely on RIA knowledge 
have been developed previously. One such method is mass isotopomer distribution 
analysis (MIDA) (Hellerstein and Neese, 1992, 1999). After labeling an organism with a 
single labeled amino acid tracer, the precursor RIA can be calculated based on the ratio 
between the intensities of singly and doubly labeled peptide populations. However, 
adapting the MIDA method to precursor pools whose RIA is changing is not 
straightforward, since proteins synthesized over the course of the labeling process are 
exposed to non-homogeneous precursor RIAs. The second limitation of the MIDA 
approach is that only tracer amino acid-containing peptides are amenable to turnover 
analysis. In one MIDA-based study chicken were labeled with valine as a tracer (Doherty et 
al., 2005). Using this approach protein turnover can only be calculated for 
valine-containing peptides after determining the precursor RIA. The chicken was chosen in 
this study because of its continuous diet intake which leads to a quick increase and 
plateauing of precursor RIA that subsequently remains constant. However, this method is 
not applicable to other mammals including mice. 
In an alternative approach, stable isotope labeled water, 2H2O or H2
18O, has been orally 
administered to determine protein dynamics (Rachdaoui et al., 2009). In this case the 
labeled water is utilized by the animal for the synthesis of amino acids and proteins (Foster 
et al., 1938). The assumption of this strategy is that a fast equilibration can be achieved 
between body water and free amino acid. Isotopologue analysis is used to determine the 
protein turnover. However, the small change in isotopologue distribution resulting from 
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low tracer incorporation makes the analysis of slow turnover and low abundant proteins 
difficult. Moreover, the hydrogen/deuterium exchange is reversible and can result in a 
back-exchange from deuterium to hydrogen during sample preparation in aqueous 
solvents (Kipping and Schierhorn, 2003; Mandell et al., 1998). 
Stable isotope labeling with amino acids in cell culture (SILAC) (Ong et al., 2002) was 
originally introduced to relatively quantify two or more proteomes from different 
physiological cellular states. More recently, the SILAC method has also been adapted for 
the determination of protein dynamics in cultured cell systems (Doherty et al., 2009). In 
HeLa cells the effect of microRNAs on protein synthesis was investigated by the pulsed 
SILAC (pSILAC) approach (Selbach et al., 2008). However, for incomplete precursor RIA the 
SILAC peptides derived from newly synthesized protein can only have two patterns: 
labeled or unlabeled. The peptide signals derived from the unlabeled newly synthesized 
protein overlaps with the one from unlabeled pre-existing protein. In case of a low 
precursor RIA the majority of the peptide signal derived from newly synthesized protein 
shows up in its unlabeled form. Hence the knowledge of the amino acid precursor RIA is 
mandatory if one wants to apply the pSILAC approach to living animals. Since the SILAC 
tryptic peptides only contain one labeled tracer amino acid (unless proteins are cleaved 
incompletely) and the precursor RIA in living animals is continuously changing after tracer 
administration, calculation of the precursor RIA with the MIDA method cannot be 
performed. In a recent report pSILAC was also applied to living mice (58th ASMS 
Conference on Mass Spectrometry and Allied Topics poster “Proteome wide determination 
of true turnover rates in mice” by Ruhs et al.). Here the precursor RIA was calculated by 
fitting an exponential function to proteins with the highest incorporation rates. However, 
data from multiple labeling time points had to be acquired. Furthermore, the calculated 
precursor RIA resulting from the labeled fractions of a few proteins with a fast turnover 
may not correspond to the real-time RIA when the animal is sacrificed. Hence, if the 
precursor RIA for different proteins is not homogeneous, the method is prone to error. 
The major advantage of the protein turnover analysis method we are presenting here is 
that precursor RIA determination is not required. The accuracy of our method depends on 
the match between measured and theoretical isotopologue distributions. Deviations 
between the two are more pronounced for peptides derived from low abundant proteins 
due to poor mass spectrometry ion statistics (Xu et al., 2010) and the variable decay rates 
for different isotopic species in certain mass spectrometer detectors (Bresson et al., 1998). 
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However, using a weighted average isotopologue distribution of all spectra across the 
entire elution time of a peptide improves this situation. 
15N labeling periods for brain and plasma of 7 days and 2 days, respectively, resulted in the 
determination of FSRs for a great number of proteins, typically showing ratios between 
labeled and unlabeled protein fractions neither too low nor too high. This results in a small 
overlap of the mass spectrometry signals from the two peptide populations that the 
ProTurnyzer software can easily deal with. 
Our data indicate that protein FSRs differ from each other to a significant extent. For an 
in-depth analysis, two labeling time points can be applied in order to capture proteins 
covering a wide range of FSRs. For instance, a 1-day labeling period is sufficient for the 
plasma protein plasminogen (FSR > 50%/day). In this case longer labeling times would 
result in the disappearance of the pre-existing natural protein fraction which makes FSR 
determination difficult. Brain heat shock protein 70kDa FSR was much lower than that of 
plasminogen. Here longer labeling times can reduce the error caused by the monoisotopic 
peptide signal derived from proteins that are newly synthesized shortly after onset of 
labeling while precursor RIA is still low. Using proper labeling times our method succeeds 
in measuring individual protein dynamics. Based on our data the labeling time window is 
reasonably wide and results in comparable FSRs even when different labeling times are 
used. 
As mentioned in the ’Introduction’ mRNA and its corresponding protein levels do not 
always correlate. Protein turnover is one important aspect of translatomics since it reflects 
the rate of protein translation and serves as an important link between mRNA and protein. 
Methods able to determine protein turnover in a high throughput manner, especially in 
living animals, are critical to obtain a better understanding of the poor correlation 
between mRNA and protein quantities. We have been able to analyze FSRs for a great 
number of proteins, and the KEGG pathway and GO analyses have shown that protein 
turnover correlates with biological processes and organelle protein distribution. 
In the medical sciences protein turnover analysis can deliver important information for 
biomarker research that is more sensitive than simple protein quantitation. Particularly in 
the blood where proteins are rapidly turned over standard analyses for protein expression 
levels may not be able to catch subtle differences between healthy and diseased states 
and FSR analysis could provide a more sensitive platform for protein biomarker assays. 
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This becomes especially relevant in the case of low abundant proteins. Even in cases 
where protein expression levels are detectable the analysis of protein turnover may sense 
these upcoming changes at a much earlier time point, which is critical for the early 
detection of disease.
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5 Perspectives 
The presented studies have demonstrated that a combination of proteomics 
and metabolomics is able to identify molecular pathways pertinent for the 
anxiety phenotype in a mouse model. The identified proteins and metabolites 
allow the elucidation of biological networks, which provide a global view of 
disease pathobiology. Based on the presented findings on the anxiety mouse 
model two lines of future research can be considered. On one hand an 
investigation of the possibility of translating the results from the mouse model 
to the clinic should be performed. After successful clinical validation of a 
candidate biomarker, the latter can serve to indicate the anxiety phenotype in 
case / control studies and to monitor treatment response. Even without 
knowing a biomarker’s role in modulating anxiety disorders, it still can assist 
the psychiatrist to get a better diagnosis for patients. The second level of 
studies is related to preclinical research. Although several pathways that are 
relevant to psychiatric disorders are suggested in the present study, the 
ultimate disease cause is still not understood. The current study opens several 
directions for psychiatric disease research. Among others the identified 
pathways can be used for drug development efforts by the pharmaceutical 
industry. 
Besides protein expression quantification, the 15N metabolic labeling 
technology enables us to detect the protein turnover rate, whose alteration is 
thought to be more sensitive than protein expression. The protein turnover 
information opens another venue for biomarker discovery efforts, as changes in 
protein levels are apparent at a much earlier time point using turnover analysis 
and those changes are not yet reflected by the total protein amount. Moreover, 
protein turnover studies may help us to get a better understanding of the poor 
correlation between mRNA and protein quantities. 
Another focus when it comes to technology development is the analysis of 
clinical samples. Disease specific signature proteins and metabolites should be 
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quantified by an assay procedure in a standard and fast manner. The current 
-omics platforms are relatively time consuming. There is a need to improve the 
shotgun proteomics workflow to analyze low abundant biomarkers in a 
targeted fashion precisely and fast.
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7 Supplementary tables 
Supplementary table 1. Proteins expressed 
differentially between HAB/LAB hippocampal 
cytosol (indirect comparison) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00271166.4 Htt -7.2 28 
IPI00128071.7 Uso1 -4.1 14 
IPI00320831.3 Nbea -3.9 107 
IPI00652358.5 Arsb -3.6 13 
IPI00377455.3 Gcc2 -3.4 12 
IPI00336281.1 Golga3 -3 39 
IPI00115663.2 Dctn1 -3 50 
IPI00228222.1 Ubr3 -3 13 
IPI00788324.1 Myh9 -2.9 11 
IPI00331299.9 Ncdn -2.9 173 
IPI00112001.1 Cap2 -2.8 22 
IPI00466610.5 Map2k1 -2.7 10 
IPI00453996.1 Myh14 -2.7 16 
IPI00114894.1 Myh11 -2.7 116 
IPI00421179.1 Eif4g1 -2.6 28 
IPI00308938.6 Capn2 -2.6 14 
IPI00123181.3 Myh9 -2.5 352 
IPI00400432.2 Eif4a2 -2.4 16 
IPI00621417.1 Hbb-b1 -2.4 231 
IPI00467383.2 Cul3 -2.3 41 
IPI00225961.5 Phgdh -2.3 21 
IPI00130390.5 Kif1b -2.2 31 
IPI00221817.5 
Loh11cr2
a 
-2.2 23 
IPI00453613.3 Huwe1 -2.2 89 
IPI00761751.2 Kif13b -2.2 12 
IPI00480321.2 Grlf1 -2.1 27 
IPI00338604.5 Myh10 -2.1 558 
IPI00331444.7 Ipo7 -2.1 58 
IPI00123709.1 Akap12 -2 36 
IPI00123465.1 Cops7a -2 23 
IPI00118120.1 Myo5a -2 94 
IPI00128341.1 Wasf3 -2 12 
IPI00453615.3 Huwe1 -2 21 
IPI00420562.5 Cand1 -2 281 
IPI00119762.4 Dclk1 -2 26 
IPI00453803.5 Ube2o -2 93 
IPI00114667.1 Psmd7 -1.9 14 
IPI00116752.7 Sec23ip -1.9 22 
IPI00115833.2 Mtap6 -1.9 165 
IPI00319320.4 Nckap1 -1.9 94 
IPI00407835.2 Ubap2l -1.9 30 
IPI00229483.3 Sec24c -1.9 28 
IPI00262114.1 Pak3 -1.9 12 
IPI00117929.1 Oxr1 -1.9 238 
IPI00377609.2 Vcpip1 -1.9 25 
IPI00464181.4 BC067047 -1.8 11 
IPI00224151.5 Ap1g1 -1.8 14 
IPI00118676.3 Eif4a1 -1.8 17 
IPI00377592.7 Sec31a -1.8 137 
IPI00554992.2 Kif1a -1.8 63 
IPI00132762.1 Trap1 -1.8 83 
IPI00129350.1 Aldh18a1 -1.7 12 
IPI00270877.5 Usp14 -1.7 11 
IPI00136350.3 Dlg3 -1.7 36 
IPI00108388.1 Usp9x -1.7 131 
IPI00407144.1 Kif1b -1.7 18 
IPI00405625.9 Cyfip2 -1.7 134 
IPI00187356.1 Ankfy1 -1.7 22 
IPI00626501.3 Kif1a -1.7 58 
IPI00124614.1 Epm2aip1 -1.7 36 
IPI00399840.2 Ube3a -1.7 21 
IPI00343557.1 Mapre3 -1.7 31 
IPI00321646.3 AI314180 -1.7 21 
IPI00881540.2 Synj1 -1.7 11 
IPI00115824.1 Nipsnap1 -1.7 43 
IPI00108150.1 Rock2 -1.7 172 
IPI00221769.5 Ak3 -1.7 14 
IPI00229080.7 Hsp90ab1 -1.7 883 
IPI00172221.2 Dnm1l -1.7 60 
IPI00133132.1 Ptk2b -1.6 54 
IPI00132080.1 Pgls -1.6 51 
IPI00321734.7 Glo1 -1.6 207 
IPI00125135.1 Ube2d2 -1.6 41 
IPI00465648.3 Dnm1 -1.6 31 
IPI00331016.1 Sec24b -1.6 37 
IPI00312128.3 Trim28 -1.6 52 
IPI00227236.2 Cadps2 -1.5 28 
IPI00109044.8 
2900073G
15Rik 
-1.5 12 
IPI00330476.3 Cyfip1 -1.5 202 
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IPI00459745.3 Rap1gap -1.5 39 
IPI00229647.5 Tln2 -1.5 62 
IPI00123624.8 
2610301G
19Rik 
-1.5 53 
IPI00352986.2 Strn -1.5 38 
IPI00129526.1 Hsp90b1 -1.5 337 
IPI00808550.1 
B230112C
05Rik 
-1.5 18 
IPI00458854.2 Sart3 -1.5 30 
IPI00117087.1 Cdc37 -1.4 12 
IPI00116546.2 Prkar2a -1.4 10 
IPI00129282.1 Dlg2 -1.4 31 
IPI00311461.1 Atp6v1h -1.4 25 
IPI00758170.2 Synj1 -1.4 116 
IPI00222496.3 Pdia6 -1.4 18 
IPI00123349.2 Sec23a -1.4 42 
IPI00120076.2 Ckmt2 -1.4 41 
IPI00331076.4 Slk -1.4 169 
IPI00137331.6 Cap1 -1.4 109 
IPI00314439.3 Psmd3 -1.4 19 
IPI00113214.1 Usp5 -1.4 373 
IPI00331568.7 Hgs -1.4 23 
IPI00310091.8 Ppp2r1a -1.4 75 
IPI00330804.4 Hsp90aa1 -1.4 614 
IPI00465786.3 Tln1 -1.3 41 
IPI00323483.3 Pdcd6ip -1.3 50 
IPI00406624.2 Mgea5 -1.3 41 
IPI00132993.1 Pak1 -1.3 64 
IPI00127707.1 Pcbp2 -1.3 14 
IPI00131692.7 Rabep1 -1.3 62 
IPI00323881.1 Kpnb1 -1.3 100 
IPI00469103.1 Kars -1.3 23 
IPI00112335.1 Map2k4 -1.3 24 
IPI00381019.1 Smarcc2 -1.3 21 
IPI00123379.1 Hdlbp -1.3 16 
IPI00221723.1 Wasf2 -1.2 12 
IPI00123518.1 Lypla2 -1.2 18 
IPI00261627.1 Sucla2 -1.2 59 
IPI00850983.1 Synj1 -1.2 665 
IPI00351252.4 Gmps -1.2 78 
IPI00468516.3 
D6Wsu11
6e 
-1.2 23 
IPI00123292.5 Fubp1 -1.2 59 
IPI00225231.1 Ank2 -1.2 20 
IPI00312076.4 Kif3a -1.2 10 
IPI00108147.1 Rock1 -1.1 25 
IPI00415908.4 Ppme1 -1.1 23 
IPI00128127.1 Dgkg -1.1 15 
IPI00132278.1 Cplx1 -1.1 12 
IPI00226602.3 6-Sep -1.1 22 
IPI00762897.2 Ugcgl1 -1.1 208 
IPI00330163.4 Cadps -1.1 203 
IPI00116554.2 Ptpn11 -1.1 37 
IPI00118075.1 Mtap2 -1.1 3147 
IPI00420870.4 Ogt -1.1 114 
IPI00119689.1 Ap2b1 -1.1 159 
IPI00555125.1 Kif5b -1.1 27 
IPI00329843.4 Ankfy1 -1.1 40 
IPI00154004.1 
LOC10004
6081 
-1.1 86 
IPI00222306.5 Ppp2r1b -1.1 68 
IPI00109420.2 Kif5a -1.1 120 
IPI00169448.1 Ube2m -1.1 26 
IPI00187407.4 Cops8 -1.1 36 
IPI00119876.1 Dync1h1 -1.1 1143 
IPI00165854.3 Ube2n -1.1 65 
IPI00381365.1 Abr -1.1 64 
IPI00224128.7 Nmt1 -1 15 
IPI00130992.1 Capns1 -1 11 
IPI00420385.4 11-Sep -1 17 
IPI00127176.3 
6720456B
07Rik 
-1 24 
IPI00471372.2 Wasf1 -1 54 
IPI00668903.1 Cadps -1 14 
IPI00134344.6 Spnb3 -1 606 
IPI00853823.2 Rapgef2 -1 134 
IPI00127492.1 Smap1 -1 29 
IPI00310131.5 Ap2a2 -1 76 
IPI00114241.2 Nefh -1 43 
IPI00405227.3 Vcl -1 214 
IPI00347394.7 
1300001I
01Rik 
-1 48 
IPI00124787.3 Arl3 -1 36 
IPI00876559.1 Khsrp -1 20 
IPI00110990.1 Dusp3 -1 123 
IPI00128867.3 Purb -1 21 
IPI00894724.1 Mtap2 -1 43 
IPI00308446.2 Ahcyl2 -1 16 
IPI00127172.3 Ddx1 -1 42 
IPI00849505.1 
LOC10004
3998 
-1 138 
IPI00379625.2 Nova2 -1 15 
IPI00228113.5 Mthfd1l -1 32 
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IPI00453849.3 Rnmt -1 10 
IPI00553419.3 Dsp 1 40 
IPI00229598.4 Cnp 1 19 
IPI00129519.3 Basp1 1 94 
IPI00130280.1 Atp5a1 1 124 
IPI00468481.2 Atp5b 1 132 
IPI00330523.1 Pcca 1 109 
IPI00308976.1 Me3 1 249 
IPI00223216.5 Tst 1 78 
IPI00272401.4 Acyp2 1 114 
IPI00126172.1 
4931406C
07Rik 
1 17 
IPI00317309.5 Anxa5 1 139 
IPI00336881.1 Ddah2 1 31 
IPI00114710.2 Pcx 1 637 
IPI00127450.1 Man2c1 1 82 
IPI00110351.1 
2310007H
09Rik 
1 16 
IPI00459279.2 Qdpr 1 138 
IPI00459326.1 
Uncharact
erized 
1 23 
IPI00626662.3 Aldh1a1 1.1 11 
IPI00118011.6 Manba 1.1 27 
IPI00121440.4 Etfb 1.1 63 
IPI00109169.1 Idh3g 1.1 93 
IPI00116753.4 Etfa 1.1 187 
IPI00230351.1 Sdha 1.1 121 
IPI00329927.4 Nfasc 1.1 127 
IPI00380195.1 
1700012G
19Rik 
1.1 69 
IPI00109109.1 Sod2 1.1 360 
IPI00108980.2 Cpne4 1.1 14 
IPI00123744.1 Cst3 1.1 128 
IPI00130344.3 Clic1 1.1 20 
IPI00170307.1 Apoa1bp 1.1 156 
IPI00228253.2 Acat2 1.1 80 
IPI00131830.1 Serpina3k 1.1 56 
IPI00469548.2 Syn2 1.2 10 
IPI00132653.1 Oxct1 1.2 354 
IPI00122971.1 Ncam1 1.2 80 
IPI00315452.5 Pnp1 1.2 25 
IPI00120030.1 Crym 1.2 423 
IPI00315302.5 Ndufa2 1.2 18 
IPI00123014.1 Padi2 1.2 69 
IPI00310035.3 Fah 1.2 33 
IPI00133557.1 Tppp3 1.2 61 
IPI00139788.2 Trf 1.2 219 
IPI00223060.1 Pck2 1.3 96 
IPI00653664.2 Enoph1 1.3 26 
IPI00137736.1 Rps28 1.3 19 
IPI00127267.4 Gldc 1.3 26 
IPI00331094.3 Aspa 1.3 11 
IPI00471246.2 Ivd 1.5 58 
IPI00670735.1 
LOC67731
7 
1.5 24 
IPI00117042.3 Gfap 1.6 75 
IPI00121038.2 Vcan 1.6 50 
IPI00115240.1 Mbp 1.7 12 
IPI00312058.5 Cat 1.7 22 
IPI00121534.1
1 
Car2 1.7 267 
IPI00229475.1 Jup 1.9 39 
IPI00133034.3 Hint2 1.9 47 
IPI00112719.1 Alad 1.9 55 
IPI00138274.1 Cryab 2 10 
IPI00130640.5 Hrsp12 2.2 242 
IPI00127560.1 Ttr 2.5 54 
IPI00131695.3 Alb 3.2 412 
IPI00222228.5 
4732456N
10Rik 
3.5 33 
IPI00762198.2 Hbb-b1 5.3 233 
IPI00330039.3 Srgap3 8.1 14 
 
Supplementary table 2. Proteins expressed 
differentially between HAB/LAB hippocampal 
microsome (indirect comparison) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00116222.1 Hibadh -5.1 41 
IPI00135915.1 Glb1 -5 10 
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IPI00466610.5 Map2k1 -2.7 60 
IPI00464166.2 Ptpn23 -2.4 24 
IPI00116331.1 Sgta -2.3 27 
IPI00378557.3 Pfdn4 -2.2 12 
IPI00114894.1 Myh11 -2.1 95 
IPI00421179.1 Eif4g1 -2 41 
IPI00331299.9 Ncdn -1.9 267 
IPI00453615.3 Huwe1 -1.8 18 
IPI00119762.4 Dclk1 -1.7 36 
IPI00453996.1 Myh14 -1.7 23 
IPI00336281.1 Golga3 -1.7 22 
IPI00123181.3 Myh9 -1.7 320 
IPI00282957.4 Mtap7d1 -1.7 16 
IPI00115663.2 Dctn1 -1.7 141 
IPI00123624.8 
2610301G
19Rik 
-1.7 85 
IPI00752390.4 Sbf1 -1.6 87 
IPI00453613.3 Huwe1 -1.6 99 
IPI00172221.2 Dnm1l -1.6 176 
IPI00788324.1 Myh9 -1.5 19 
IPI00118120.1 Myo5a -1.5 242 
IPI00338604.5 Myh10 -1.5 573 
IPI00118676.3 Eif4a1 -1.4 41 
IPI00467383.2 Cul3 -1.4 38 
IPI00321734.7 Glo1 -1.4 146 
IPI00407835.2 Ubap2l -1.4 43 
IPI00128296.1 Ckmt1 -1.4 307 
IPI00321922.2 Pacs1 -1.3 17 
IPI00407425.2 Myo18a -1.3 73 
IPI00137331.6 Cap1 -1.3 210 
IPI00403682.2 Mapre2 -1.3 15 
IPI00420562.5 Cand1 -1.3 288 
IPI00377609.2 Vcpip1 -1.2 21 
IPI00222496.3 Pdia6 -1.2 38 
IPI00115097.1 Copb2 -1.2 26 
IPI00122069.1 Prkcc -1.2 153 
IPI00132993.1 Pak1 -1.2 12 
IPI00377592.7 Sec31a -1.2 77 
IPI00117063.1 Fus -1.2 17 
IPI00112001.1 Cap2 -1.2 50 
IPI00462934.2 Khsrp -1.2 68 
IPI00119876.1 Dync1h1 -1.2 1527 
IPI00312128.3 Trim28 -1.2 52 
IPI00461469.3 Mars -1.1 42 
IPI00115833.2 Mtap6 -1.1 157 
IPI00108147.1 Rock1 -1.1 17 
IPI00319320.4 Nckap1 -1.1 114 
IPI00120076.2 Ckmt2 -1.1 79 
IPI00139795.2 Rplp2 -1.1 66 
IPI00458854.2 Sart3 -1.1 32 
IPI00321646.3 AI314180 -1.1 105 
IPI00896700.1 Mtap1b -1.1 40 
IPI00124223.3 Psme1 -1 23 
IPI00127176.3 
6720456B
07Rik 
-1 10 
IPI00114801.2 Inpp1 -1 17 
IPI00123465.1 Cops7a -1 52 
IPI00553419.3 Dsp -1 28 
IPI00312752.3 Sh3gl1 -1 21 
IPI00122826.1 Cend1 -1 12 
IPI00471372.2 Wasf1 -1 50 
IPI00330476.3 Cyfip1 -1 156 
IPI00225533.1 Necap1 -1 34 
IPI00626501.3 Kif1a -1 42 
IPI00117929.1 Oxr1 -1 173 
IPI00114667.1 Psmd7 -1 73 
IPI00270877.5 Usp14 -1 17 
IPI00320831.3 Nbea -1 78 
IPI00133428.3 Psmc1 -1 30 
IPI00115546.4 Gnao1 1 319 
IPI00109727.1 Thy1 1 141 
IPI00230277.3 Mapk3 1 12 
IPI00154054.1 Acat1 1 246 
IPI00331745.2 Lxn 1 36 
IPI00117312.1 Got2 1 719 
IPI00126635.1 Idh3b 1 124 
IPI00468653.3 Pccb 1 53 
IPI00110827.1 Acta1 1 814 
IPI00110850.1 Actb 1 1062 
IPI00226430.2 Acaa2 1 38 
IPI00380195.1 
1700012G
19Rik 
1 48 
IPI00115679.1 Ganab 1 159 
IPI00269481.7 Capzb 1 164 
IPI00116120.3 Pdcd5 1 24 
IPI00128857.1 Me1 1 94 
IPI00126940.1 Adk 1 19 
IPI00317309.5 Anxa5 1 106 
IPI00471246.2 Ivd 1 37 
IPI00555059.2 Prdx6 1 130 
IPI00135977.3 Clic4 1 10 
IPI00119035.1 Acan 1 49 
IPI00116134.1 Dpp3 1 98 
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IPI00139788.2 Trf 1 123 
IPI00153400.2 H2afj 1.1 31 
IPI00222228.5 
4732456N
10Rik 
1.1 27 
IPI00128973.1 Gap43 1.1 21 
IPI00323592.2 Mdh2 1.1 1244 
IPI00116192.1 Prdx3 1.1 182 
IPI00308976.1 Me3 1.1 181 
IPI00116074.1 Aco2 1.1 1609 
IPI00132653.1 Oxct1 1.1 205 
IPI00461964.3 Aldh6a1 1.1 56 
IPI00330480.1 EG432987 1.2 169 
IPI00113052.1 Tsfm 1.2 17 
IPI00114241.2 Nefh 1.2 38 
IPI00109169.1 Idh3g 1.2 95 
IPI00116753.4 Etfa 1.2 140 
IPI00330523.1 Pcca 1.2 111 
IPI00121013.1 Pea15a 1.2 51 
IPI00124692.1 Taldo1 1.2 69 
IPI00127450.1 Man2c1 1.2 53 
IPI00340165.5 
21 kDa 
protein 
1.2 16 
IPI00230013.3 Cacna2d1 1.2 74 
IPI00459279.2 Qdpr 1.2 90 
IPI00130391.1 Tcrb-V20 1.3 208 
IPI00229475.1 Jup 1.3 38 
IPI00120045.1 EG628438 1.3 114 
IPI00109109.1 Sod2 1.3 206 
IPI00122971.1 Ncam1 1.3 313 
IPI00122265.1 Sh3bgrl 1.3 41 
IPI00170307.1 Apoa1bp 1.3 96 
IPI00115620.1 Psat1 1.3 69 
IPI00222515.5 Psmd11 1.3 61 
IPI00759847.1 Ndrg2 1.4 15 
IPI00169622.3 Phyhip 1.4 108 
IPI00118825.2 Csl 1.4 10 
IPI00121566.1 Gmpr 1.4 35 
IPI00118011.6 Manba 1.5 13 
IPI00229718.1
0 
Gltp 1.5 15 
IPI00121105.2 Hadh 1.5 29 
IPI00120030.1 Crym 1.6 319 
IPI00123014.1 Padi2 1.6 38 
IPI00121534.1
1 
Car2 1.6 215 
IPI00222149.4 Chl1 1.7 75 
IPI00123379.1 Hdlbp 2 35 
IPI00114710.2 Pcx 2 459 
IPI00112719.1 Alad 2.1 48 
IPI00131830.1 Serpina3k 2.1 37 
IPI00130640.5 Hrsp12 2.3 92 
IPI00138274.1 Cryab 2.3 19 
IPI00762198.2 Hbb-b1 4.2 123 
IPI00454053.7 
2010300C
02Rik 
5.1 12 
IPI00118757.1 Phpt1 6.3 43 
 
Supplementary table 3. Proteins expressed 
differentially between HAB/LAB plasma 
(indirect comparison) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00877236.1 Apoa1 -6.2 190 
IPI00831484.1 382044 -4.4 76 
IPI00177214.1 Igh-6 -4.3 63 
IPI00116548.1 Reg3b -3.8 12 
IPI00855108.2 Hbb-b1 -3.5 75 
IPI00113806.1 Reg3g -3 85 
IPI00118130.1 Orm1 -2.3 441 
IPI00118455.1 Saa1 -2.1 87 
IPI00309214.1 Apcs -2 668 
IPI00453488.1 Antxr2 -2 30 
IPI00128484.1 Hpx -1.8 5713 
IPI00663742.3 Dnahc10 -1.8 40 
IPI00122312.2 Fgg -1.6 1416 
IPI00279079.1 Fgb -1.4 1439 
IPI00115522.3 Fga -1.4 1253 
IPI00124725.2 Itih3 -1.4 1093 
IPI00462363.1 BC026782 -1.4 71 
IPI00468477.4 
25 kDa 
protein 
-1.4 26 
IPI00129250.1 Lrg1 -1.3 183 
IPI00222228.5 
4732456N
10Rik 
-1.3 15 
IPI00119299.1 Lifr -1.2 247 
IPI00314141.5 Serpina3n -1.2 228 
IPI00130010.4 Cfh -1.1 2741 
IPI00121055.1 EG214403 -1.1 116 
IPI00378649.1 LOC63510 -1.1 38 
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1 
IPI00107952.2 Lyz2 -1.1 11 
IPI00137599.2 Sepp1 -1 172 
IPI00459201.1 Igh -1 51 
IPI00133751.1 Mfap4 -1 31 
IPI00114099.2 Apoc3 1 317 
IPI00109996.1 H2-Q2 1 62 
IPI00468281.5 Rsad2 1.1 20 
IPI00850317.1 
LOC10004
4179 
1.2 60 
IPI00323571.1 Apoe 1.3 668 
IPI00127560.1 Ttr 1.4 689 
IPI00122429.1 Rbp4 1.4 463 
IPI00111315.1 Apoa2 1.4 185 
IPI00317356.1
0 
Pon1 1.4 137 
IPI00118994.1 Apoc4 1.4 54 
IPI00119676.1 Apoc1 1.5 77 
IPI00869381.1 Apoa2 1.6 190 
IPI00666034.3 Apob 1.7 2182 
IPI00138892.2 
OTTMUS
G0000000
4411 
1.7 14 
IPI00828873.1 Hbb 3.7 44 
IPI00117910.3 Prdx2 5.7 36 
IPI00621417.1 Hbb-b1 5.8 362 
IPI00762198.2 Hbb-b1 6.4 556 
IPI00230320.6 Car1 8.9 13 
 
Supplementary table 4. Proteins expressed 
differentially between 14N-HAB/15N-HAB 
Hippocampal cytosol (Isotope effect) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00378172.2 Armc9 -7.3 13 
IPI00338604.5 Myh10 -1.4 184 
IPI00123181.3 Myh9 -1.3 112 
IPI00229834.3 Copa -1.1 10 
IPI00114894.1 Myh11 -1.1 54 
IPI00115363.2 Nhej1 -1 11 
IPI00134344.6 Spnb3 -1 192 
IPI00115827.1 Gbas 1 19 
IPI00127560.1 Ttr 1 30 
IPI00323800.6 Nefm 1 67 
IPI00453777.2 Atp5d 1.1 11 
IPI00221769.5 Ak3 1.1 12 
IPI00129755.2 Serpina1b 1.1 18 
IPI00131830.1 Serpina3k 1.1 145 
IPI00121038.2 Vcan 1.2 17 
IPI00153400.2 H2afj 1.2 17 
IPI00122349.1 Dpysl3 1.2 204 
IPI00122549.1 Vdac1 1.3 16 
IPI00229598.4 Cnp 1.3 81 
IPI00624192.3 Dpysl5 1.3 158 
IPI00407425.2 Myo18a 1.7 17 
IPI00117857.2 Serpina1c 1.7 47 
IPI00224067.2 Hdgfrp3 1.9 10 
IPI00221825.1 Clic6 1.9 21 
IPI00403938.2 Tnc 1.9 68 
IPI00621417.1 Hbb-b1 2 43 
IPI00831055.2 Beta-globi
n 
2.1 18 
IPI00762198.2 Hbb-b1 2.4 116 
IPI00128441.3 Hnrnpr 2.9 28 
IPI00553419.3 Dsp 4.1 77 
IPI00329998.3 11 kDa 
protein 
4.7 10 
IPI00222228.5 4732456N
10Rik 
5 17 
IPI00117042.3 Gfap 5.5 78 
IPI00118011.6 Manba 6 24 
IPI00131674.3 2210010C
04Rik 
6 32 
IPI00468203.3 Anxa2 6.3 20 
IPI00229475.1 Jup 6.3 29 
IPI00130391.1 Tcrb-V20 6.7 104 
IPI00330480.1 EG432987 6.8 68 
 
Supplementary table 5. Proteins expressed 
differentially between 14N-HAB/15N-HAB 
plasma (Isotope effect) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00457439.1 Ssna1 -6.9 12 
IPI00115553.2 BC005624 -2.1 23 
IPI00411007.1 Man1c1 -2 50 
IPI00230760.5 Mb -1.9 18 
IPI00112331.1 Gli1 -1.8 12 
IPI00116105.1 Serpina6 -1.3 219 
IPI00623506.3 Ank3 -1.2 15 
IPI00118413.2 Thbs1 -1.2 37 
IPI00881564.1 Serpina6 -1 22 
IPI00222188.4 Col1a2 -1 34 
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IPI00119676.1 Apoc1 1 15 
IPI00135547.1 Saa4 1.1 77 
IPI00123924.1 Serpina1d 1.1 123 
IPI00556721.1 Igfals 1.2 111 
IPI00119299.1 Lifr 1.3 74 
IPI00117857.2 Serpina1c 1.3 748 
IPI00138892.2 
OTTMUS
G0000000
4411 
1.5 11 
IPI00648416.1 C8a 1.5 18 
IPI00122122.1 C8g 1.5 54 
IPI00118437.1 C8g 1.5 177 
IPI00407657.2 C8a 1.5 303 
IPI00121274.2 C8b 1.5 327 
IPI00314270.3 C6 1.6 50 
IPI00123223.2 Mug1 1.7 6074 
IPI00890309.1 
2610016E
04Rik 
1.9 22 
IPI00621417.1 Hbb-b1 1.9 65 
IPI00121190.1 Egfr 1.9 310 
IPI00831055.2 
Beta-globi
n 
2 32 
IPI00115241.1 Mup4 2.1 13 
IPI00117910.3 Prdx2 2.1 22 
IPI00762198.2 Hbb-b1 2.2 149 
IPI00230718.3 C9 2.3 205 
IPI00113996.7 Blvrb 2.4 20 
IPI00120832.1 Mup3 2.5 67 
IPI00330913.1 
OTTMUS
G0000000
2.6 29 
0231 
IPI00378649.1 
LOC63510
1 
2.7 17 
IPI00230320.6 Car1 3.2 11 
IPI00719897.1 Try10 3.6 13 
IPI00115243.1 Mup5 4.1 22 
IPI00131674.3 
2210010C
04Rik 
5.1 39 
IPI00132542.1 Mup2 5.1 125 
IPI00468281.5 Rsad2 5.5 13 
IPI00117042.3 Gfap 5.6 49 
IPI00135701.3 Slco1a5 5.8 25 
IPI00466399.1 Mup2 5.9 72 
IPI00263313.1 Drg1 6.1 11 
IPI00124590.3 Casp8ap2 6.4 19 
IPI00118161.1 Usp26 6.8 15 
IPI00458776.3 Irak1bp1 7.2 13 
IPI00330480.1 EG432987 7.2 69 
IPI00130391.1 Tcrb-V20 7.2 135 
 
Supplementary table 6. Proteins expressed 
differentially between HAB/NAB hippocampal 
cotysol (Indirect comparison) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00621417.1 Hbb-b1 -8.7 102 
IPI00221825.1 Clic6 -5.4 23 
IPI00474783.4 Acaca -4.8 23 
IPI00123379.1 Hdlbp -4 30 
IPI00135151.1 
9030624J
02Rik 
-3.9 12 
IPI00224067.2 Hdgfrp3 -2.9 13 
IPI00221769.5 Ak3 -2.2 22 
IPI00407425.2 Myo18a -2.1 31 
IPI00128071.7 Uso1 -2.1 13 
IPI00115663.2 Dctn1 -2 61 
IPI00228693.4 
2310035C
23Rik 
-2 25 
IPI00459177.6 Mtap7d2 -2 12 
IPI00115824.1 Nipsnap1 -1.9 31 
IPI00114241.2 Nefh -1.9 28 
IPI00119202.1 S100a11 -1.9 10 
IPI00128319.1 Centg3 -1.9 10 
IPI00125135.1 Ube2d2 -1.8 34 
IPI00336281.1 Golga3 -1.8 30 
IPI00420426.1 Ap3b2 -1.8 19 
IPI00407835.2 Ubap2l -1.7 26 
IPI00115833.2 Mtap6 -1.6 197 
IPI00120076.2 Ckmt2 -1.6 44 
IPI00262349.2 Cpne7 -1.6 33 
IPI00229483.3 Sec24c -1.6 33 
IPI00123709.1 Akap12 -1.5 61 
IPI00469103.1 Kars -1.5 47 
IPI00222759.3 AI427515 -1.5 42 
IPI00226872.1 Efhd2 -1.5 25 
IPI00808550.1 
B230112C
05Rik 
-1.5 25 
IPI00129526.1 Hsp90b1 -1.4 510 
IPI00762198.2 Hbb-b1 -1.4 249 
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IPI00320831.3 Nbea -1.4 84 
IPI00128076.1 Serpina3c -1.4 36 
IPI00785480.2 Inpp4a -1.4 25 
IPI00138089.4 Lrrc47 -1.4 13 
IPI00229598.4 Cnp -1.3 94 
IPI00323800.6 Nefm -1.3 90 
IPI00343557.1 Mapre3 -1.3 58 
IPI00468516.3 
D6Wsu11
6e 
-1.3 22 
IPI00377609.2 Vcpip1 -1.3 19 
IPI00465809.2 Kif3b -1.3 12 
IPI00330862.5 Ezr -1.2 114 
IPI00118120.1 Myo5a -1.2 111 
IPI00132762.1 Trap1 -1.2 102 
IPI00331444.7 Ipo7 -1.2 93 
IPI00381019.1 Smarcc2 -1.2 36 
IPI00128341.1 Wasf3 -1.2 21 
IPI00130555.1 Rasal1 -1.2 20 
IPI00312076.4 Kif3a -1.2 15 
IPI00458894.3 Tnfaip8 -1.2 14 
IPI00551348.1 Rapgef6 -1.2 13 
IPI00420562.5 Cand1 -1.1 350 
IPI00128296.1 Ckmt1 -1.1 246 
IPI00223253.1 Hnrnpk -1.1 228 
IPI00849505.1 
LOC10004
3998 
-1.1 114 
IPI00312128.3 Trim28 -1.1 92 
IPI00626501.3 Kif1a -1.1 47 
IPI00314153.4 Yars -1.1 40 
IPI00399840.2 Ube3a -1.1 35 
IPI00331568.7 Hgs -1.1 34 
IPI00136054.1 Lsm2 -1.1 32 
IPI00379625.2 Nova2 -1.1 31 
IPI00132539.3 Btf3l4 -1.1 28 
IPI00308324.2 Rdx -1.1 26 
IPI00111876.2 Abhd14b -1.1 11 
IPI00308446.2 Ahcyl2 -1.1 11 
IPI00229080.7 Hsp90ab1 -1 996 
IPI00108150.1 Rock2 -1 147 
IPI00108388.1 Usp9x -1 127 
IPI00111218.1 Aldh2 -1 108 
IPI00453803.5 Ube2o -1 84 
IPI00127172.3 Ddx1 -1 75 
IPI00132080.1 Pgls -1 64 
IPI00119762.4 Dclk1 -1 43 
IPI00128867.3 Purb -1 38 
IPI00224151.5 Ap1g1 -1 34 
IPI00271905.2 Rabggta -1 28 
IPI00153400.2 H2afj -1 27 
IPI00116850.3 
D10Wsu5
2e 
-1 21 
IPI00464296.5 Epb4.1l3 -1 18 
IPI00131873.1 Cops6 -1 13 
IPI00130439.1 Camk1 -1 10 
IPI00129451.1 Cpne6 1 461 
IPI00136372.3 Syn1 1 332 
IPI00134492.4 Syn2 1 272 
IPI00117042.3 Gfap 1 105 
IPI00222833.1 Lsamp 1 27 
IPI00132087.1 Fdx1l 1 23 
IPI00337980.5 Rab21 1 20 
IPI00138406.1 Rap1a 1 17 
IPI00153144.3 Suox 1 11 
IPI00656325.2 Nsf 1.1 488 
IPI00115546.4 Gnao1 1.1 58 
IPI00118011.6 Manba 1.1 36 
IPI00132722.8 Anxa3 1.1 28 
IPI00229703.6 Vamp2 1.1 21 
IPI00352984.4 Xdh 1.1 16 
IPI00308333.3 Ccdc128 1.1 15 
IPI00223060.1 Pck2 1.2 130 
IPI00129519.3 Basp1 1.2 103 
IPI00221456.1 Sv2b 1.2 42 
IPI00132276.1 Vamp3 1.2 36 
IPI00281761.3 Prrt2 1.2 15 
IPI00116072.7 Ak5 1.2 15 
IPI00121218.5 Fahd2a 1.3 77 
IPI00316495.3 Rab3c 1.3 53 
IPI00624175.1 Acp6 1.3 24 
IPI00227168.1 Nlgn3 1.3 20 
IPI00312058.5 Cat 1.5 78 
IPI00670735.1 
LOC67731
7 
1.5 33 
IPI00470962.1 Camk2b 1.5 23 
IPI00132506.3 Chac2 1.5 21 
IPI00762636.2 Acsf3 1.5 16 
IPI00133690.2 Tsta3 1.5 11 
IPI00162780.3 Gnb2 1.5 10 
IPI00230096.1 Camk2a 1.6 51 
IPI00113149.1 Stx1b 1.6 23 
IPI00876208.1 Me3 1.6 15 
IPI00318595.1 Erap1 1.6 12 
IPI00283531.8 Gstp2 1.7 420 
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IPI00127558.3 Acox1 1.7 18 
IPI00555023.2 Gstp1 1.8 148 
IPI00120716.3 Gnb1 1.8 46 
IPI00222228.5 
4732456N
10Rik 
2 27 
IPI00230408.2 Mapt 2.1 19 
IPI00122069.1 Prkcc 2.2 258 
IPI00109727.1 Thy1 2.4 42 
IPI00117083.1 Grpel1 2.5 11 
IPI00553419.3 Dsp 2.9 97 
IPI00420725.4 Camk2a 2.9 32 
IPI00831055.2 
Beta-globi
n 
3.4 24 
IPI00648312.3 Nt5dc3 6.1 115 
 
Supplementary table 7. Proteins expressed 
differentially between HAB/NAB plasma 
(Indirect comparison) 
Accession Gene 
symbol 
Log2 
Ratio 
Peptide 
number 
IPI00177214.1 Igh-6 -7.9 13 
IPI00466399.1 Mup2 -6 239 
IPI00480401.3 
OTTMUS
G0000000
7428 
-6 23 
IPI00890309.1 
2610016E
04Rik 
-5.1 55 
IPI00132542.1 Mup2 -4.9 261 
IPI00115243.1 Mup5 -4.4 56 
IPI00120832.1 Mup3 -3 136 
IPI00378649.1 
LOC63510
1 
-2.9 28 
IPI00330913.1 
OTTMUS
G0000000
0231 
-2.3 32 
IPI00381881.7 C7 -2.2 149 
IPI00123411.1 Serpina3g -2.1 59 
IPI00402967.3 F13a1 -2 70 
IPI00121190.1 Egfr -1.7 565 
IPI00119299.1 Lifr -1.7 152 
IPI00458159.1 Igh-VJ558 -1.7 56 
IPI00459201.1 Igh -1.7 39 
IPI00648416.1 C8a -1.6 45 
IPI00131830.1 Serpina3k -1.3 5633 
IPI00121274.2 C8b -1.3 432 
IPI00553546.4 EG381806 -1.3 24 
IPI00407657.2 C8a -1.2 465 
IPI00118437.1 C8g -1.2 366 
IPI00230718.3 C9 -1.2 331 
IPI00137599.2 Sepp1 -1.2 143 
IPI00272690.2 Ace -1.2 98 
IPI00123927.1 Serpina1e -1.2 24 
IPI00122272.1 Ecm1 -1.2 22 
IPI00123223.2 Mug1 -1.1 13081 
IPI00128076.1 Serpina3c -1.1 1646 
IPI00556721.1 Igfals -1.1 198 
IPI00115658.2 Igf1 -1.1 44 
IPI00320239.1 Clec3b -1.1 27 
IPI00230320.6 Car1 -1.1 16 
IPI00377351.2 Apoa4 -1 1160 
IPI00113879.1 Il1rap -1 58 
IPI00222419.5 
ENSMUSG
00000058
927 
-1 16 
IPI00109324.3 Retnla -1 10 
IPI00310049.3 Cpb2 1 69 
IPI00762198.2 Hbb-b1 1.2 528 
IPI00468477.4 
25 kDa 
protein 
1.2 26 
IPI00119818.1 Itih4 1.3 1215 
IPI00124725.2 Itih3 1.3 844 
IPI00336324.1
1 
Mdh1 1.3 13 
IPI00312711.3 Itih4 1.4 98 
IPI00850317.1 
LOC10004
4179 
1.4 26 
IPI00666034.3 Apob 1.5 3348 
IPI00323571.1 Apoe 1.7 671 
IPI00663742.3 Dnahc10 1.9 26 
IPI00309214.1 Apcs 2 447 
IPI00230760.5 Mb 3.1 55 
IPI00138860.3 Golga4 5.3 17 
IPI00831055.2 
Beta-globi
n 
5.5 66 
IPI00755694.1 
LOC10004
5680 
6.4 73 
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8 Abbreviations 
1-DE one-dimensional gel electrophoresis 
2-DE two-dimensional gel electrophoresis 
5-HT 5-Hydroxytryptamine 
AA amino acid 
ACTH adrenocorticotrophic hormone 
AD Alzheimer's disease 
AQUA absolute quantification of proteins 
CA2 carbonic anhydrase 2 
CBG corticosteroid-binding globulin 
CRF corticotropin-releasing factor  
CRH corticotropin-releasing hormone 
DSM diagnostic and statistical manual 
DST dexamethasone suppression test 
ECS electroconvulsive seizures 
EGF epidermal growth factor 
EI electron ionization 
ELISA enzyme-linked immunosorbent assay 
EPM elevated plus maze 
ERK extracellular signal-regulated kinase 
ESI electrospray ionization 
FDR false discovery rate 
FSR fractional synthesis rate 
FST forced swim test 
FT-IR fourier transform infrared spectroscopy 
GABA gamma amino butyric acid 
GC-MS gas chromatography-mass spectrometry 
GDP guanosine diphosphate 
Glo1 glyoxalase-I 
GO gene ontology 
GTP guanosine-5'-triphosphate 
HAB high anxiety-related behavior 
HCCA 4-hydroxy-α-cyano-cinnamic acid 
HPA hypothalamic-pituitary-adrenal 
HPLC high-performance liquid chromatography 
ICAT isotope-coded affinity tag 
ICPL isotope coded protein label 
IEF isoelectric focusing 
IPG immobilized pH gradient 
iTRAQ isotope tags for relative and absolute quantification 
KEGG Kyoto encyclopedia of genes and genomes 
LAB low anxiety-related behavior 
LC liquid chromatography 
LC-MS liquid chromatography-mass spectrometry 
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LTP long-term synaptic potentiation 
m/z mass-to-charge 
MALDI matrix-assisted laser desorption ionization 
MAO monoamine oxidase 
MAPK mitogen-activated protein (MAP) kinases 
MEK mitogen-activated protein kinase kinase 
MIDA mass isotopomer distribution analysis  
MRM multiple reaction monitoring 
MS mass spectrometry 
MSTFA N-methyl-N-trimethylsilyltrifluoroacetamide 
MUP major urinary protein 
Myh10 myosin, heavy polypeptide 10 
NAB normal anxiety-related behavior 
Nefh neurofilament heavy polypeptide 
NIH national institute of health 
NMR nuclear magnetic resonance 
OCD obsessive-compulsive disorder 
PCA principle component analysis 
PD Parkinson's disease 
PLTP phospholipid transfer protein 
PMF peptide mass fingerprinting 
PND postnatal day 
PQD pulsed q dissociation 
PTM post-translational modifications 
PVDF polyvinylidene fluoride 
RIA relative isotope abundance 
RIA radio immunoassay 
RTK receptor tyrosine kinases 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SILAC Stable isotope labeling with amino acids in cell culture 
SILAM stable isotope labeling of amino acids in mammals  
SILIP stable isotope labeling in planta 
SRM selected reaction monitoring  
SSRI serotonin–selective reuptake inhibitor 
TCA cycle tricarboxylic acid cycle 
TMT tandem mass tags 
TOF time-of-flight 
TST tail suspension test 
TTR transthyretin 
UPLC ultra performance liquid chromatography 
USV ultrasonic vocalization test 
WHO world health organization 
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